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Abstract 
 
The G protein-coupled receptor (GPCR) family is composed of hundreds of 
members and is expressed in eukaryotes. Each GPCR has seven transmembrane domains 
and is in charge of sensing changes from the environment, transducing signals, and 
activating a series of biological responses. The signal transduction pathway of the 
receptor starts from sensing outside signal and then activates G proteins. This signaling 
requires a tight control for activation without which impaired cellular function leads to 
pathology. We have used the pheromone alpha-factor receptor (Ste2p) of the yeast 
Saccharomyces cerevisiae as a model system to understand ligand binding, receptor 
activation, and G protein interaction. One method we have used to study ligand binding is 
to incorporate the photo-reactive crosslinker p-benzoyl-L-phenylalanine (Bpa) into Ste2p 
to capture alpha-factor. This powerful tool requires the incorporation of Bpa, an unnatural 
amino acid, into Ste2p by a special genetic manipulation designed in the lab of Peter 
Schulz (Scripps Institute) and adapted by our lab for Ste2p. Another method to study 
ligand binding that we have adapted for use in our system is to incorporate a chemical 
crosslinker [3,4-dihydroxylphenylacetyl (DHPA)] into alpha-factor for periodate-
mediated crosslinking to Ste2p. The interacting domain between alpha-factor and 
transmembrane domain 2 to 3 of Ste2p was identified after DOPAC crosslinking, 
cyanogen bromide digestion and MALDI-TOF mass spectrometry. After ligand binding, 
signal transduction is mediated by the interaction of activated Ste2p with its G protein 
(Gpa1p). We studied this interaction by replacing natural residues in the intracellular loop 
3 of Ste2p and C-terminal end of Gpa1p with cysteine and then determining disulfide 
crosslinking between Ste2p and Gpa1p. Some residues were found to be in close 
proximity and displayed different interacting patterns due to conformational changes of 
the receptor upon ligand binding. The information we gathered here allows us to 
understand more about the physical interactions of alpha-factor, Ste2p, and Gpa1p and 
provides us insights about the initiation and activation of the signal transduction pathway 
of a peptide ligand receptor. 
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Chapter 1 
G Protein-Coupled Receptors: An Overview 
Basic Information about G-Protein-Coupled Receptors 
G protein-coupled receptors (GPCRs) are characterized by seven transmembrane 
domains with an extracellular N-terminus and intracellular C-terminus (1). The main 
function of a GPCR is to transduce extracellular signals into the cytoplasm of the cells 
and activate a variety of cellular responses according to different environmental stimuli. 
GPCRs control our sensations of vision, smell, taste, and pain (2), as well as responses to 
hormones and neurotransmitters (3). They are among the largest and most diverse protein 
families in mammalian genomes and represent targets for approximately 40% of all 
marketed drugs. 
GPCRs serve as regulators with special structural motifs to interact with both 
extracellular ligands and intracellular proteins (4). A study examining the structure 
domains of three GPCRs, rhodopsin, thyrotropin stimulating hormone (TSH) receptors, 
and vasopressin 2 (V2) receptors, has revealed that genetic variations affect the receptors 
in ligand binding and G protein coupling (5).  As the matter of relationships between 
GPCR structures and functions, the N-terminus and extracellular domains of GPCRs are 
suggested to play roles in ligand binding, intracellular trafficking, and down-regulation 
(6). Helix-helix interactions in the transmembrane domains are important to maintain the 
stability of the receptors in preferred structures for ligand binding and activation (7). 
Intracellular loop domains are essential for G protein interactions and signal transduction 
(8-10). Some receptors appear to exist as homodimers and heterodimers (11), such as the 
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GABAB receptor (12), and oligomeric assembly affects the receptor biosynthetic steps of 
maturation and trafficking and internalization internalization during down-regulation 
after signaling occurs. 
 
GPCR Crystal Structure 
Rhodopsin was the first GPCR structure to be crystallized (13), which set up the 
cornerstone for providing insights about receptor activation and interactions with ligand 
and G proteins. In addition to rhodopsin, crystal structures of β1 and β2-adrenergic 
receptors (14-16), adenosine receptor (17), CXCR4 chemokine receptor(18), Dopamine 
D3 receptor (19), and Histamine H1 receptor (20) have also been recently obtained. With 
the increasing availability of GPCR crystal structures, some of the key issues in GPCR 
biology, such as the ligand-binding pocket, extracellular disulfide bridges, and 
transmembrane domains orientations, have been elucidated (21). The information of 
three-dimensional GPCR structure supports homology modeling studies and benefits 
structure-based drug design (22). 
 
Lignand binding domain of GPCR crystal structures  
Rhodopsin consists of the chromophore 11-cis-retinal covalently linked with the 
protein opsin at the lysine residue at position 296 (13). Absorption of a photon changes 
the conformation of chromophore to all-trans-retinal and results in activation of 
Rhodopsin. According to the crystal structure of rhodoposin, several residues (Tyr43, 
Met44, Leu47, Thr94, Glu113, Gly114, Ala117, Thr118, Gly120, Gly121, Glu122, Cys167, Ser186, 
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Cys187, Gly188, Ile189, Tyr191, Met207, His211, Phe212, Phe261, Trp265, Tyr268, Ala269, and 
Phe293) from extracellular loops and  transmembrane domains form the binding pocket for 
the chromophore. 
The β1-adrenergic receptor couples to the Gs pathway (adenylyl cyclase, cAMP, 
and protein kinase A) in cardiac cells, which when activated increases the heart rate (23) 
and induces myocyte hypertrophy and apoptosis by Gs-protein kinase A-independent 
activation of calmodulinkinase II signaling. The β2-adrenergic receptor couples to Gs and 
Gi pathway and protects cardiomyocytes from apoptosis via a Gi–phosphatidylinositol 3 
kinase (PI3K) pathway (24). The crystal structure of human β2-adrenergic receptor (14) 
reveals extensive interactions between the receptor and the ligand, carazolol, at positions 
Trp286, Phe289, and Phe290. The direct interaction between the receptor and carazolol is 
through an aromatic interaction with Phe193 at extracellular loop 2 (EL2) (25). The 
common binding pocket for timolol and carazolo includes Asp113, Asn312, and Tyr316. 
Timolol binds deeper into the receptor pocket and forms a polar interaction with Asn293, 
which allows an additional hydrogen bonding interaction with Thr118 (26). In human β1-
adrenergic receptor, similar to that of carazolol in β2-adrenergic receptor, the ligand 
biding pocket includes Asp121, Phe201, Thr203, Ser211, and Asn329 (15). The Ser211 residue 
displays ligand-induced rotamer conformational changes to stabilize the binding pocket. 
Adenosine receptors play an essential role in responding to adenosine in the 
central nervous system and are major targets of caffeine (27). The ligand binding pocket 
of A2A Adenosine receptor for the antagonist theophylline (ZM241385) has been 
identified (17) to reside at Phe168, Glu169, Trp246, Leu249, His250, Asn253, His264, Leu267, 
5 
 
Met270, and Ile274. The agonist (UK-432097) binds into the A2A Adenosine receptor at 
Tyr9, Ala63, Val84, Leu85, Thr88, Glu169, Met177, Trp246, Leu249, His250, Asn253, His264, 
Leu267, Met270, Tyr271, Ser277, and His278 (28). The residues Glu169 (EL2), Tyr197 (TM6), 
and Phe201 (TM6) function as switches for rotamer conformation after ligand binding. 
 
Transmembrane domain (TM) interaction of GPCR crystal structures 
According to the crystal structure of rhodopsin (13), interactions among 
transmembrane domains (Leu40-Phe293-Phe294- Cys264, Asn55-Asp83-Ala299, Asn73- Tyr306, 
Asn78- Ser127-Thr160-Trp161, Asp83-Gly120, Cys110-Cys187, Glu122-Met163-His211, Glu134-
Arg135-Glu247-Thr251) was observed to stabilize the inactive structure. The (D/E)R(Y/W) 
motif (Glu134-Arg135-Tyr136) forms hydrogen bonds with surrounding residues. The 
tripeptide sequence Val137-Val138-Val139 covers the cytoplasmic side of Glu134 and Arg135 
and maintains the conformation of rhodopdin. Photoactivation is likely to interfere with 
the transmembrane constrains, such as Phe294, Ala299, Asn302, and Tyr306, and unfold the 
active conformation. 
In human β2-adrenergic receptor (14), there are two disulfide bonds (Cys184-
Cys190 and Cys191-Cys106) stabilizing extracellular loop 2. The interactions among 
Trp286, Phe289, and Phe290 constrain the inactive state of the receptor. There are ionic 
interactions and salt bridges between residues at different TM domains (Lys60-Glu338 and 
Lys305-Asp192) to maintain the receptor structure (25). Upon ligand binding in the β1-
adrenergic receptor, Ser212 forms a hydrogen bond with Asn310 (29) and the rotamer 
change of Ser215 appears to break the interaction of Val172-Ser215. Also Tyr149 forms a 
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hydrogen bond with Asp138 (15). A short α-helix in intracellular loop 2 interacts directly 
with the highly conserved Asp138-Arg139-Tyr140 (DRY) motif in TM3 (15). 
Adenosine receptor forms hydrogen bonds in Asp101-Tyr112-Thr41 and disulfide 
bonds at Cys71-Cys159, Cys74-Cys146, Cys77-Cys166, and Cys259-Cys262 (17). The D/ERY 
(Asp101-Arg102-Tyr103) motif plays a role in stabilizing the polar interactions with TM2 
(Thr41), IL2 (Tyr112), and TM6 (Glu228), which possibly modulates G protein activation. 
There are interactions at IL2 (Tyr112-Asp138) and Thr88-Ser277-His278. Upon ligand 
binding, the residue His250 moves ~1.8 Å inward and Trp246 indole moves ~1.9 Å to avoid 
the steric clash with the ligand (28).  The conserved NPxxY motif composed of Asn284, 
Pro285, Phe286, Ile287, and Tyr288 at the cytoplasmic end of TM7 shifts about 4 to 5 Å 
inward, resulting in reorganizations of these side chains, especially at the residue Tyr288. 
 
G protein interaction of GPCR crystal structures 
In all GPCRs, intracellular loops, especially IL2 and IL3, are critical to activate 
and provide variability among related GPCRs as a result to specific G-protein activation 
(13, 15). The C-terminal end of rhodopsin is surrounded by hydrophobic residues from 
TM2 (Pro71, Leu72), intracellular loop 2 (Phe148), TM5 (Leu226, Val230), and TM6 (Val250, 
Met253), forming the binding site for a G protein (13). In the β1-adrenergic receptor 
(Warne 2008 Nature 486), intracellular loop 2 is proposed to play a key role in G-protein 
coupling and activation (15).  
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Chapter 2 
Alpha-factor Pheromone and its G Protein-coupled Receptor (Ste2p) of 
Saccharomyces cerevisiae 
Yeast Mating Pheromone Response Pathway 
In yeast two distinct GPCR systems have been identified: one is for pheromone 
signaling (Figure 1.1) and the other is for glucose sensing (30). Our lab uses the 
pheromone response pathway in Saccharomyces cerevisiae as a model system for the 
study of GPCR-ligand interaction. The MATα cell generates the 13-residue peptide 
[WHWLQLKPGQPMY] α-factor, which activates the Ste2p receptor on the MATa cell. 
The MATa cell generates the 12-residue lipopeptide 
[YIIKGVFWDPAC(farnesyl)OCH3] a-factor, which targets the Ste3p receptor on the 
MATα cell (31). The two mating peptides bind to residues on the extracellular side of 
receptors and cause conformational changes that transmit a signal to the G proteins inside 
the cells. 
G protein subunits serve as intermediate modulators between the cell surface 
receptors and the intracellular effectors (32), transducing pheromone binding signal into 
cytoplasmic response. Upon ligand binding, Gpa1p (Gα subunit) bound GDP is replaced 
by GTP, and Ste4p/Ste18p (Gβγ subunits) are then released, which in turn transmits the 
signal required for mating. Recent studies have shown that Gpa1p can also stimulate 
downstream signaling. A GTPase-deficient mutant (GDP-bound form) of Gpa1p was 
found to couple with an RNA binding protein Scp160 (33) and endosomal 
phosphatidylinositol 3-kinase Vps15/Vps34 subunits (34), suggesting a role of Gpa1p not 
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only as a negative regulator of Ste4p/Ste18p (35, 36), but also as an inducer of the mating 
signal pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Components of the pheromone response pathway in yeast. This figure was 
taken from reference (37). 
 
Released Ste4p/Ste18p subunits transmit the signal to a mitogen-activated protein 
(MAP) kinase cascade through at least three effector proteins (32): a guanine-nucleotide 
exchange factor Cdc24p (38), a protein kinase Ste20p (39), and a kinase scaffolding 
protein Ste5p (40).  Cdc24p is the guanine nucleotide exchange factor for the Rho G-
protein Cdc42p (41); Cdc42p regulates MAP kinase signaling through PAK (p21-
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activated kinase)-family kinase Ste20p (42). After binding with Ste4p/Ste18p and 
Cdc42p (43, 44), Ste20p activates the downstream MAP kinase cascade. Pheromone 
response protein Ste5p serves as a scaffold (45, 46) to facilitate interactions among 
member of the MAP kinase cascade: Ste11p (MAPKKK), Ste7p (MAPKK) and Fus3p 
(MAPK). MAP kinase kinase kinase Ste11p phosphorylates MAP kinase kinase Ste7p, 
and Ste7p phosphorylates MAP kinase Fus3p. Mating specific Fus3p then phosphorylates 
Far1p (47) and Ste12p, a transcription factor (48). Far1p inhibits Cdc28-G1 cyclin 
complex and promotes G1 cell cycle growth arrest (49). The transcriptional 
transactivatior Ste12p binds to the pheromone response element (PRE) at the promoter 
region of target genes (50), such as FUS1, FUS2, FIG1, FIG2, AGA1 that are induced for 
cell fusion. MATa and MATα cells form shmoos with the apical tips directing toward 
each other (51). Eventually at the contact points of two opposite mating types, 
degradation of the cell wall and plasma membrane followed by nuclear fusion allow two 
haploid cells to become one a/α diploid zygote (52). 
 
Regulation of Mating Pheromone Response Pathway 
Figure 1.2 summarizes the activation, desensitization, and internalization of the 
Ste2p signaling pathway (53). Yeast cells start a mating cell cycle and trigger G1 growth 
arrest when there is nutrient starvation or the presence of mating factor from the other 
mating type (54). Eventually yeast cells would have to recover from mating state and 
continue proliferation through the mitotic cell cycle (32). The MATa cell produces an 
extracellular protease, Bar1p, which cleaves α-factor (55) and allow cells to recover from 
10 
 
α-factor induced growth arrest.  Expression of RGS (regulator of G-protein signaling) 
Sst2p is highly induced by the activation of Ste2p. Membrane-associate Sst2p is a direct 
negative regulator (56) that interferes with GTP-bound Gpa1p and down-regulates mating 
signal. Yeast casein kinases, Yck1p and Yck2p, are involved in bud morphogenesis and 
internalization of pheromone receptors (57).  Yck-mediated phosphorylation of the 
mating receptors is required for endocytosis at the cell membrane (58). Eventually 
phosphorylation at the C-terminus of the receptor leads to ubiquination, internalization 
and degradation (32). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Sst2-mediated activation, desensitization, and internalization of Ste2p. 
This figure was taken from reference (53). 
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Abstract for Part II 
Ste2p is the G protein-coupled receptor (GPCR) for the tridecapeptide pheromone 
alpha factor of Saccharomyces cerevisiae. This receptor-pheromone pair has been used 
extensively as a paradigm for investigating GPCR structure and function. Expression in 
yeast harboring a cognate tRNA/aminoacyl-tRNA synthetase pair specifically evolved to 
incorporate p-benzoyl- l-phenylalanine (Bpa) in response to the amber codon allowed the 
biosynthesis of Bpa-substituted Ste2p in its native cell. We replaced natural amino acid 
residues in Ste2p with Bpa by engineering amber TAG stop codons into STE2 encoded 
on a plasmid. Several of the expressed Bpa-substituted Ste2p receptors exhibited high-
affinity ligand binding, and incorporation of Bpa into Ste2p influenced biological activity 
as measured by growth arrest of whole cells in response to alpha factor. We found that, at 
concentrations of 0.1-0.5 mM, a dipeptide containing Bpa could be used to enhance 
delivery of Bpa into the cell, while at 2 mM, both dipeptide and Bpa were equally 
effective. The application of a peptide delivery system for unnatural amino acids will 
extend the use of the unnatural amino acid replacement methodology to amino acids that 
are impermeable to yeast. Incorporation of Bpa into Ste2p was verified by mass 
spectrometric analysis, and two Bpa-Ste2p mutants were able to selectively capture alpha 
factor into the ligand-binding site after photoactivation. To our knowledge, this is the first 
experimental evidence documenting an unnatural amino acid replacement in a GPCR 
expressed in its native environment and the use of a mutated receptor to photocapture a 
peptide ligand. 
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Chapter 1 
Introduction 
G protein-coupled receptors (GPCRs) are activated upon binding their cognate 
ligands. Ligand binding initiates a change in the conformation of these integral 
membrane proteins. This promotes signal transduction across the membrane and the 
activation of the G protein-mediated signal transduction cascade (1, 2). The interactions 
between ligands and their receptors are defined for a number of GPCRs (3). However, the 
ligand-induced changes in protein structure, which initiate signal transduction, are 
difficult to study. Although site-directed mutagenesis has been used to address the issue 
of GPCR activation, more methods for studying ligand-dependent conformational 
changes upon receptor activation are needed. One promising approach, which may be 
adapted to the study of the dynamics of the GPCR structure, is the use of orthogonal pairs 
of tRNA/aminoacyl-tRNA synthetases evolved and expressed in the target cell to 
incorporate unnatural amino acids (4-7). 
Non-naturally occurring amino acids can be synthesized to contain a variety of 
chemical moieties for use as photoaffinity labels or fluorescent and/or spectroscopic 
probes. To autonomously incorporate unnatural amino acids into proteins in living cells, 
the mutated tRNA is designed to recognize a specific codon, usually a nonsense codon, 
such as the amber TAG stop. Provided that there is a sufficient quantity of the unnatural 
amino acid in the cytoplasm, the evolved cognate aminoacyl-tRNA synthetase 
specifically charges its orthogonal tRNA with this novel amino acid for delivery into the 
protein. 
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The genetic codes of Escherichia coli, yeast, and mammalian cells have been 
altered to allow for the translational insertion of more than 30 unnatural amino acids with 
a variety of novel properties useful in the study of protein structure and function(5, 8). 
Thus far, these applications have focused primarily on soluble proteins. With respect to 
eukaryotic membrane proteins expressed in mammalian cells, unnatural amino acids have 
been introduced into the nicotinic acetycholine receptor in both CHO and cultured 
neuronal cells (9) and in the epidermal growth factor receptor in HEK293 cells (10). A 
heterologous Xenopus oocyte expression system has also been used extensively to insert 
non-natural amino acids into the nicotinic acetylcholine receptor (11) the neurokinin-2 
receptor (12), the GABAA receptor (13), the NMDA receptor (14), and numerous 
channel proteins, including the serotonin-gated ion channel (15), the inwardly rectifying 
potassium channel (16), and the voltage-sensitive sodium channel (17). In both the 
mammalian and Xenopus expression systems, a tRNA chemically charged with the non-
natural amino acid is introduced into the cell along with the target mRNA. While these 
systems are useful for the short-term studies of protein properties, they are not amenable 
to large-scale production of proteins into which unnatural amino acids have been 
incorporated. Recently, it was demonstrated in CHO cells that unnatural amino acids 
could be introduced into green fluorescent protein (GFP) using specific orthogonal 
tRNA/aminoacyl-tRNA synthetase pairs (6). Because the yeast Saccharomyces cerevisiae 
provides a tractable system in which to develop this methodology, we report here the 
genetic incorporation of an unnatural amino acid into a polytopic membrane protein in its 
native eukaryotic host cell. 
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To date in S. cerevisiae, orthologous tRNA/aminoacyl-tRNA synthetase pairs 
have been used to incorporate a variety of unnatural amino acids, including the 
photoactivatable amino acid analogue p-benzoyl-L-phenylalanine (Bpa) (4), the 
fluorescent amino acid dansyl alanine (18), and acetylene- and azide-containing amino 
acids (7, 19), into the soluble protein human superoxide dismutase. Here, we report the 
site-specific incorporation of Bpa into Ste2p, a yeast GPCR, using an orthologous 
tRNA/aminoacyl-tRNA synthetase pair. In this system, the amber TAG stop codon was 
engineered into specific sites within the STE2 coding region. Bpa was supplied to the 
cells either as the free amino acid analogue or as the dipeptide Met−Bpa. Upon 
translation of the message, Bpa was incorporated into the nascent Ste2p and ultimately 
expressed at the cell surface. Two of our Bpa−Ste2p receptors were used to selectively 
photocapture biotinylated α factor. To our knowledge, this is the first report of the 
expression in the native host cell of a GPCR containing a photoactivatable amino acid. 
The successful photocapture of α factor by novel Ste2p mutants shows that GPCRs 
containing unnatural amino acids can be used to capture ligand and study changes in 
domain−domain interactions during GPCR activation. 
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Chapter 2 
Material and Methods 
Media, Reagents, Strains, and Plasmids 
S. cerevisiae strain DK102 (MATa, ura3−52 lys2−801am ade201oc trp1-Δ63 his3-
Δ200 leu2-Δ1 ste2::HIS3 sst1-Δ5) was used for growth arrest and binding assays, and the 
protease-deficient strain BJS21 (MATa, prc1−407 prb1−1122 pep4−3 leu2 trp1 ura3−52 
ste2::KanR) was used for protein isolation and immunoblot analysis. C-Terminal FLAG 
and His-tagged STE2 was PCR-amplified from plasmid pNED1 (20) and cloned into the 
plasmid p426-GPD (21) to yield plasmid pCL01. The plasmid pCL01 was engineered by 
single-stranded mutagenesis to incorporate TAG stop codons at eight specific positions 
within the STE2 coding region (Figure 2.1). The sequence of all TAG mutants was 
verified by DNA sequence analysis completed by the Molecular Biology Resource 
Facility located on the campus of the University of Tennessee. Mutagenic and sequencing 
primers were purchased from Sigma/Genosys (The Woodlands, TX) or IDT (Coralville, 
IA). The pCL01 TAG mutant plasmids were cotransformed by the method of Geitz (22) 
into DK102 and BJS21 cells along with plasmid pECTyrRS/tRNACUA, encoding the 
orthogonal amber suppressor tRNA synthetase−tRNA pair genetically modified to allow 
for incorporation of p-benzoyl-L-phenylalanine (Bpa) (4). Transformants were selected 
by growth on minimal medium (23) lacking tryptophan and uracil (designated as 
MLWU) to maintain selection for the plasmids. Cells used in the assays described below 
were cultured in MLWU and grown to mid-log phase at room temperature with shaking 
(200 rpm) in the presence or absence of 2 mM Bpa, unless otherwise specified. 
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Methionyl-Bpa was synthesized by standard solution phase techniques (24) and purified 
by reverse-phase high-performance liquid chromatography (HPLC) to greater than 99% 
homogeneity. All media components were obtained from BD (Franklin Lakes, NJ) and 
were of the highest quality available. Bpa was purchased from Bachem (Torrance, CA) 
and was dissolved in NaOH (1 N) at a final concentration of 100 mM immediately before 
use. 
 
Growth Arrest Assays 
DK102 cells expressing the wild-type (WT) or TAG constructs were grown at 
30°C in MLWU, harvested, washed 3 times with sterile water, and resuspended at a final 
concentration of 5 × 106 cells/mL. Cells (1 mL) were combined with 3.5 mL agar noble 
(1.1%) with or without the addition of Bpa (2 mM final concentration) and poured as a 
top agar lawn onto MLWU medium. Filter disks (BD, Franklin Lakes, NJ) impregnated 
with the tridecapeptide pheromone α factor (WHWLQLKPGQPNle12Y) synthesized and 
characterized as previously described (25) were placed on the top agar, and the plates 
were incubated at room temperature (23°C) for 48−72 h. The growth arrest assays were 
repeated a minimum of 3 times, and similar results were observed for each replicate. 
 
Immunoblots 
BJS21 cells expressing WT or TAG-STE2 constructs grown in the presence or 
absence of Bpa were used to prepare total cell membranes isolated as previously 
described (20). The protein concentration was determined (BioRad, Hercules, CA), and 
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membranes were solubilized in sodium dodecyl sulfate (SDS) sample buffer. Proteins (2 
µg/lane for WT and 30 µg/lane for mutants) were fractioned by SDS−polyacrylamide gel 
electrophoresis (PAGE) and immunoblotted. Blots were probed with FLAG antibody 
(Sigma/Aldrich Chemical, St. Louis, MO) or an antibody directed against the N-terminal 
100 amino acids of Ste2p generously provided by J. Konopka (26). The immunoblots 
were imaged, and band density was quantitated using Quantity One software (version 
4.5.1) on a Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA). 
Multiple repeats of immunoblot experiments yielded the same results. 
 
Binding Assays 
Tritiated α factor (10.2 Ci/mmol, 12 µM) prepared as previously described (25) 
was used in saturation binding assays on whole cells. DK102 cells expressing WT or 
TAG constructs were harvested, washed 3 times with YM1 (20), and adjusted to a final 
concentration of 2 × 107 cells/mL. Cells (600 µL) were combined with 150 µL of ice-cold 
5× binding medium (YM1 plus protease inhibitors [YM1i (20)] supplemented with [3H]α 
factor) and incubated at room temperature for 30 min. The final concentration of [3H]α 
factor ranged from 0.5 × 10−10 to 1 × 10−6 M. Upon completion of the incubation interval, 
200 µL aliquots of the cell−pheromone mixture were collected in triplicate and washed 
over glass fiber filter mats using the Standard Cell Harvester (Skatron Instruments, 
Sterling, VA). Retained radioactivity on the filter was counted by liquid scintillation 
spectroscopy. DK102 cells lacking Ste2p were used as a nonspecific binding control for 
the assays. Binding assays were repeated a minimum of 3 times, and similar results were 
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observed for each replicate. Specific binding for each mutant receptor was calculated by 
subtracting the nonspecific values from those obtained for total binding. Specific binding 
data were analyzed by nonlinear regression analysis for single-site binding using Prism 
software (GraphPad Software, San Diego, CA) to determine the Km (in nanomolars) and 
Bmax values (receptors/cell) for each mutant receptor. 
 
Matrix-Assisted Laser Desorption Ionization−Time of Flight (MALDI−TOF) 
BJS21 cells expressing either the WT or G188TAG Ste2p were grown in the 
presence or absence of Bpa and used to prepare total cell membranes as previously 
described (20). Approximately 3 mg of cell membranes was resuspended in ice-cold 
solubilization buffer [50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), and 1% Triton X-100] with protease inhibitors 
(PMSF, pepstatin A, and leupeptin), incubated overnight at 4°C with end-over-end 
mixing, and then centrifuged at 15000g for 30 min to remove nonsoluble material. The 
solubilized proteins were then mixed with FLAG resin (Sigma/Aldrich Chemical Co., St. 
Louis, MO) and incubated at 4°C with end-over-end mixing for 6 h. The resin was 
collected by centrifugation at low speed (800g for 1 min) and resuspended and collected 
4 times in TBS buffer (25 mM Tris-HCl, 140 mM NaCl, and 3 mM KCl at pH 7.4). Ste2p 
was eluted by resuspending the resin in 1 mL of ice-cold elution buffer (0.1 M glycine 
HCl at pH 3.5) and incubated at 4°C with end-over-end mixing for 5 min. The resin was 
pelleted by centrifugation (2000g for 1 min), and the supernatant, containing the eluted 
Ste2p, was transferred to a fresh tube containing 20 µL of 0.5 M Tris-HCl at pH 7.4 and 
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1.5 M NaCl. Purity and concentration of samples was estimated by Coomassie Blue and 
silver staining of SDS−PAGE gels. The samples were also analyzed by immunoblotting 
using an antibody to the FLAG epitope on the C terminus of Ste2p. 
Samples containing eluted Ste2p (50 µg) were dried by vacuum centrifugation 
(Thermo Scientific, Waltham, MA) and then dissolved in 100% trifluoroacetic acid 
(TFA) containing 10 mg/mL cyanogen bromide (CNBr). Deionized−distilled water 
(ddH2O) was then added to adjust the final TFA concentration to 70%, and the sample 
was incubated at 37°C in the dark for 18 h. The samples were dried by vacuum 
centrifugation and washed 3 times with ddH2O and resuspended in 0.1% TFA. The 
resulting CNBr peptide fragments were further washed and concentrated using ZipTip 
pipet tips (Millipore Corporation, Billerica, MA) following the directions of the 
manufacturer and resuspended in 70% acetonitrile/30% water (0.1% TFA). For 
MALDI−TOF analysis, α-cyano-4-hydroxy-trans-cinnamic acid (ACHA, Sigma/Aldrich 
Chemical Co., St. Louis, MO) at a concentration of 20 mg/mL in 50% acetonitrile/50% 
water (0.1% TFA) was used as the matrix. The digested samples (0.5 µL eluate from 
ZipTip) were either mixed with 0.5 µL of matrix before spotting on the target or 1.0 µL 
of matrix was spotted and allowed to dry before applying 1.0 µL of samples. 
MADLI−TOF spectra were acquired on a Bruker Daltonics (Boston, MA) Microflex 
using both reflector and linear methods. 
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Crosslinking 
A biotinylated form of α factor, [K7(biotinylamidocaproate), Nle12]α factor, was 
prepared as previously described (27). Membranes prepared from BJS21 cells expressing 
the F55TAG, G188TAG, and Y193TAG receptors, grown at room temperature in the presence 
or absence of Bpa (1 mM), were suspended in PPBi buffer [0.5 M potassium phosphate at 
pH 6.2, 10 mM tert-amyl methyl ether (TAME), 10 mM sodium azide, 10 mM potassium 
fluoride, and 0.1% bovine serum albumin (BSA)], incubated with biotinylated 
pheromone (1 µM) in the presence or absence of nonbiotinylated pheromone (100 µM) 
for 30 min at room temperature, and then chilled to 4°C for the remainder of the 
procedure. Cross-linking was performed as previously described (27). Briefly, the 
membranes were exposed to UV light at 365 nm using a Stratalinker (Stratagene, La 
Jolla, CA) for three 15 min intervals. The cross-linked membranes were washed 3 times 
with CAPS buffer [10 mM N-cyclohexyl-3-aminopropanesulfonic acid (Sigma, St. Louis, 
MO) at pH 10] by centrifugation to remove noncross-linked biotinylated α factor, 
fractionated by SDS−PAGE and immunoblotted with antibody to Ste2p and with 
Neutravidin−horseradish peroxidase (HRP) conjugate (Pierce, Rockford, IL) to detect the 
biotinylated pheromone covalently linked to the receptor. The signal generated by the 
Neutravidin−HRP conjugate associated with the biotinylated ligand−receptor complex 
was quantitated by measurement of the band density using Quantity One software 
(version 4.5.1) on a Chemi-Doc XRS photodocumentation system (BioRad, Hercules, 
CA). Before fractionation by SDS−PAGE, the amount of protein in each sample was 
determined, and amounts specified in the text were loaded into each lane.  
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Chapter 3 
Results 
Effect of Bpa Incorporation on Ste2p Expression and Signal Transduction 
 The amber stop codon TAG was inserted into the STE2 coding sequence by site-
directed mutagenesis at the eight sites indicated in Figure 2.1. On the basis of the latest 
information concerning Ste2p topology (28-30), the sites were located in the first 
transmembrane domain (F55TAG), in the first (S107TAG, G115TAG, and V127TAG) and 
second (Y193TAG and F204TAG) extracellular loops, at the border between the fourth 
transmembrane domain and the second loop (G188TAG) and in the sixth transmembrane 
domain (Y266TAG). These residues were selected on the basis of several criteria: (i) 
location, either in an extracellular loop or near the interface between a TM and an 
extracellullar surface, (ii) prior site-directed mutagenesis studies indicating that the 
residues (S107, G115, V127, and G188) were tolerant to amino acid substitution (31), 
and (iii) conservation of the aromatic functional group (F55, F204, and Y266) (32, 33). 
The plasmids bearing these mutations and the plasmid pECTyrRS/tRNACUA, which 
encoded the tRNA/tRNA synthetase pair, were transformed into DK102 and BJS21 cells. 
Cell membranes isolated from strain BJS21 expressing the TAG mutant constructs and 
the tRNA/tRNA synthetase pair were immunoblotted and probed with antibodies directed 
against the C-terminal FLAG epitope tag and the N-terminal 100 amino acids of Ste2p 
(26) to determine the effect of the amber stop codon on protein synthesis in the presence 
and absence of Bpa. 
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Figure 2.1 Sites targeted for Bpa insertion into Ste2p. The coding region of the STE2 
gene was modified to introduce the amber TAG codon, resulting in the insertion of Bpa 
into Ste2p at the sites indicated in black (F55, S107, G115, V127, G188, Y193, F204, and 
Y266). The FLAG and His tags are underlined. 
 
To determine if the Ste2p−Bpa mutant proteins were able to bind ligand and 
ultimately transduce the signal across the cell membrane, growth arrest or “halo” assays 
were conducted on these transformed cells. Disks impregnated with α factor were placed 
onto a top agar lawn of DK102 cells putatively expressing Ste2p−Bpa receptors, and the 
plates were incubated at room temperature for 48−72 h. The rationale to conduct these 
studies was 2-fold. In the absence of Bpa, the tRNA should not be charged, resulting in 
the production of truncated Ste2p. In this case, the cells should not respond to pheromone 
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and growth arrest should not occur. In the presence of Bpa, the TAG codon should be 
suppressed by the charged tRNA and full-length protein should be synthesized. If the 
incorporation of Bpa results in expression, the mutant Ste2p proteins might bind 
pheromone, resulting in the initiation of signal transduction ultimately resulting in growth 
arrest, indicated by the formation of a clear halo around the disk. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Halo assays of WT and Bpa mutant receptors. Cells lacking receptor (A 
and B), cells containing WT Ste2p (C and D), or cells with mutated Ste2p (E−T) were 
plated onto medium in the presence and absence of Bpa. Disks containing α factor (2, 1, 
0.5, 0.2, and 0.1 µg/disk, starting at the 12 O’clock position on each plate and moving 
counter-clockwise) were placed onto the lawn of cells. The plates were incubated for 
48−72 h at room temperature. 
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For cells expressing WT Ste2p, dose-dependent halos with well-defined borders 
and clear zones of inhibition were formed in both the presence and absence of Bpa, 
indicating that Bpa addition to growth medium did not affect the pheromone response 
(parts C and D of Figure 2.2). Full-length WT Ste2p was synthesized in both the presence 
and absence of Bpa and could be detected by both N-terminal (Figure 2.3A) and C-
terminal (Figure 2.3B) antibodies. Cells that were deleted for Ste2p did not form halos in 
either the presence or absence of Bpa (parts A and B of Figure 2.2), and Ste2p was not 
detected on immunoblots (Figure 2.4). 
The mutants F55TAG (Figure 2.2E) and F204TAG (Figure 2.2Q) formed dose-
dependent halos in the absence of Bpa, although these halos were “fuzzy”, referring to 
the poor definition of the borders and reduced clarity of the zone of inhibition compared 
to the WT control. The fuzzy nature of these halos is most likely due to a decreased 
receptor number or to more rapid desensitization of the Bpa mutant receptor, resulting in 
a recovery from the growth arrest response (34, 35). Immunoblot analysis indicated that, 
in the absence of Bpa, the protein expression level of the F55TAG mutant was below the 
limit of detection (Figure 2.3A) and the expression of the F204TAG mutant was very low 
(Figure 2.4). Despite the inability to visualize the F55TAG protein on the immunoblot, 
sufficient protein was made by read-through expression to produce the biological 
response and to be detected by the ligand binding assay (see below). The observation that 
low levels of Ste2p are sufficient to result in signal transduction was made previously 
(36). These investigators reported that only a fraction of the receptors in a normal cell are 
necessary for signaling and that reduction of the receptor level to below 5% of the normal 
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level led to smaller, turbid, fuzzy-edged growth arrest zones in response to α factor. The 
lack of receptor expression was required to completely block α-factor-induced growth 
arrest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Immunoblots of membranes isolated from cells expressing Bpa mutant 
Ste2p. In each panel, the arrow at the left indicates the band corresponding to full-length 
Ste2p. (A) C-Terminal FLAG and (B) N-terminal anti-Ste2p immunoblots prepared from 
cells expressing the F55, G188, and Y193 receptors grown in the presence and absence of 
2 mM Bpa. In B, the arrows in the lower portion of the figure indicate truncated forms of 
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Ste2p. (C) FLAG immunoblot of membranes prepared from cells expressing the F55TAG 
receptor in the presence of increasing concentrations of Bpa. 
 
 
 
 
 
 
 
Figure 2.4  Immunoblots of membranes isolated from cells expressing Ste2p mutants 
with the TAG codon inserted at specific residues indicated in the figure. The arrow at 
the left indicates the band corresponding to full length Ste2p. The receptors were detected 
with an antibody to the C-terminal FLAG epitope. Membranes were prepared from cells 
grown in the presence (+) and absence (-) of 2 mM Bpa as indicated in the figure. 
 
 The presence of halos for the F55TAG and F204TAG receptors in the absence of Bpa 
indicates that there was “read-through” of the amber stop codon (allows translation to 
read through the amber stop codon and produces full-length protein), resulting in the 
production of a functional receptor. In contrast, in the presence of Bpa, these same 
mutants did not form halos (parts F and R of Figure 2.2). Subsequent immunoblot 
analysis indicated that the expression of the F55TAG (Figure 2.3A) and F204TAG receptors 
was enhanced in cells grown in the presence of Bpa (Figure 2.4), suggesting that Bpa was 
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incorporated into Ste2p but was not tolerated at those positions, resulting in nonsignaling 
receptors. The expression was at relatively low levels; 15 times more protein was loaded 
for the mutants to allow for detection by the immunoblot compared to that of the WT (30 
versus 2 µg). 
 Receptors with mutations at positions S107 (Figure 2.2G), G115 (Figure 2.2I), 
and V127 (Figure 2.2 K) also exhibited read-through expression. Halos formed in the 
absence of Bpa, although they were fuzzy for the G115TAG and V127TAG receptors. Little 
or no protein was detected by immunoblot analysis for these three receptors when cells 
were grown in the absence of Bpa (Figure 2.4) indicating again, as in the case of F55TAG, 
expression was below the limit of detection for the immunoblot even though sufficient 
protein was made by read-through expression to produce the biological response. In the 
presence of Bpa, expression of these three mutants resulted in halo formation, although 
the halos were not well-delineated (parts H, J, and L of Figure 2.2, respectively). 
Immunoblot analysis indicated that expression of these three proteins was enhanced in 
cells grown in the presence of Bpa (Figure 2.4). Thus, the decline in halo definition, 
despite the fact that there was an increase in Ste2p protein, indicates that Bpa was 
incorporated into these receptors but the function was compromised. 
 For the mutant at position Y193, no halos were formed in the absence of Bpa, 
suggesting that no functional Ste2p was expressed (Figure 2.2O), although a low-level 
full-length protein was detected by immunoblot analysis with the C-terminal antibody 
(Figure 2.3A). In contrast, in the presence of Bpa, dose-dependent fuzzy halos were 
formed, indicating that Bpa was inserted in response to the TAG codon, resulting in a 
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functional protein (Figure 2.2P). In parallel with this increase in Ste2p function, there was 
a concomitant increase in protein expression (Figure 2.3A) for cells grown in the 
presence of Bpa. The G188TAG mutant had a similar phenotype (parts M and N of 
Figure 2.2) but with less defined halos observed only at the highest amount of pheromone 
and only in the presence of Bpa. The poor definition of the halos suggested that Bpa was 
not well-tolerated at this position. For the G188 receptor, there was no detectable protein 
produced in the absence of Bpa and a weak but clearly discernible band was detected in 
membranes obtained from cells grown in the presence of Bpa (Figure 2.3A). Finally, the 
Y266TAG receptor was not functional in either the presence or absence of Bpa (parts S and 
T of Figure 2.2), and immunoblot analysis (Figure 2.4) indicated that this receptor was 
not expressed under either condition. 
 C-Terminally truncated forms of the receptor can be seen for the G188TAG and 
Y193TAG receptors using antibody to the N terminus (Figure 2.3B). Three major bands 
were detected at 23, 21, and 18 kDa for the G188TAG and at 24, 22, and 19 kDa for the 
Y193TAG receptor. These bands corresponded to the expected size of the nonglycosylated 
receptor and its two major glycosylated states truncated at the inserted stop codons (37). 
The origin of the bands of higher molecular weight (between 22 and 50 kDa) in the 
G188TAG and Y193TAG lanes (Figure 2.3B) was not investigated, although these bands are 
not related to the absence or presence of Bpa. Truncated forms of the F55TAG receptor 
were not detected with the N-terminal antibody (Figure 2.3B) on this immunoblot 
because the predicted receptor fragment (6 kDa) would not have been retained on the gel. 
Note that the full-length Ste2p band intensity (52 kDa) for the WT strain is less intense as 
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detected by the N-terminal antibody (Figure 2.3B) than that of the same membranes 
probed with the FLAG antibody (Figure 2.3A). In our hands, the FLAG antibody always 
yields a stronger signal than the N-terminal antibody. This provides an explanation for 
the observation that, although full-length Bpa-containing proteins can be detected with 
the FLAG antibody, they are barely discernible by the N-terminal antibody. Expression 
of the full-length F55TAG Bpa-containing receptor was enhanced in response to an 
increased Bpa concentration in the growth medium (Figure 2.3C). At a low concentration 
(0.2 mM Bpa), no increase over control (no Bpa) was observed, while at higher 
concentrations (2 mM), the signal corresponding to Ste2p on the immunoblot was 
enhanced, increasing by 2.6-fold over the control as measured by band intensity. Similar 
results were obtained for the G188TAG and Y193TAG mutants (data not shown), suggesting 
that entry of Bpa into the cell is one factor determining the efficiency of Bpa insertion 
into the protein. 
 
Effect of Bpa-Containing Peptides on the Expression of Ste2p 
The data for the F55TAG, G188 TAG, and Y193 TAG receptors described above 
suggests that the expression of Bpa-containing Ste2p could be enhanced if Bpa were 
more efficiently delivered into the cell. It is known that small peptides enter yeast cells 
intact through the di/tripeptide transporter Ptr2p (38, 39), and upon entry into the cell, 
these peptides are hydrolyzed to free amino acids. In an attempt to increase the delivery 
of Bpa into the cell, a Bpa-containing dipeptide (Met−Bpa) was synthesized. Methionyl 
di- and tripeptides are excellent substrates for the yeast peptide transport system (40). 
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Cells expressing the F55TAG, G188TAG, and Y193TAG receptor constructs were grown in 
the presence and absence of Met−Bpa, and membranes were isolated and probed with the 
C-terminal FLAG antibody to detect full-length protein. The expression of full-length 
WT Ste2p was not affected by the presence of Met−Bpa, confirming that this compound 
did not interfere with normal Ste2p expression at the concentrations indicated (Figure 
2.5A). The Y193TAG mutant expressed minimal FLAG-reactive Ste2p in the absence of 
Bpa, but in the presence of Met−Bpa (Figure 2.5B), full-length protein was detected.  
 
 
 
 
 
 
 
 
Figure 2.5 Use of a peptidyl form of Bpa. FLAG immunoblot analysis of membranes 
from cells expressing either WT (A) or Y193TAG (B) Ste2p receptors grown in the 
presence of the dipeptide Met−Bpa or free Bpa at the concentrations indicated. Protein 
loads were 2 and 30 µg for the WT and Y193 mutant, respectively. 
 
In comparison to the expression of Y193TAG grown in the presence of 0.1 mM 
Met−Bpa to that grown in the presence of 0.1 mM Bpa (Figure 2.5B), expression was 
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greater for the dipeptide (3.1-fold increase). At higher concentrations (0.5 and 2 mM), 
growth on Met−Bpa and Bpa yielded similar levels of expression (1.4-fold increase at 
each concentration). Similar results were obtained for the F55TAG and Y193TAG mutants. 
Growth on dipeptide at 0.1 mM resulted in 2.4- and 2.0-fold increases in expression 
compared to growth on 0.1 mM Bpa for the F55TAG and Y193TAG mutants, respectively. 
At higher concentrations of peptide (0.5 mM and 2 mM), growth on Met−Bpa did not 
increase Ste2p expression when compared to the same concentration of Bpa. 
 
Cell-Surface Expression of Bpa Mutants Determined by Saturation Binding Assay 
 To characterize the cell-surface expression and binding affinity of the Ste2p Bpa 
mutants, DK102 cells expressing the F55TAG, G188TAG, and Y193TAG receptors were used 
in whole-cell binding assays. Binding of radiolabeled α factor was detected for cells 
expressing the WT receptor when cultured in either the presence or absence of Bpa. In 
experiments using the WT receptor, Bpa did not have any significant effect on the Bmax 
and binding affinity (Bmax = 152,470 ± 6900 receptors per cell, Kd = 9.7 ± 1.4 nM) when 
compared to cells cultured in the absence of Bpa (Bmax = 158,100 ± 6500 receptors per 
cell, Kd = 11.0 ± 1.0 nM). For the mutant receptors, binding was not detected for cells 
grown in the absence of Bpa (data not shown). However, for cells grown in the presence 
of Bpa, saturable binding was observed (Figure 2.6). The Bmax values for the mutants 
were reduced by 10−20-fold compared to the WT receptor (Figure 2.5), which is 
consistent with the low level of expression observed in the immunoblots (Figure 2.3). 
The binding affinity (Kd) of the Y193TAG and G188TAG mutants (12.8 ± 4.9 and 17.5 ± 5.7 
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nM, respectively) were similar to that for the WT receptor, indicating that substitution of 
Bpa for the endogenous amino acid at these positions did not affect the interaction of the 
ligand with the receptor. In contrast, for the F55TAG mutant, the binding affinity was 
reduced to 78.9 ± 46.1 nM, indicating that the substitution of Bpa for phenylalanine at 
this position affected ligand binding, which correlates to the relative low signaling 
activity of this receptor. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Whole cell saturation binding assay of [3H]α factor to WT Ste2p and 
Ste2p−TAG mutant receptors. Cells expressing the WT receptor and the indicated Bpa 
mutants were grown in the presence of 2 mM Bpa. (Inset) Saturation binding assay for 
TAG mutant receptors plotted on an expanded scale. The data represent specific binding 
to cells as determined by subtracting the binding to an isogenic strain lacking the receptor 
from binding to cells containing WT or mutant Ste2p. 
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MALDI−TOF Indicates that Bpa Is Incorporated into Ste2p at Position G188 
 To confirm the incorporation of Bpa into Ste2p, MALDI−TOF mass 
spectrometric analysis of purified WT and G188TAG receptors was performed. The 
G188TAG receptor was chosen for this analysis based on nearby naturally occurring 
methionine sites in Ste2p that would yield a small peptide (residues 181−189) upon 
CNBr cleavage to facilitate mass spectroscopy. The substitution of glycine (75.07 Da) for 
Bpa (269.30 Da) at position 188 should result in a mass shift of 194 Da in the 188Bpa-
containing peptide. To estimate purity and concentration of the samples prior to CNBr 
cleavage and MALDI−TOF analysis, Coomassie Blue and silver staining of SDS−PAGE 
gels was performed on the purified G188TAG and WT receptors. In the Coomassie-stained 
gel, only two bands, corresponding in molecular weight to the glycosylated and 
nonglycosylated forms of Ste2p (50−52 kDa), were observed. Using the more sensitive 
silver-staining technique on the same sample, the same two bands were detected, along 
with some very faint bands not corresponding to Ste2p. Immunoblot analysis confirmed 
that the two major bands were Ste2p (data not shown). After CNBr cleavage of WT and 
G188TAG receptors, we carried out a MALDI−TOF analysis of the peptide fragments 
generated, focusing on the molecular-weight region corresponding to the peptide with the 
putative Gly to Bpa substitution. Our analysis of the CNBr-cleaved WT and G188TAG 
receptors (Figure 2.7) revealed a mass shift from 954.154 Da in WT to 1146.46 Da in 
G188TAG, corresponding to a 192 Da increase. Other peaks of identical mass 
corresponding to CNBr fragments of Ste2p were observed in both the WT (1473.81 and 
1505.39 Da) and G188Bpa (1474.45 and 1506.19 Da) receptors. Some peaks not 
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corresponding to any of the theoretical masses of Ste2p CNBr fragments were also 
observed and are likely due to the degradation of Ste2p, which occurred during the 
overnight incubation at 37°C during CNBr cleavage, or the presence of other peptides in 
the preparation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 MALDI−TOF analysis of CNBr cleavage fragments of WT and G188TAG 
receptors. A peak (954.15 Da) corresponding to residues 181−189 (YFVSAVKGM) in 
the WT receptor was not present in the G188TAG receptor. The masses for the CNBr 
fragments indicated that the carboxyl-terminal methionine is converted to homoserine 
lactone. A new peak (1146.46 Da) corresponding to 181−189 with Bpa at position 188 
was detected. Other peaks corresponding to residues 55−69 and 166−180 were observed 
for both WT and G188TAG receptors.  
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Bpa at Positions F55 and Y193 Can Cross-link to the α-Factor Ligand 
 To determine if Bpa incorporated into Ste2p could be used to cross-link to and 
thus capture the α-pheromone, cells expressing the WT, F55TAG, G188TAG, and Y193TAG 
receptors as well as cells lacking Ste2p as a control were grown in the presence of Bpa. 
Membranes were prepared and incubated with or without [K7(biotinylamidocaproate)]α 
factor, an α factor analogue that contains biotin on the position seven lysine of the 
pheromone and binds to the receptor with high affinity (27). Cross-linking was also 
evaluated in the presence or absence of 100-fold excess nonbiotinylated α factor. After 
incubation, the membranes were exposed to UV light to activate capture of pheromone to 
the Bpa-labeled receptor. The membranes were fractionated by SDS−PAGE, blotted, and 
then probed with FLAG antibody to detect Ste2p (Figure 2.8A) or Neutravidin−HRP to 
detect biotinylated ligand (Figure 2.8B). WT receptor was expressed at levels higher than 
any of the mutant receptors (Figure 2.7A) as seen in previous experiments (Figure 2.3). 
When the immunoblots were probed with Neutravidin−HRP (Figure 2.8B), a distinct 
band was detected at the size expected for Ste2p in the F55TAG and Y193TAG receptors, 
indicating that the biotinylated α factor was cross-linked. Despite the fact that at least 20 
times as much WT Ste2p was expressed when compared to the F55TAG or Y193TAG 
receptors (Figure 2.8A), covalent labeling as detected with Neutravidin−HRP was 
significantly stronger for the mutants (Figure 2.8B). Moreover, labeling of the F55TAG 
and Y193TAG Bpa-containing receptors was reduced in the presence of excess 
nonbiotinylated α factor (Figure 2.8B) by 83 and 64%, respectively, as determined by 
quantitation of the band density. Similar results were observed in three independent 
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replicates of this experiment. For membranes prepared from cells lacking the receptor, as 
well as for the WT and the G188TAG receptors, a faint band at approximately 50 kDa was 
observed (Figure 2.8B) that was dependent upon incubation of the membranes with 
biotinylated pheromone. The signal was not affected by the presence of nonbiotinylated 
pheromone. Thus, this signal is the result of nonspecific association of the biotinylated 
pheromone with the membranes in a Ste2p-independent manner. 
 
 
 
 
 
 
 
 
Figure 2.8 Cross-linking of biotinylated α factor into Bpa-containing receptors. 
Membranes prepared from cells expressing the WT, F55TAG, G188TAG, and Y193TAG 
receptors grown in the presence of Bpa were incubated with [K7(biotinylamidocaproate), 
Nle12]α factor (1 µM) in the presence (+) or absence (−) of nonbiotinylated α factor (100 
µM). Membranes were also prepared from cells lacking the receptor as a negative 
control. (A) After photoactivation, membranes (2 µg for WT and 25 µg for mutants and 
the negative control) were immublotted and probed with FLAG antibody to detect Ste2p. 
(B) Membranes (25 µg for each lane) were immunoblotted and probed with 
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Neutravidin−HRP to detect biotinylated ligand. The arrow in both panels indicates the 
expected size for Ste2p. 
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Chapter 4 
Discussion 
Many experiments have been performed with a variety of methodologies to 
provide a wealth of knowledge concerning GPCR structure and function. However, an 
understanding of the mechanism of activation is still in its infancy. The gold standard 
would be to obtain crystal structures of the GPCR in both the resting and active state. 
Thus far, bovine rhodopsin and the human β-adrenergic receptor are the only GPCRs to 
have had their crystal structure solved (41-43). For rhodopsin, the receptor was 
crystallized in the inactive state, although recent reports of an active-state crystal at 
moderate to low resolution (2.7−5.5 Å) have been published (44). Crystallization of the 
β-adrenergic receptor required expression as a fusion protein (43) or interaction with an 
inverse agonist  (42) to stabilize receptor conformation. The use of unnatural amino acid 
replacement provides an alternate method for examining the receptor structure as well as 
exploring the changes that occur in GPCRs upon receptor activation. 
In an earlier study, a fluorescent amino acid was incorporated into a GPCR, the 
neurokinin-2 receptor, using heterologous expression in Xenopus oocytes (12). In this 
paper, we report the first evidence that an unnatural amino acid can be incorporated into 
the GPCR Ste2p expressed in its native environment in the yeast cell and still retain 
function. The incorporation was verified by mass spectrometry, and our studies indicate 
that, once incorporated, the photoactivatable Bpa in Ste2p can be used to covalently link 
the α-factor ligand to the receptor. Although there are many examples in the literature of 
photoactivated cross-linking of ligand to receptor, in all of those cases, the ligand 
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contained the photoactivatable moiety. To our knowledge, our study represents the first 
example of cross-linking of ligand to a GPCR in which the receptor contained the 
photoactivatable group used to “capture” the ligand. 
We demonstrated that incorporation of Bpa into both the F55 (located in TM1) 
and Y193 (located in EL2) receptors resulted in capture of biotinylated pheromone. 
Photochemical capture of the ligand could be largely inhibited by the presence of excess 
nonbiotinylated pheromone. While F55 is positioned in the binding pocket of the receptor 
and was expected to interact with the pheromone (27), the ability of Y193 to capture the 
ligand suggests a possible role for EL2 in ligand binding. Previous studies using domain 
swapping indicated that EL2 was not a determinant of ligand specificity of the S. 
cerevisiae and S. kluyveri α-factor receptors (45). Thus, our observation of a putative 
contact between the EL2 region of Ste2p and α factor indicates the need for further study 
of EL2−α-factor interactions. Because of the low level of protein expression, it was 
unclear whether the G188 receptor was functional with respect to ligand capture, despite 
the fact that this receptor was determined to contain Bpa by mass spectrometry analysis 
(Figure 2.7). Saturation binding analysis (Figure 2.6) indicated that the G188TAG receptor 
was expressed on the cell surface at levels comparable to that of the F55TAG receptor, in 
which we were able to detect cross-linking of the receptor to the pheromone. In this light, 
despite the low level of total protein expression observed on the immunoblot, it is likely 
that there is enough of the G188TAG receptor on the cell surface to allow for cross-linking 
if the pheromone has access to the Bpa residue. Previously published data using cysteine 
scanning of Ste2p indicated that G188 is between 25 and 50% exposed on the basis of the 
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reaction with sulfhydryl reagents (46); thus, it is accessible to the solvent. If the 
pheromone was interacting nonspecifically with the receptor or if residue G188 was 
involved in ligand binding, then Bpa at this position should have been able to capture 
ligand. 
In addition to ligand capture experiments, we can envision other applications of 
this mutagenesis methodology, such as studying changes in domain−domain interactions 
upon ligand binding, which will shed light on the receptor activation mechanism. An 
advantage of using the orthologous tRNA/aminoacyl-tRNA synthetase pair to incorporate 
Bpa into Ste2p in the yeast cell is that the GPCR remains in its native environment and is 
thus able to interact with downstream effector molecules, such as the heterotrimeric G-
proteins, thus making assessment of both ligand binding and signal transduction possible. 
Although the use of unnatural amino acids has the potential to answer very 
important questions in GPCR biology, there are still obstacles to overcome. In the 
experiments presented in this paper, eight mutant STE2 constructs (F55TAG, S107TAG, 
G115TAG, V127TAG, G188TAG, Y193TAG, F204TAG, and Y266TAG) were created with the 
amber TAG stop codon engineered at different sites within the open-reading frame. 
Theoretically, when the cells expressing these mutant receptors were grown in the 
presence of Bpa, the unnatural amino acid would be incorporated into the protein by the 
cognate tRNA/aminoacyl-tRNA synthetase also expressed in the cell. In the absence of 
Bpa, it was expected that the TAG codon would result in termination of protein synthesis, 
resulting in a truncated protein. For the mutants G188TAG and Y193TAG, this was the case; 
in the presence of Bpa, cells responded to pheromone (Figure 2.2) and full-length 
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receptor was detected by immunoblot analysis (Figure 2.3, 2.4) and both bound ligand 
(Figure 2.6) with near WT affinity. However, mutants with TAG amber stops at positions 
F55, S107, G115, V127, and F204 exhibited variable amounts of inefficient stop codon 
recognition or read-through expression, as evidence by the halo assay, which in the 
context of the present experiments results in the production of full-length protein even in 
the absence of Bpa. 
The efficiency with which nonsense codons, such as the UAG amber stop in 
mRNA, are suppressed can be affected by the context of the adjacent codons and poses a 
challenge (47). In S. cerevisiae, nucleotides within six bases flanking the stop codon can 
influence the efficiency of termination (48) and it has been determined that “backup” or 
tandem stop codons can be found three codons downstream of the authentic stop for some 
genes (49). In the case of read-through expression, noncognate tRNA species can misread 
the stop codon and insert an inappropriate amino acid. In the case of the UAG codon in 
yeast mRNA, the tRNAGln can insert glutamine at the stop codon when it is present in a 
context unfavorable for release-factor recognition (50). In another tRNA/aminoacyl-
tRNA synthetase system evolved to incorporate the fluorescent amino acid dansyl-alanine 
in response to the amber stop codon, read-through expression in the absence of dansyl-
alanine was eliminated by mutation of the aminoacyl-tRNA synthetase to increase 
selectivity of the enzyme for dansyl-alanine (18). Thus, to optimize the system for 
insertion of Bpa into Ste2p, genetic manipulations in protein translation machinery (i.e., 
ribosomes, tRNAs, etc.) might be warranted. 
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Interestingly, for the mutants F55TAG and F204TAG, protein function but not 
expression was eliminated when the cells were grown in the presence of Bpa (Figures 
2.2, 2.3, 2.4). This indicates that the unnatural amino acid was incorporated into the 
protein but did not result in a signal-transducing receptor at the cell surface. The presence 
of mutant Ste2p or other GPCRs that are expressed and bind ligand but do not signal has 
been extensively reported (3). Indeed, binding without signaling is characteristic of 
antagonists, and mutation of GPCRs to preferentially recognize antagonists has been 
documented (32, 33). 
Incorporation of Bpa into the various TAG mutant receptors was not 100% 
efficient, as can be seen by the presence of truncated receptors on immunoblots (Figure 
2.3B), which could potentially interfere with the function of a full-length receptor. 
However, previous studies showed that overexpression of 14 different truncated Ste2p 
receptors failed to produce any significant alteration in Ste2p function (51). Thus, the loss 
of signaling function (F55TAG and F204TAG) in the halo assays that we observed likely 
results from intolerance of Bpa at the positions into which it was inserted rather than to 
the interference by truncated receptors. 
Using the orthologous tRNA/aminoacyl-tRNA synthetase pairs to incorporate Bpa 
at the engineered amber stop codon requires the presence of Bpa in the cytoplasm at 
sufficient concentrations to allow for effective charging of the tRNA. We have used a 
novel means to supply Bpa to yeast cells via the di/tripeptide transport system that is 
common to many eukaryotes (52, 53). In yeast, di/tripeptides as well as oligopeptides 
(tetra/pentapeptides) are not cleaved outside the cell but are transported intact across the 
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plasma membrane (54). Expression of the Y193TAG receptor as well as the F55TAG and 
G188TAG receptors was noticeably greater when the cells were grown in the presence of 
Met−Bpa at 0.1 mM when compared to Bpa (Figure 2.5). Because peptide transporters 
are ubiquitous in living cells (53), this method might be used to enhance the delivery of 
unnatural amino acids and extend this approach to amino acids that cannot enter cells 
through amino acid permeases. 
In summary, in this paper, we provide evidence that the unnatural 
photoactivatable amino acid p-benzoyl-l-phenylalanine can be incorporated into a GPCR 
in its native cell. The Y193TAG mutant receptor responded to α factor and bound this 
ligand with nanomolar affinity. Other mutant receptors examined were expressed at the 
membrane at levels from 5 to 10% of the WT receptor under identical conditions. Mass 
spectrometry proved that Bpa was incorporated at the expected position for the G188TAG 
receptor. Expression could be increased when the unnatural amino acid was delivered as 
a dipeptide via the peptide transport system of S. cerevisiae. The enhancement of Bpa 
delivery as a dipeptide was most effective at low (0.1−0.5 mM) concentrations; at 2 mM, 
both dipeptide and Bpa were equally effective. Two Bpa-containing receptors were able 
to capture ligand after photoactivation, providing evidence for the utility of such labeled 
GPCRs to determine ligand−receptor interactions. These results set the stage for the use 
of unnatural amino acids technology in exploring the structure and function of integral 
membrane proteins in their native environment. 
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PART III 
Changes in Conformation at the Cytoplasmic Ends of the Fifth and 
Sixth Transmembrane Helices of a Yeast G Protein-Coupled Receptor 
in Response to Ligand Binding 
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Abstract for Part III 
The third intracellular loop (IL3) of G protein-coupled receptors (GPCRs) is an 
important contact domain between GPCRs and their G proteins. Previously, the IL3 of 
Ste2p, a Saccharomyces cerevisiae GPCR, was suggested to undergo a conformational 
change upon activation as detected by differential protease susceptibility in the presence 
and absence of ligand. In this study using disulfide cross-linking experiments we show 
that the Ste2p cytoplasmic ends of helix 5 (TM5) and helix 6 (TM6) that flank the amino 
and carboxyl sides of IL3 undergo conformational changes upon ligand binding, whereas 
the center of the IL3 loop does not. Single Cys substitution of residues in the middle of 
IL3 led to receptors that formed high levels of cross-linked Ste2p, whereas Cys 
substitution at the interface of IL3 and the contiguous cytoplasmic ends of TM5 and TM6 
resulted in minimal disulfide-mediated cross-linked receptor. The alternating pattern of 
residues involved in cross-linking suggested the presence of a 310 helix in the middle of 
IL3. Agonist (WHWLQLKPGQPNleY) induced Ste2p activation reduced cross-linking 
mediated by Cys substitutions at the cytoplasmic ends of TM5 and TM6 but not by 
residues in the middle of IL3. Thus, the cytoplasmic ends of TM5 and TM6 undergo 
conformational change upon ligand binding. An α-factor antagonist (des-Trp, des-His-α-
factor) did not influence disulfide-mediated Ste2p cross-linking, suggesting that the 
interaction of the N-terminus of α-factor with Ste2p is critical for inducing 
conformational changes at TM5 and TM6. We propose that the changes in conformation 
revealed for residues at the ends of TM5 and TM6 are affected by the presence of G 
protein but not G protein activation. This study provides new information about role of 
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specific residues of a GPCR in signal transduction and how peptide ligand binding 
activates the receptor. 
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Chapter 1 
Introduction 
  G protein-coupled receptors (GPCRs) are integral membrane proteins that are 
known to play important roles in cell communication by activating intracellular events 
through both G protein-dependent and -independent processes (1-3). These receptors are 
encoded by the largest gene family in mammals, constitute the main target of prescribed 
drugs, and represent promising targets for new drug development (1, 3-6). They are 
composed of seven transmembrane (TM) helical segments connected by intracellular and 
extracellular loops. The core region of the receptor containing the seven TMs has been 
found to be generally responsible for binding of small ligands, whereas peptide ligands 
often bind to the extracellular portions as well as the core of GPCRs (7, 8). In the 
classical model of ligand activation of a GPCR signal transduction pathway, the binding 
of an agonist to the receptor induces conformational changes in the TMs propagated to 
the cytoplasmic ends of a GPCR for G protein activation and transduction to various 
intracellular metabolic events (1, 9). 
The cytoplasmic surfaces of GPCRs contain multiple contact regions responsible 
for receptor coupling to signal transduction complexes. The most prominent domains in 
GPCRs for coupling are the second and third (IL3) intracellular loops as well as the C-
terminal tail and TM boundaries (1-3). Comparing the crystal structure of opsin and 
rhodopsin shows that the cytoplasmic end of TM6 is shifted outward from the center of 
the bundle relative to its position in the inactive state (rhodopsin) and is closer to TM5 in 
the active state (opsin) (10). Such movements have also been observed in other receptor 
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such as M3 and adrenergic receptors using disulfide cross-linking of Cys mutant 
receptors. In the M3 receptor, agonist binding increased the proximity between the 
cytoplasmic ends of TM5 and TM6. Possible TM6 rotational movements were also 
observed in the M3 receptor (11). 
Several studies have shown that peptide ligands bind GPCRs and occupy a pocket 
defined by side chains from extracellular loops and helices. The binding of the ligand 
induces changes at the extracellular surface of the receptor resulting in conformational 
changes at the cytoplasmic surfaces. These phenomena are believed to be critical for 
GPCR activation (2). An explosion of recent crystal structures of ligand-bound 
(activated) β1-adrenergic (12), β2-adrenergic (13), and A2a (14) receptors indicated major 
changes in the cytoplasmic ends of TM5 and TM6 as a result of receptor activation. 
Ste2p, the yeast Saccharomyces cerevisiae receptor for the pheromone α-factor, is 
believed to have a structure similar to that of mammalian GPCRs. The third intracellular 
loop of Ste2p has been shown to play an important role in signal transduction and is 
involved in Gpa1p (the S. cerevisiae Gα protein) activation (15-18). Analysis of the Ste2p 
IL3 demonstrated that IL3 becomes hypersensitive to proteolytic digestion with trypsin in 
response to ligand binding, indicating that IL3 undergoes a conformational change that is 
likely to be important for G protein activation(19), although specific residues that are 
involved in these conformational changes were not identified. The TM5 and TM6 that 
flank the IL3 have also been shown to interact with each other and have been suggested 
to play a critical role in signaling (20). It is important to note that the Gα protein of the 
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heteromeric G protein complex need not dissociate from Ste2p during receptor activation 
as indicated by the full activity of a Ste2p-Gpa1p fusion chimera (21). 
In this study, we have investigated IL3 and flanking TM5 and TM6 
conformational changes by determining the propensity for disulfide cross-linking 
between receptors carrying Cys substitutions. The IL3-Cys mutant receptors were 
observed to form dimers with the pattern of dimer formation, suggesting the presence of a 
310 helix in the middle of the IL3 loop. Addition of α-factor affected the levels of 
disulfide formation in Cys-substituted receptors in portions of TM5 and TM6 contiguous 
with IL3, implying that activation of Ste2p involved ligand-induced conformational 
changes in the cytoplasmic ends of TM5 and TM6. In contrast, disulfide formation 
involving residues in the middle of IL3 was not sensitive to ligand addition, indicating 
that residues in the IL3 loop do not change conformation or availability during receptor 
activation. The presence of an α-factor antagonist or a non-hydrolyzable GTP analogue 
did not influence the levels of disulfide-mediated dimerization, suggesting that receptor 
activation but not Gα activation was necessary for the observed conformational changes. 
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Chapter 2 
Material and Methods 
Media, Reagents, and Strains and Transformation 
Saccharomyces cerevisiae strain LM102 [MATa, bar1, leu2, trp1, ura3, FUS1-
lacZ::URA3, ste2Δ (22)] was used for Ste2p growth arrest and FUS1-lacZ assays. The 
protease-deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR (23)] and TM5117 [MATa, bar1, leu2, his3, ura3, FUS1-lacZ::URA3, ste2Δ, 
gpa1Δ (22)] were used for protein isolation and immunoblot analysis and disulfide cross-
linking. Plasmids coding for the STE2 mutants and GPA1 mutants were transformed by 
the method previously described (22) into LM102, TM5117, and BJS21 cells. 
Transformants were selected by growth on minimal medium (24) lacking tryptophan 
(designated as MLT) or lacking both tryptophan and uracil (designated as MLTU) to 
maintain selection for the plasmids. All media components were obtained from Becton-
Dickinson (Franklin Lakes, NJ). 
 
Cysteine Scanning Mutagenesis 
C-terminal FLAG and His-tagged STE2 with the two native cysteine residues 
(Cys59 and Cys252) substituted with serine and cloned into the plasmid p424-GPD (high 
copy plasmid) to yield plasmid pBEC2 (22) was used as the backbone for mutagenesis of 
Ste2p. The plasmid pBEC2 was engineered by site-directed mutagenesis to individually 
replace 30 residues in Ste2p (V224-Q253, see Figure 3.1) with cysteine as previously 
described (22). 
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Figure 3.1 Schematic diagram of Ste2p. Single cysteine at positions 224 to 253 (solid 
circles) were introduced into the IL3 region of the STE2 gene. The FLAG and His tags 
are underlined in the C-terminal tail. 
 
Membrane Extraction and Immunoblots 
BJS21 cells expressing STE2 and GPA1 constructs grown in their selective media 
were used to prepare total cell membranes isolated as previously described (25). Cells 
were harvested and lysed by agitation with glass beads in 700 μL of HEPES buffer (50 
mM HEPES, 150 mM NaCl, pH 7.5) and the following concentrations of protease 
inhibitors: 1.0 mM leupeptin,10 μM pepstatin A, and 5.0 mM phenylmethanesulfonyl 
fluoride. The lysate was cleared by centrifugation at 3000g for 2 min. The membrane 
fraction was harvested by centrifugation at 15000g for 30 min and was then resuspended 
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in the HEPES buffer with 20% glycerol. Protein concentration was determined by 
BioRad (BioRad, Hercules, CA) protein assay as previously described (22). For 
immunoblot analyses the membrane extract was solubilized in SDS sample buffer 
(BioRad, Hercules, CA), and 5 μg was fractioned by 10% SDS-PAGE. Blots were probed 
with FLAG antibody (Sigma/Aldrich Chemical, St. Louis, MO) to detect Ste2p. The 
signals generated were analyzed using Quantity One software (Version 4.5.1) on a 
Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA). The student’s t 
test was used to analyze differences in dimer formation (cross-linking) between 
pheromone treated and nontreated receptors. A probability of p ≤ 0.01 was regarded as 
statistically significant. Statistical analyses were performed with Prism (GraphPad 
Software, San Diego, CA). 
 
Growth Arrest Assays 
 LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at 
30°C in MLT, harvested by centrifugation, washed three times with water, and 
resuspended at a final concentration of 5 × 106 cells/mL according to previously 
described procedures (23). Cells (1 mL) were combined with 3.5 mL of agar noble 
(1.1%) and poured as a top agar lawn onto MLT medium agar plates. Filter disks 
(Whatman #1 paper) impregnated with α-factor pheromone (0.125–2.0 μg) were placed 
on the top agar. The plates were incubated at 30°C for 18 h and then observed for clear 
halos around the discs. The diameter of halos around the discs were measured, plotted as 
diameter versus pheromone amount, and analyzed by linear regression analysis using 
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Prism software (GraphPad Software, San Diego, CA) to determine the amount of 
pheromone that yielded a 15 mm halo. The experiment was repeated at least three times, 
and reported values represent the mean of these tests. 
 
Fus1-lacZ Assays 
LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants 
were grown at 30°C in selective media, harvested, washed three times with fresh media, 
and resuspended at a final concentration of 5 × 107 cells/mL. Cells (0.5 mL) were 
combined with α-factor pheromone (final concentration of 1 μM) and incubated at 30°C 
for 90 min. The cells were transferred to a 96-well flat-bottom plate in triplicates and 
permeabilized with 0.5% Triton X-100 in 25 mM PIPES buffer, and then β-galactosidase 
assays were carried out using fluorescein di-β-galactopyranoside (Molecular Probes, OR) 
as a substrate (26). The reaction mixtures were incubated at 37°C for 60 min, and 1.0 M 
Na2CO3 was added to stop the reaction. The fluorescence of the samples (excitation of 
485 nm and emission of 530 nM) was determined using a 96-well plate reader Synergy2 
(BioTek Instruments, Inc., Winooski, VT). The data were analyzed using Prism software 
(GraphPad Software, San Diego, CA). The experiments were repeated at least three 
times, and reported values represent the mean of these tests. 
 
Saturation Binding Assay 
Tritiated α-factor (9.3 Ci/mmol) was used in saturation binding assays on whole 
cells. LM102 cells expressing Ste2p Cys-less as the wild-type and mutants with the Cys 
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substitutions in IL3 (L228C, A229C, R233C, R234C, L248C, and I249C) were 
harvested, washed three times with YM1 [yeast minimum medium with 0.5 M potassium 
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium 
fluoride, and 1% BSA], and adjusted to a final concentration of 4 × 107 cells/mL in 
binding medium YM1i (YM1 plus protease inhibitors). Cells (630 μL) were combined 
with 70 μL of 10X YM1i supplemented with [3H]α-factor and incubated at room 
temperature for 30 min. The final concentration of [3H]α-factor ranged from 0.4× 10–9 to 
50 × 10–9 M. Upon completion of the incubation interval, 200 μL aliquots of the cell–
pheromone mixture were collected in triplicate and washed over glass fiber filter mats 
using the Standard Cell Harvester (Skatron Instruments, Sterling, VA). Retained 
radioactivity on the filter was counted by liquid scintillation spectroscopy. LM102 cells 
lacking Ste2p were used as a nonspecific binding control for the assays. Specific binding 
for each mutant receptor was calculated by subtracting the nonspecific values from those 
obtained for total binding. Specific binding data were analyzed by nonlinear regression 
analysis for single-site binding using Prism software (GraphPad Software, San Diego, 
CA) to determine the Kd (nM), and Bmax values (receptors/cell) for each mutant receptor 
were calculated. The final values represent the binding constants from at least three 
independent experiments. 
 
Binding Competition Assays 
This assay was performed using LM102 cells expressing C-terminal FLAG and 
His-tagged Ste2p. Tritiated [3H]-α-factor (10.2 Ci/mmol, 12 μM) prepared as previously 
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described (23, 27) was used in competition binding assays on whole cells. The cells were 
grown at 30°C in MLT, harvested, washed three times with YM1 [0.5 M potassium 
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium 
fluoride, and 1% BSA], and adjusted to a final concentration of 2 × 107 cells/mL in YM1 
plus protease inhibitors [YM1i (25)]. For the competition binding studies, cells (600 μL) 
were combined with 150 μL of ice-cold 5X YM1i supplemented with 6nM [3H]α-factor 
in the presence or absence α-factor or α-factor antagonist and incubated at room 
temperature for 30 min. The final concentrations of α-factor and α-factor antagonist 
varied from 0.5 × 10–10 to 1 × 10–6 M. After incubation, triplicate samples of 200 μL 
aliquots were filtered and washed over glass fiber filter mats using the Standard Cell 
Harvester (Skatron Instruments, Sterling, VA) and placed in scintillation vials. The 
radioactivity [3H] on the filter was counted by liquid scintillation spectroscopy. The 
binding data were analyzed by nonlinear regression analysis for one-site competition 
binding using Prism software (GraphPad Software, San Diego, CA) (28). The final values 
represent the binding constants from at least three independent experiments. 
 
Disulfide Cross-Linking 
Membrane proteins (in HEPES buffer, 20% glycerol) extracted from BJS21 cells 
expressing Ste2p mutants coexpressed with wild-type Gpa1p were treated with CuP (1.0 
μM Cu and 3.0 μM 1,10-phenanthroline) and incubated at room temperature for 30 min. 
The reaction was quenched by addition of EDTA (ethylenediaminetetraacetic acid) and 
NEM (N-ethylmaleimide) to final concentration of 10 mM. The cross-linked samples 
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were resuspended in nonreducing SDS sample buffer (BioRad, Hercules, CA) and 
resolved on 10% SDS-PAGE as described above. The disulfide reaction was reversed by 
reducing with 4% 2-mercaptoethanol (β-ME) in the SDS sample buffer before resolving 
it on SDS-PAGE. To investigate the effects of ligand or GTP-γ-S on cross-linking, 
membrane fractions were incubated in HEPES buffer containing 5 μM α-factor 
(WHWLQLKPGQPNleY) or 5 μM α-factor antagonist (desW,desH-α-factor = 
WLQLKPGQPNleY) in the presence or absence of 0.1 mM GTP-γ-S1 before CuP 
treatment. 
For in vivo (whole cell) cross-linking, cells were grown to mid-log phase, 
harvested, and washed with water by centrifugation (4000g for 5 min). The cells were 
resuspended in 100 mM LiAc and incubated at 30°C for 30 min with mixing. After 
centrifugation, the cells were resuspended in 25% PEG with 250 mM LiAc and incubated 
for 60 min to make them permeable to CuP. Cells were washed with HEPES buffer three 
times after LiAc treatment and then resuspended in YM1i buffer containing 5 μM α-
factor or α-factor-antagonist and incubated at room temperature for 30 min. Disulfide 
cross-linking was induced by adding CuP to final concentrations of 0.5 mM Cu and 1.5 
mM 1,10-phenanthroline as previously described for yeast whole cell cross-linking (29). 
The mixture was incubated at room temperature for 60 min with end-over-end mixing. 
EDTA and NEM to final concentrations of 10 mM were added to stop the reaction. The 
cells were washed three times with HEPES buffer containing EDTA (10 mM) and NEM 
(10 mM). Membrane extraction was carried as described above with HEPES buffer 
containing 10 mM EDTA/NEM. Reducing conditions of disulfide bond were carried out 
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by resuspending membrane samples in SDS-PAGE sample buffer containing 4% β-ME 
and incubating at room temperature for at least 15 min. To investigate the role of Gpa1p 
in the TM5-IL3-TM6 conformational changes, disulfide cross-linking of Cysless, L228C 
(TM5), L236 (IL3), and I249C (TM6) was carried out in a Gpa1p deleted strain, TM5117 
as described above. For the time course experiments, the CuP-mediated disulfide cross-
linking in BJS21 was terminated at the indicated time points by addition of EDTA and 
NEM to final concentrations of 10 mM. 
 
Prediction and Modeling 
All models of 3-D structures were generated by the Phyre Structural Bioinformatics 
Group prediction tools (30). The structures were viewed and labeled with the PyMOL 
pdb viewer software (DeLano Scientific LLC, Palo Alto, CA). 
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Chapter 3 
Results 
Phenotypes of Ste2p IL3 Cys Substitution Mutants 
The signaling activities of the cysteine mutants were examined by α-factor-
induced growth arrest and FUS1-lacZ induction assays. The growth arrest assay is a 
sensitive test that measures the ability of cells expressing Ste2p to maintain pheromone-
induced cell division arrest at the G1 phase over a 24–36 h time frame, whereas the 
FUS1-lacZ induction assay measures an early response of the yeast cell to pheromone. 
The strains used in this study contain a reporter gene construct consisting of a fusion 
between FUS1 promoter and the lacZ gene encoding the enzyme β-galactosidase (26). 
This allows for rapid, sensitive detection of mating pathway activation by assessing β-
galactosidase activity in response to mating pheromone. 
 The Cys-less Ste2p engineered as the background for the specific cysteine 
mutations has been shown to have biological activities identical to the wild-type receptor 
(22). In this study we grouped the IL3 residues into three categories based on their 
position as follows: group 1 (TM5-IL3 boundary) residues, V224–S232; group 2 (middle 
IL3) residues, R233–Q240; and group 3 (IL3-TM6 boundary) residues, F241–Q253 
(Figure 3.1). Substitution of single cysteine residues in intracellular loop 3 (IL3) of Cys-
less Ste2p resulted in constructs that were expressed and had biological activities 
identical or similar to that of the Cys-less receptor, except for K225C which was 
biologically inactive (see Table 3.1). The decreased sensitivity in biological assays 
caused by the K225C mutation has been observed in previous studies (31). 
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Table 3.1 Summary of Phenotypes of Ste2p IL3 Cys Substitution Mutantsa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aThe expression levels as measured by Western blots (Figures 3.3 and 3.6) and biological 
activities all had standard deviations between ±2 and ±5%. All assays were done at least 
three times independently. 
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Figure 3.2 Whole cell saturation binding assay of [3H]α-factor to Cysless and IL3 
Cys mutant receptors. A graph of CPM (count per minute of radioactivity of cells) 
versus the concentration of the [3H]α-factor is shown. The data represents specific 
binding to cells as determined by subtracting the binding to cells lacking the receptor 
from binding to cells containing the Ste2p Cys mutant receptors. Below the graph is a 
table containing a summary of the binding affinities (Kd) and surface expression of the 
receptors. 
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Receptor expression was measured by Western blot signals that were quantitated 
using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation 
system (BioRad, Hercules, CA). The Cys-less receptor signal was used as the measure of 
100% expression. In addition to quantitation of the Western blot signals, saturation 
binding assays were carried out on selected mutants (L228C and A229C) from the TM5–
IL3 boundary, (R233C and R234C) from the middle of IL3, and (L248C and I249C) from 
the IL3–TM6 boundary (Figure 3.2). The receptors showed almost equal Kd values for 
ligand binding, and receptors L228C, A229C, L248C, and I249C were expressed at levels 
within 12% of the Cys-less control, whereas R233C and R234C were expressed to about 
55–63% of control, as judged by Bmax values. 
 
IL3 Cys Mutants Form Dimers 
One of the most commonly used strategies to investigate GPCR agonist-induced 
conformational change is disulfide cross-linking involving cysteine-substituted mutant 
GPCRs. This approach involves determination of differences in disulfide formation 
between two receptor monomers containing Cys residues in the presence and absence of 
ligand (29, 32, 33). Ste2p predominates in SDS-PAGE as a monomer of about 50 kDa as 
noncovalent interactions between receptors are disrupted by the conditions of the SDS-
PAGE. As observed in many studies (8, 22), some SDS-resistant dimers persist in all 
lanes including that of the Cys-less receptor (Figure 3.3). We observed strong dimer 
formation in some of the IL3 Cys mutant receptors when treated with CuP. Compared to 
the Cys-less receptor, which showed little or no increase in the dimer band at 100 kDa 
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upon incubation of membranes with CuP, both the R233C and R234C receptors showed 
marked increases in the dimer band. This increase was completely (R234C) or almost 
completely (R233C) reversed by addition of β-ME, indicating the involvement of 
disulfide bonds in stabilization of the dimer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Ste2p IL3 Cys mutants form dimers. Membranes from various mutants 
were incubated with or without CuP in the presence or absence of α-factor as described in 
the Material and Methods. The membrane extracts were run on SDS-PAGE gels; the gels 
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were blotted and probed with anti-FLAG antibody to detect the presence of Ste2p at 
either the monomer (M) or dimer (D) positions. Each preparation was untreated (lanes −, 
−) or treated with CuP (lanes −, +) or with α-factor and CuP (lanes +, +). 
 
 Given that the disulfide cross-linking was observed with Ste2p(R233C) and 
Ste2p(R234C), a comprehensive examination of the cross-linking of Cys mutants in the 
IL3 region of the receptor was conducted. These experiments were done in the presence 
and absence of ligand in order to determine whether cross-linking changed during 
activation of the receptor (Figure 3.3). Examination of the ratio of dimer to monomer in 
the gels of all the IL3 Cys mutants showed that some mutants exhibited high levels of 
disulfide formation [e.g., Ste2p(L236C), group 2; Figure 3.3)], whereas others exhibited 
only a small increase in dimer content with the monomer remaining the predominant 
species (e.g., L228C, group 1; Figure 3.3). When treated with CuP in the absence of 
ligand, disulfide cross-linked receptor formation for the 22 single Cys mutants studied 
varied from 10% to 96% of the total Ste2p related bands (monomer plus dimer) (Figure 
3.3, compare lanes “– –”and “– +”). Group 1 (L228C–S232C) and group 3 (F241C–
I249C) residues displayed about 10–45% increase in disulfide formation upon incubation 
with CuP in the absence of ligand compared to the untreated receptor. In contrast, upon 
treatment with CuP in the absence of ligand group 2 (R233C–Q240C) mutants showed a 
greater increase (54–96%) in percent of cross-linked receptor. 
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Figure 3.4 Analyses of Ste2p dimerization in whole yeast cells. Cells expressing 
various Ste2p IL3 cysteine mutants were permeabilized and exposed to CuP. (A) Images 
of cells treated with various reagents used during the whole cell disulfide cross-linking 
CuP treatment. (B) Blots of seven IL3 Cys mutants selected for whole cell cross-linking 
evaluation. The samples were probed with anti-FLAG antibody to detect the presence of 
Ste2p at either the monomer (M) or dimer (D) positions. Each preparation was untreated 
(lanes −, −) or treated with β-ME (lanes −, +) or CuP (lanes +, −) or with CuP and β-ME 
(lanes +, +). (C) A graph comparing the percentage of the Ste2p mutant receptors that 
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formed cross-linked dimers in membrane preparations and whole cells. (D) Whole cells 
expressing receptors L228C and I249C were untreated or incubated with ligand prior to 
Cu–P treatments. The blots were probed with anti-FLAG antibody to detect the presence 
of Ste2p at either the monomer or dimer positions, respectively. Each preparation was 
untreated (lanes −, −) or treated with Cu–P (lanes −, +) or with α-factor and Cu–P (lanes 
α, +) or with α-factor antagonist and Cu–P (lanes a, +). 
 
The high degree of disulfide cross-linking found in some of the IL3 Cys mutants 
suggested that IL3 loops in two receptor subunits were within close proximity. However, 
we were concerned that some of these protein–protein interactions may have been 
artifacts related to the use of membranes. To determine whether disulfide formation was 
the same or different in whole cells in comparison to membrane preparations, an in vivo 
CuP treatment assay was performed. For this experiment we chose seven IL3 Cys 
mutants representing each group in IL3 and treated these receptors with CuP in live 
permeabilized cells (Figure 3.4). Microscopic observation (Figure 3.4A) showed that the 
cells were not morphologically affected by CuP treatment, and these treated cells were 
fully viable upon plating on growth media (data not shown). As was true with 
membranes, the disulfide formation catalyzed by CuP was reversed to various extents in 
the presence of β-ME (Figure 3.4B, +/+ lane). Comparison of the percent cross-linking in 
membranes and whole cells (Figure 3.4B, immunoblots, and Figure 3.4C, bar graph 
dimer/monomer ratio) showed that the trend for dimer formation in different IL3 mutants 
was similar in both preparations. Dimerization of some mutants was reduced or 
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disappeared upon α-factor addition; this together with the variations in the amount of 
dimerization among the Ste2p-IL3 Cys mutants observed in at least three independent 
experiments allows us to conclude that the dimer formation was reproducible and 
specific. 
 
Conformational Changes in TM5 and TM6 upon α-Factor Binding 
In previous studies it has been shown that binding of α-factor affected Ste2p 
dimer formation mediated through the TM regions, suggesting that these regions undergo 
conformational changes(29, 34, 35). We investigated whether incubation with α-factor 
would have any effect on CuP-mediated cross-linking of the IL3 mutants. While ligand 
binding had only a minor effect on disulfide formation in receptors carrying mutations in 
group 2 residues (Figure 3.3, R233C to Q240C, compare lanes “– +”and “+ +”), a 
reduction in cross-linking was observed for mutation near TM5 (I230C and R231C) and 
TM6 (F241C, S243C and H245C). Dimer formation was almost completely inhibited at 
boundaries between IL3 and TM5 (L228C and A229C) and TM6 (L247C, L248C, and 
I249C). The results suggest that α-factor binding induces conformational changes at the 
TM5 and TM6 cytoplasmic ends of Ste2p that change the availability of the Cys residues 
for chemical cross-linking, whereas in most of the IL3 loop the reactivity of these 
residues is not affected by ligand binding. We observed similar inhibition of cross-linking 
by α-factor in experiments using intact whole cells (Figure 3.4D). 
A graphical representation showing the pattern of cross-link formation of IL3 Cys 
mutants of Ste2p in the inactive (ligand unbound) and active (ligand bound) states is 
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presented in Figure 3.5A. Analysis of the time course of disulfide (dimer) formation 
(Figure 3.5B) showed that the TM5 (e.g., A228C) and TM6 (e.g., L248C) Ste2p mutants 
formed dimers with a half-maximal time of about 3 min, whereas residues in the middle 
of IL3 loop (e.g., F235C) exhibited half-maximal time of about 1.5 min. The slower 
dimer formation at the TM5 and TM6 extracellular ends may suggest that these residues 
are farther from each other compared to residues in the IL3 loop. It is clear from these 
time course studies that formation of dimer is complete by 30 min under these 
experimental conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Dimer formation in Ste2p IL3. (A) Relative amount (%) of IL3-mediated 
dimer formation in the presence and absence of pheromone. The graph was plotted from 
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three independent experimental values. (*) The differences between the mean values 
were statistically significant (P < 0.01). (B) Time course of dimer formation after CuP 
treatment of Ste2p mutants L228C (TM5), F235C (IL3), and L248C (TM6). Preparations 
were treated for the indicated time and then analyzed on Western blots for dimer 
formation. Results represent the average of four to five independent experiments. Error 
bars indicate the standard deviation. 
 
α-Factor Antagonist Did Not Induce Conformational Changes in TM5 and TM6 
Biochemical and cross-linking studies in our lab have shown that the N-terminus 
of α-factor is necessary for activation but not binding to Ste2p (36-38). Recently, we 
showed that Trp1 of α-factor interacts with Lys269 (TM6) of Ste2p (8). The question of 
whether receptor activation involving the N-terminus of α-factor is important for the 
changes in conformation at the cytoplasmic ends of TM5 and TM6 was investigated. 
Membrane samples containing TM5 (L228C, A229C, I230C) and TM6 (I246C, L247C, 
L248C, I249C) receptors were incubated with α-factor (WHWLQLKPGQPNle12Y) or an 
α-factor antagonist (desW1,desH2-WLQLKPGQPNle12Y) prior to Cu–P treatment. The 
results (Figure 3.6A, compare lanes label “α” and “a”) showed that, in contrast to the 
native α-factor, treatment with antagonist did not significantly change the percent of 
cross-linked product relative to that found in the unliganded receptor. Specifically for the 
L228, A229, I230 L247, L248, and I249 Cys mutant receptors the cross-link percentages 
for the unliganded and antagonist bound receptors were nearly identical, whereas 
minimal cross-linking was found in the presence of α-factor. We also examined 
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conformational changes in residues at positions 224–227 and 250–253 at the ends of the 
TM5 and TM6 helices, respectively. Dimer (disulfide bond) formation was observed in 
some residues (K225C, I227C, M250C, S251C, and Q253C) as shown in Figure 3.6B 
that were also affected by the presence of α-factor, suggesting that the cytoplasmic ends 
of the TM5/TM5 and TM6/TM6 helices in a dimeric receptor are indeed in very close 
proximity and that they participate in the conformational change associated with ligand 
binding. 
 
 
 
 
 
 
 
 
Figure 3.6 Effects α-factor antagonist on dimerization of TM5 and TM6 Cys 
mutants: (A) membranes from cells expressing Ste2p cysteine mutants at cytoplasmic 
ends of the helices and (B) membranes from cells expressing Ste2p cysteine mutants in 
helices that are suggested to be buried in the membrane were treated were incubated with 
CuP in the presence or absence of α-factor or α-factor antagonist as described in the 
Material and Methods. The membrane extracts were run on SDS-PAGE gels. The blots 
were probed with anti-FLAG antibody to detect the presence of Ste2p at either the 
 
 
91
monomer (M, 53–55 kDa) or dimer (D, 106–110 kDa) positions. Each preparation was 
untreated (lanes −, −) or treated with Cu–P (lanes −, +) or with α-factor and Cu–P (lanes 
α, +) or with α-factor antagonist and Cu–P (lanes a, +). 
 
GTP Did Not Affect Dimer Formation and Conformational Changes 
The recent crystal structure of opsin with the 11 C-terminal residues of the Gα 
protein led the authors to conclude that the active conformation of this GPCR was 
stabilized by its interaction with Gα (10). Another study also reported GTP may affect the 
interaction of receptor with Gα (39). We therefore determined whether the presence or 
the absence of GTP would affect disulfide formation observed in this study. We 
coexpressed the IL3 Cys mutants A228C and I249C with wild-type Gpa1p under the 
control of the same promoter in order to maintain equal level of the receptor and its Gα 
protein and repeated the Cu–P treatment in the presence of GTP-γ-S. The results (Figure 
3.7A) suggest that GTP-γ-S addition had no effect on the level of disulfide formation, 
indicating that Gα protein activation is not required for the observed conformational 
changes. In contrast, when cross-linking was carried out in a Gpa1p deleted strain (Figure 
3.7B), the level of disulfide formation in the presence of ligand was not significantly 
reduced at the TM5 and TM6 ends in comparison to that observed in the Gpa1p 
background (Figures 3.7A, 3.3, and 3.6A). 
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Figure 3.7 Effects of G protein expression and activation on TM5 and TM6 ligand 
induced conformational changes. (A) Whole cell membranes containing receptors 
A228C and I249C were treated with or without ligand in the presence or absence of 0.1 
mM GTP-γ-S prior to Cu–P treatments. The blots were probed with anti-FLAG antibody 
to detect the presence of Ste2p at either the monomer (M, 53–55 kDa) or dimer (D, 106–
110 kDa) positions. Each preparation was untreated (lanes −, −) or treated with Cu–P 
(lanes −, +) or with α-factor and Cu–P (lanes α, +) or with α-factor antagonist and Cu–P 
(lanes a, +). (B) Analyses of Ste2p dimerization in yeast cells (TM5117) devoid of Gα 
protein. Whole cell membranes containing Cysless, A228C, L236C, and I249C Ste2p, 
from cells lacking Gα were treated with or without ligand prior to Cu–P treatments. The 
blots were probed with anti-FLAG antibody to detect the presence of Ste2p at either the 
monomer or dimer positions. 
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Chapter 4 
Discussion 
 We have used disulfide cross-linking analysis to probe conformational changes 
of residues in the third intracellular loop (IL3) and the ends of the contiguous fifth (TM5) 
and sixth (TM6) transmembrane domains of Ste2p during ligand-induced activation. An 
assumption of this approach is that the cysteine mutations may act as surrogates of the 
native residues in Ste2p. Therefore, it is critical that the mutations not affect the activity 
of the receptor, its conformation, or its spatial relationships to other receptor molecules or 
interacting proteins. Several studies have reported that individual residue mutations in 
Ste2p IL3 did not significantly affect receptor activity (15-17). Consistent with previous 
studies (31), Ste2p with mutations in IL3 was observed to tolerate Cys substitutions in 
our experiments except for the K225C receptor. The tolerance for substitutions in IL3 
suggests that the contact points revealed in the cross-linking analysis likely exist in the 
native receptor and that activation of G protein by Ste2p involves multiple intermolecular 
interactions as observed for mammalian GPCRs (40, 41). 
Given that IL3 has been suggested to be involved in receptor-Gα protein (Ste2p–
Gpa1p) interactions (15-17), it is interesting that strong dimer formation occurred in the 
IL3 Cys mutants. This is consistent with the conclusion that IL3 in rhodopsin has been 
identified to play a role in receptor oligomerization (42-44). In addition, molecular 
dynamics simulations, correlated-mutation analysis, and evolutionary-trace analysis all 
predict the involvement of IL3 in GPCR dimerization (32). The dimer formations 
observed in our study were also detected in intact cells, indicating that the disulfide bond 
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formation between the two monomers of Ste2p occurs in the native environment of the 
receptor. Substitution cysteine accessibility studies on Ste2p-IL3 residues suggested all 
the residues, L228–I249, were accessible, and even though residues I246C and L247C 
were about 2-fold more accessible than most IL3 (R233–Q240) residues (31), in our 
study when treated with CuP these residues (I246C, L247C) exhibited only 22–30% 
dimer formation compared to the 54–96% dimer formation found for residues R233C–
Q240C. In addition, though K225C, I227C, M250C, S251C, and Q253C at the 
cytoplasmic ends of the TM5 and TM6 helices have been shown to be buried in the 
membrane and not solvent accessible (31), we observed disulfide formation involving 
these residues that was reduced by the presence of α-factor, suggesting that the 
cytoplasmic ends of the TM5/TM5 and TM6/TM6 helices in the inactive state of Ste2p 
are in closer proximity than when activated by ligand. The differences in the results of the 
cysteine accessibility and disulfide cross-linking studies of Ste2p IL3 cysteine mutants 
suggest that the cross-linking (dimer formation) that we observed is not due to the fact 
that these residues are accessible and randomly cross-linking. Rather, we suggest that 
these results indicate that specific residues in the IL3 region are in positions and 
orientations that permit disulfide bond formation while others are not, irrespective of 
their accessibility. 
The IL3 of Ste2p has been suggested to have the potential to form an α-helix with 
a distinct amphipathic character (45). The pattern of disulfide formation in our study, 
with R233C, L236C, and K239C mutant receptors having the highest percent of disulfide 
formation (Figures 3.3 and 3.5), suggests that the group 2 residues in IL3 (R233–Q240) 
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may form a 310 helix as shown in Figure 3.8A. The Phyre structural bioinformatics group 
tools (30) also predicted a 310 helix in the 3-D structure of IL3 (Figure 3.8B) consistent 
with our cross-linking studies. The IL3 310 helix (RRFLGLKQ) is highly positively 
charged. It might be expected that in the wild-type Ste2p dimer there should be charge 
repulsion between IL3 loop residues in the two Ste2p monomers. However, in the 
mutants studied herein the data strongly suggest that the substituted Cys residues are 
close enough to effectively form disulfide bonds. One might suggest that the Cys 
substitution alone changes the physical chemical characteristics of the loop leading to 
non-native interactions. However, the L236C mutant still contains all three positive 
residues (R233, R234, and K239) yet is capable of forming about 95% dimer, indicating 
that the IL3 residues in the dimeric receptor are indeed in very close proximity. We 
conclude that in native dimers of Ste2p the IL3 residues are close enough to make 
contacts that can be captured in disulfide cross-linking experiments. As pointed out by 
others, the interpretation of such dimers in terms of receptor function must be tempered 
by the possible changes in the monomer–dimer equilibrium that are effected by chemical 
cross-linking (29, 35). 
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Figure 3.8 Helical wheel projections and 3D model of IL3 residues involved in 
Ste2p–Ste2p interactions. (A) The IL3 residues R233 to Q240 are suggested to form a 
310 helix structure with a periodicity of 3.2 residues per turn in the helical wheel (46). (B) 
The 3D structure of two Ste2p molecules showing regions TM5, TM6, and IL3 with a 
310 helix in IL3 as predicted by the Phyre Structural Bioinformatics Group prediction 
tools (30). The IL3 310 helixes of two Ste2p subunits are suggested to be in close 
proximity that permit disulfide cross-linking. (C) A schematic diagram showing possible 
shifts at the cytoplasmic ends of TM5 and TM6 upon ligand binding. The vertical arrows 
indicate a shift of the TMs away from each other. 
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A previous study used limited trypsin digestion of Ste2p to identify 
conformational changes induced by the binding of α-factor. The presence of α-factor 
caused the third intracellular loop of the receptor to become more accessible to trypsin, 
suggesting that α-factor binding to Ste2p-induced conformational changes of IL3 (19). 
However, specific residues or regions of the IL3 involved in such changes were not 
identified. As judged by their availability to form disulfide cross-links, our data suggest 
that the residues in the middle of IL3 do not undergo conformational change, whereas the 
residues at the TM5–IL3 and IL3–TM6 boundaries do, leading to a change in their 
availability for disulfide formation. 
The recent crystal structure of chemokine receptor, CXCR4, in the dimer form 
suggests that the monomers interact only at the extracellular side of helices TM5 and 
TM6 to play an important role in stabilizing the dimeric receptor (7). Our results suggest 
that Ste2p TM5/TM5 and TM6/TM6 interact at the cytoplasmic ends. We propose that 
the Ste2p residues in TM5 (K225, I227, L228, A229, I230) and in TM6 (L247, L248, 
I249, S251, and Q253) at the cytoplasmic ends may be involved in Ste2p–Ste2p 
interactions. Such interactions are disrupted upon ligand binding as shown by the 
disappearance or reduction of disulfide-mediated dimerization of the various Cys mutants 
in the presence of α-factor. The α-factor induced similar changes in the cross-linking of 
the various receptors in intact whole cells (Figure 3.4D). Since in this latter experiment α-
factor should only bind to the receptors at the cell surface (at the plasma membrane), the 
results suggest that the changes at the TM5 and TM6 cytoplasmic ends found in disulfide 
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cross-linking experiments reflect the native state of these receptors. Disulfide cross-
linking efficiencies reflect both the spatial proximity of the sulfhydryl groups and their 
mobility. Thus, changes in conformation at the ends of TM5 and TM6 upon α-factor 
induced Ste2p activation can be inferred from the data. Another possibility is that α-
factor activation changes the flexibility of these regions of Ste2p. A model consistent 
with our experimental data would have the TM5 and TM6 ends of a Ste2p dimer shift 
away from each other so that it is not possible to form a disulfide bond as shown in 
Figure 3.8C. A similar reorientation of TM5 and TM6 has been proposed for activated 
forms of mammalian GPCRs (11, 47-49) and shown recently in a series of X-ray 
crystallographic studies (12-14, 50). Antagonist-bond dopamine receptor also showed 
reorientation of TM regions (50). 
It is possible that the 100 kDa band observed in the gels represents interaction of 
Ste2p with some protein other than itself. The fact that all Ste2p Cys mutants we 
examined form this band makes this possibility highly unlikely. In addition, a number of 
papers (8, 22, 23, 29, 35, 51-54) showed that Ste2p labeled by a variety of epitopes 
(FLAG, MYC, RHO) react with antibodies to these epitopes at positions in the gels that 
correspond to the molecular weight of a dimer of Ste2p. The antibodies react with no 
other bands except proteins at the Ste2p dimer or monomer position in these SDS-PAGE 
immunoblots. Similar results are obtained with an antibody generated against the N-
terminus of Ste2p. Furthermore, purified Ste2p confirmed by MALDI-TOF and 
nanospray MS exhibits a 100 kDa at the same position we have attributed to the Ste2p 
dimer (55). Most importantly, the major conclusion of this paper is that the results 
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indicate that the cytoplasmic ends of TM5 and TM6 undergo conformational change 
upon ligand binding. This conclusion would remain even if there were a second partner. 
At the TM6 cytoplasmic end, residues L247, L248 I249, M250, S251, and Q253 all 
formed about 10–20% Ste2p-Ste2p dimers; however, in the presence of ligand the 
percent of Ste2p–Ste2p dimer is greatly reduced, and residues L247C and I249C interact 
with Gpa1p (Umanah, unpublished). The switch of L247C and I249C from involvement 
in Ste2p–Ste2p interaction in the inactive state to Ste2p–Gpa1p heterodimer interactions 
in the active state would be consistent with a clockwise rotation of this region of the 
receptor as observed in other mammalian GPCRs (11, 47-49). In the inactive state the 
TM5 cytoplasmic ends residues K225, I227, L228, A229, and I230 also formed about 
10–15% Ste2p–Ste2p homodimers, and in the presence of ligand, these residues 
displayed reduced Ste2p–Ste2p homodimer formation and L228C formed a Ste2p–Gpa1p 
heterodimer (Umanah, unpublished). We therefore propose that the TM5 cytoplasmic end 
undergoes a counterclockwise rotation as observed in other GPCRs (56). 
Previously, we showed that Ste2p Tyr266 (on the extracellular end of TM6) 
interacted with Asn205 (on the extracellular end of TM5) only in the active conformation 
of the receptor (57), suggesting that these extracellular regions of the Ste2p TM5 and 
TM6 undergo conformational changes upon α-factor binding. Thus, our cross-linking 
results would support a model where binding of α-factor to Ste2p leads to conformational 
changes at the extracellular regions of TM5 and TM6 which are propagated to the 
cytoplasmic ends of these helices and result in exposure of L247C, L248, and I249C for 
activation of Gα. 
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The N-terminus of α-factor pheromone has been suggested to interact with Ste2p 
residues, S251–M294 which comprises part of TM6, the third extracellular loop, and part 
of TM7 (36-38). Recently, we show that Trp1 of α-factor interacts with K269 located at 
the extracellular boundary of TM6 (8). Previous studies showed that the α-factor 
antagonist was capable of competing out α-factor binding to Ste2p but did not exhibit 
measurable biological activities, suggesting that the interactions of the first two amino 
acids of α-factor with residues at extracellular regions of Ste2p TM5/TM6 are critical for 
receptor activation. The experiments presented in this study suggest that the antagonist 
was not able to block or reduce disulfide formation compared to the native α-factor, 
implying that antagonist binding to Ste2p does not induce the conformational changes or 
changes in flexibility at the TM5 and TM6 cytoplasmic ends. 
It has been shown that the exchange of GDP for GTP in Gα proteins during receptor 
activation is induced by interactions of Gα with the receptor during activation and also 
that GTP binding to Gα may affect ligand affinity for its GPCR (1). The addition of GTP-
γ-S to membrane fractions prior to CuP treatment to induce disulfide cross-linking did 
not have any observable effects on dimer formation though Ste2p and Gpa1p were 
expressed under the same promoter. Cross-linking carried out in a Gpa1p deleted strain 
was not affected by a large excess of agonist, suggesting that Gpa1p–Ste2p interactions 
may influence conformational changes or changes in side chain flexibility at the 
cytoplasmic ends of TM5 and TM6. We conclude that the putative conformational 
changes at the cytoplasmic ends of TM5 and TM6 in Ste2p require interactions of the N-
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terminal amino residues of α-factor and are affected by the interactions with Gα, but not 
by Gα activation. 
In conclusion, we show for the first time changes in receptor conformation or 
flexibility that influence the availability for disulfide formation of residues in the region 
of IL3 of Ste2p close to the contiguous TM5 and TM6 helices. The hydrophilic residues 
located in the middle of the IL3 loop (R231–Q240) do not change 
conformation/availability during receptor activation, whereas many hydrophobic residues 
at the TM5 and TM6 cytoplasmic junctions do. These conformational changes require 
ligand-induced activation of Ste2p and appear to depend on Ste2p–Gα protein 
interactions. The pattern of disulfide formation observed is consistent with a 310 helical 
structure in the center of IL3 and suggests that the IL3 loop of two Ste2p subunits remain 
in close proximity both in the active and inactive states of the receptors. Since Ste2p has 
been shown to have structure–function relationships similar to the physiologically and 
pharmacologically important rhodopsin-like GPCR family (58), the role of IL3 observed 
in this study has implications not only for Ste2p but also other GPCR systems. 
 
 
102
References for Part III 
1. Ratnala, V. R., and Kobilka, B. (2009) Understanding the ligand-receptor-G 
protein ternary complex for GPCR drug discovery, Methods Mol Biol 552, 67-77. 
2. Rosenbaum, D. M., Rasmussen, S. G., and Kobilka, B. K. (2009) The structure 
and function of G-protein-coupled receptors, Nature 459, 356-363. 
3. Williams, C., and Hill, S. J. (2009) GPCR signaling: understanding the pathway 
to successful drug discovery, Methods Mol Biol 552, 39-50. 
4. Panetta, R., and Greenwood, M. T. (2008) Physiological relevance of GPCR 
oligomerization and its impact on drug discovery, Drug discovery today 13, 1059-
1066. 
5. De Amici, M., Dallanoce, C., Holzgrabe, U., Trankle, C., and Mohr, K. (2010) 
Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive 
therapeutic opportunities, Medicinal research reviews 30, 463-549. 
6. Lundstrom, K. (2009) An overview on GPCRs and drug discovery: structure-
based drug design and structural biology on GPCRs, Methods Mol Biol 552, 51-
66. 
7. Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., 
Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, 
V., and Stevens, R. C. (2010) Structures of the CXCR4 chemokine GPCR with 
small-molecule and cyclic peptide antagonists, Science 330, 1066-1071. 
8. Umanah, G. K., Huang, L., Ding, F. X., Arshava, B., Farley, A. R., Link, A. J., 
Naider, F., and Becker, J. M. (2010) Identification of residue-to-residue contact 
 
 
103
between a peptide ligand and its G protein-coupled receptor using periodate-
mediated dihydroxyphenylalanine cross-linking and mass spectrometry, The 
Journal of biological chemistry 285, 39425-39436. 
9. Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., 
Mazzoni, M. R., and Hamm, H. E. (2003) Insights into G protein structure, 
function, and regulation, Endocrine reviews 24, 765-781. 
10. Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauss, N., Choe, H. W., 
Hofmann, K. P., and Ernst, O. P. (2008) Crystal structure of opsin in its G-
protein-interacting conformation, Nature 455, 497-502. 
11. Wess, J., Han, S. J., Kim, S. K., Jacobson, K. A., and Li, J. H. (2008) 
Conformational changes involved in G-protein-coupled-receptor activation, 
Trends in pharmacological sciences 29, 616-625. 
12. Warne, T., Moukhametzianov, R., Baker, J. G., Nehme, R., Edwards, P. C., 
Leslie, A. G., Schertler, G. F., and Tate, C. G. (2011) The structural basis for 
agonist and partial agonist action on a beta(1)-adrenergic receptor, Nature 469, 
241-244. 
13. Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., Arlow, D. H., 
Rasmussen, S. G., Choi, H. J., Devree, B. T., Sunahara, R. K., Chae, P. S., 
Gellman, S. H., Dror, R. O., Shaw, D. E., Weis, W. I., Caffrey, M., Gmeiner, P., 
and Kobilka, B. K. (2011) Structure and function of an irreversible agonist-
beta(2) adrenoceptor complex, Nature 469, 236-240. 
 
 
104
14. Xu, F., Wu, H., Katritch, V., Han, G. W., Jacobson, K. A., Gao, Z. G., Cherezov, 
V., and Stevens, R. C. (2011) Structure of an agonist-bound human A2A 
adenosine receptor, Science 332, 322-327. 
15. Clark, C. D., Palzkill, T., and Botstein, D. (1994) Systematic mutagenesis of the 
yeast mating pheromone receptor third intracellular loop, The Journal of 
biological chemistry 269, 8831-8841. 
16. Stefan, C. J., and Blumer, K. J. (1994) The third cytoplasmic loop of a yeast G-
protein-coupled receptor controls pathway activation, ligand discrimination, and 
receptor internalization, Molecular and cellular biology 14, 3339-3349. 
17. Celic, A., Martin, N. P., Son, C. D., Becker, J. M., Naider, F., and Dumont, M. E. 
(2003) Sequences in the intracellular loops of the yeast pheromone receptor Ste2p 
required for G protein activation, Biochemistry 42, 3004-3017. 
18. Gladue, D. P., and Konopka, J. B. (2008) Scanning mutagenesis of regions in the 
Galpha protein Gpa1 that are predicted to interact with yeast mating pheromone 
receptors, FEMS yeast research 8, 71-80. 
19. Bukusoglu, G., and Jenness, D. D. (1996) Agonist-specific conformational 
changes in the yeast alpha-factor pheromone receptor, Molecular and cellular 
biology 16, 4818-4823. 
20. Dube, P., DeCostanzo, A., and Konopka, J. B. (2000) Interaction between 
transmembrane domains five and six of the alpha -factor receptor, The Journal of 
biological chemistry 275, 26492-26499. 
 
 
105
21. Medici, R., Bianchi, E., Di Segni, G., and Tocchini-Valentini, G. P. (1997) 
Efficient signal transduction by a chimeric yeast-mammalian G protein alpha 
subunit Gpa1-Gsalpha covalently fused to the yeast receptor Ste2, The EMBO 
journal 16, 7241-7249. 
22. Hauser, M., Kauffman, S., Lee, B. K., Naider, F., and Becker, J. M. (2007) The 
first extracellular loop of the Saccharomyces cerevisiae G protein-coupled 
receptor Ste2p undergoes a conformational change upon ligand binding, The 
Journal of biological chemistry 282, 10387-10397. 
23. Huang, L. Y., Umanah, G., Hauser, M., Son, C., Arshava, B., Naider, F., and 
Becker, J. M. (2008) Unnatural amino acid replacement in a yeast G protein-
coupled receptor in its native environment, Biochemistry 47, 5638-5648. 
24. Tsevat, J., Sherman, S. N., McElwee, J. A., Mandell, K. L., Simbartl, L. A., 
Sonnenberg, F. A., and Fowler, F. J., Jr. (1999) The will to live among HIV-
infected patients, Annals of internal medicine 131, 194-198. 
25. David, N. E., Gee, M., Andersen, B., Naider, F., Thorner, J., and Stevens, R. C. 
(1997) Expression and purification of the Saccharomyces cerevisiae alpha-factor 
receptor (Ste2p), a 7-transmembrane-segment G protein-coupled receptor, The 
Journal of biological chemistry 272, 15553-15561. 
26. Trueheart, J., Boeke, J. D., and Fink, G. R. (1987) Two genes required for cell 
fusion during yeast conjugation: evidence for a pheromone-induced surface 
protein, Molecular and cellular biology 7, 2316-2328. 
 
 
106
27. Raths, S. K., Naider, F., and Becker, J. M. (1988) Peptide analogues compete with 
the binding of alpha-factor to its receptor in Saccharomyces cerevisiae, The 
Journal of biological chemistry 263, 17333-17341. 
28. Lee, B. K., Khare, S., Naider, F., and Becker, J. M. (2001) Identification of 
residues of the Saccharomyces cerevisiae G protein-coupled receptor contributing 
to alpha-factor pheromone binding, The Journal of biological chemistry 276, 
37950-37961. 
29. Wang, H. X., and Konopka, J. B. (2009) Identification of amino acids at two 
dimer interface regions of the alpha-factor receptor (Ste2), Biochemistry 48, 7132-
7139. 
30. Kelley, L. A., and Sternberg, M. J. (2009) Protein structure prediction on the 
Web: a case study using the Phyre server, Nature protocols 4, 363-371. 
31. Choi, Y., and Konopka, J. B. (2006) Accessibility of cysteine residues substituted 
into the cytoplasmic regions of the alpha-factor receptor identifies the intracellular 
residues that are available for G protein interaction, Biochemistry 45, 15310-
15317. 
32. Bouvier, M. (2001) Oligomerization of G-protein-coupled transmitter receptors, 
Nature reviews. Neuroscience 2, 274-286. 
33. Park, P. S., Filipek, S., Wells, J. W., and Palczewski, K. (2004) Oligomerization 
of G protein-coupled receptors: past, present, and future, Biochemistry 43, 15643-
15656. 
 
 
107
34. Overton, M. C., and Blumer, K. J. (2002) The extracellular N-terminal domain 
and transmembrane domains 1 and 2 mediate oligomerization of a yeast G 
protein-coupled receptor, The Journal of biological chemistry 277, 41463-41472. 
35. Kim, H., Lee, B. K., Naider, F., and Becker, J. M. (2009) Identification of specific 
transmembrane residues and ligand-induced interface changes involved in homo-
dimer formation of a yeast G protein-coupled receptor, Biochemistry 48, 10976-
10987. 
36. Eriotou-Bargiota, E., Xue, C. B., Naider, F., and Becker, J. M. (1992) 
Antagonistic and synergistic peptide analogues of the tridecapeptide mating 
pheromone of Saccharomyces cerevisiae, Biochemistry 31, 551-557. 
37. Henry, L. K., Khare, S., Son, C., Babu, V. V., Naider, F., and Becker, J. M. 
(2002) Identification of a contact region between the tridecapeptide alpha-factor 
mating pheromone of Saccharomyces cerevisiae and its G protein-coupled 
receptor by photoaffinity labeling, Biochemistry 41, 6128-6139. 
38. Son, C. D., Sargsyan, H., Hurst, G. B., Naider, F., and Becker, J. M. (2005) 
Analysis of ligand-receptor cross-linked fragments by mass spectrometry, The 
journal of peptide research : official journal of the American Peptide Society 65, 
418-426. 
39. Smith, B., Hill, C., Godfrey, E. L., Rand, D., van den Berg, H., Thornton, S., 
Hodgkin, M., Davey, J., and Ladds, G. (2009) Dual positive and negative 
regulation of GPCR signaling by GTP hydrolysis, Cellular signalling 21, 1151-
1160. 
 
 
108
40. Slessareva, J. E., Ma, H., Depree, K. M., Flood, L. A., Bae, H., Cabrera-Vera, T. 
M., Hamm, H. E., and Graber, S. G. (2003) Closely related G-protein-coupled 
receptors use multiple and distinct domains on G-protein alpha-subunits for 
selective coupling, The Journal of biological chemistry 278, 50530-50536. 
41. Kristiansen, K. (2004) Molecular mechanisms of ligand binding, signaling, and 
regulation within the superfamily of G-protein-coupled receptors: molecular 
modeling and mutagenesis approaches to receptor structure and function, 
Pharmacology & therapeutics 103, 21-80. 
42. Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A., Engel, A., and Palczewski, 
K. (2003) Atomic-force microscopy: Rhodopsin dimers in native disc membranes, 
Nature 421, 127-128. 
43. Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D. A., Palczewski, K., and Engel, 
A. (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in 
native membranes, The Journal of biological chemistry 278, 21655-21662. 
44. Filizola, M., Wang, S. X., and Weinstein, H. (2006) Dynamic models of G-
protein coupled receptor dimers: indications of asymmetry in the rhodopsin dimer 
from molecular dynamics simulations in a POPC bilayer, Journal of computer-
aided molecular design 20, 405-416. 
45. Blumer, K. J., and Thorner, J. (1991) Receptor-G protein signaling in yeast, 
Annual review of physiology 53, 37-57. 
46. Kim, S., and Cross, T. A. (2004) 2D solid state NMR spectral simulation of 3(10), 
alpha, and pi-helices, J Magn Reson 168, 187-193. 
 
 
109
47. Bhattacharya, S., Hall, S. E., and Vaidehi, N. (2008) Agonist-induced 
conformational changes in bovine rhodopsin: insight into activation of G-protein-
coupled receptors, Journal of molecular biology 382, 539-555. 
48. Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, 
J. R., Ijzerman, A. P., and Stevens, R. C. (2008) The 2.6 angstrom crystal 
structure of a human A2A adenosine receptor bound to an antagonist, Science 
322, 1211-1217. 
49. Ludeke, S., Mahalingam, M., and Vogel, R. (2009) Rhodopsin activation switches 
in a native membrane environment, Photochemistry and photobiology 85, 437-
441. 
50. Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., 
Newman, A. H., Javitch, J. A., Cherezov, V., and Stevens, R. C. (2010) Structure 
of the human dopamine D3 receptor in complex with a D2/D3 selective 
antagonist, Science 330, 1091-1095. 
51. Blumer, K. J., Reneke, J. E., and Thorner, J. (1988) The STE2 gene product is the 
ligand-binding component of the alpha-factor receptor of Saccharomyces 
cerevisiae, The Journal of biological chemistry 263, 10836-10842. 
52. Konopka, J. B., Jenness, D. D., and Hartwell, L. H. (1988) The C-terminus of the 
S. cerevisiae alpha-pheromone receptor mediates an adaptive response to 
pheromone, Cell 54, 609-620. 
 
 
110
53. Yesilaltay, A., and Jenness, D. D. (2000) Homo-oligomeric complexes of the 
yeast alpha-factor pheromone receptor are functional units of endocytosis, 
Molecular biology of the cell 11, 2873-2884. 
54. Shi, C., Shin, Y. O., Hanson, J., Cass, B., Loewen, M. C., and Durocher, Y. 
(2005) Purification and characterization of a recombinant G-protein-coupled 
receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 
EBNA1 cells, Biochemistry 44, 15705-15714. 
55. Lee, B. K., Jung, K. S., Son, C., Kim, H., VerBerkmoes, N. C., Arshava, B., 
Naider, F., and Becker, J. M. (2007) Affinity purification and characterization of a 
G-protein coupled receptor, Saccharomyces cerevisiae Ste2p, Protein expression 
and purification 56, 62-71. 
56. Domazet, I., Martin, S. S., Holleran, B. J., Morin, M. E., Lacasse, P., Lavigne, P., 
Escher, E., Leduc, R., and Guillemette, G. (2009) The fifth transmembrane 
domain of angiotensin II Type 1 receptor participates in the formation of the 
ligand-binding pocket and undergoes a counterclockwise rotation upon receptor 
activation, The Journal of biological chemistry 284, 31953-31961. 
57. Lee, Y. H., Naider, F., and Becker, J. M. (2006) Interacting residues in an 
activated state of a G protein-coupled receptor, The Journal of biological 
chemistry 281, 2263-2272. 
58. Eilers, M., Hornak, V., Smith, S. O., and Konopka, J. B. (2005) Comparison of 
class A and D G protein-coupled receptors: common features in structure and 
activation, Biochemistry 44, 8959-8975. 
 
 
111
 
 
 
 
 
 
 
PART IV 
Residue-to-Residue Interactions Between a G Protein-Coupled Receptor 
(GPCR) and its Gα Protein in the Saccharomyces cerevisiae Model 
System 
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Part IV presents collaborative work with Dr. Fred Naider’s laboratory at the City 
University of New York, Staten Island. Li-Yin Huang and George K. E. Umanah 
performed most the work, Julie Maccarone assisted with the phenotypes of the Gpa1p 
mutants and the peptides used were obtained from Dr. Naider’s laboratory. 
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Abstract for Part IV 
 Understanding the interactions between G protein-coupled receptors (GPCRs) and 
their cognate Gα proteins is an important goal for drug discovery as interference or 
enhancement of this interaction will directly modify signal transduction. Ste2p, the 
GPCR for the tridecapeptide pheromone α-factor of Saccharomyces cerevisiae, has been 
used extensively as a model for investigating GPCR structure and function as Ste2p has 
structure-function relationships similar to mammalian GPCRs. Using cysteine disulfide 
cross-linking we have identified specific residue-to-residue interactions between Ste2p 
and Gpa1p, its Gα protein. Using combinatorial expression and assay of 242 Ste2p and 
Gpa1p cysteine mutants, five Ste2p residues located at the cytoplasmic ends of the fifth 
and sixth transmembrane domains were identified to interact with five residues of the C-
terminus of Gpa1p. Different cross-linking reactions of the Ste2p residues with Gpa1p 
residues in the absence and presence of the α-factor pheromone suggested that during 
activation both transmembrane 5 and 6 of Ste2p and the α5-helix (C-terminus) of Gpa1p 
undergo conformational changes that results in withdrawal of the α5-helix from the 
receptor. This study is the first to identify specific residue-to-residue interactions between 
a GPCR and its cognate Gα protein in its active and inactive states. 
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Chapter 1 
Introduction 
 G protein-coupled receptors (GPCRs) are medically important receptors that are 
comprised of seven transmembrane domains (TMs) and function by activating 
heterotrimeric G proteins. These receptors are the most diverse group of membrane-
bound receptors and are the targets of a multitude of current prescription drugs (1-3). 
Despite the availability of crystal structures for GPCRs (4) and G proteins (5, 6), the 
molecular mechanisms leading to activation of G proteins upon ligand binding to GPCRs 
remain unclear. GPCR–G protein interactions have implications with regards to drug 
discovery:  If drugs can be identified that interfere or promote GPCR-G protein 
interaction, change the pattern of GPCR–G protein associations, or cause a GPCR to 
preferentially associate with one G protein and not others, then it would be possible to 
regulate the activities and functions of a specific receptor (1, 7-9). 
The mating pathway of Saccharomyces cerevisiae has been a valuable tool for 
studying GPCR signal transduction mechanisms for many reasons including the fact that 
the yeast mating pheromone receptors activate only one Gα (Gpa1p) making the yeast 
system highly amenable to identification of specific interactions between the receptor and 
a Gα (10-12). Ste2p, the α-factor pheromone receptor of S. cerevisiae, shows an overall 
similar structural architecture to mammalian GPCRs and Gpa1p shows about 45% 
sequence similarity with various mammalian Gα proteins (13). Comparison of Ste2p with 
the rhodopsin (class A) subfamily of GPCRs suggests that there are underlying 
similarities in the mechanism of signal transduction between Ste2p and the Class A 
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GPCRs (11). These characteristics of Ste2p make it a good model for peptide-responsive 
GPCRs. 
Studies on the interactions between Ste2p and Gpa1p indicate that the Ste2p third 
intracellular loop (IL3) is involved in Gpa1p activation (14-17). Like the mammalian Gα 
proteins, the region of Gpa1p that has been most commonly predicted to interact with 
Ste2p is the C-terminus (18, 19). Despite the intense studies carried out on the 
interactions of Ste2p with Gpa1p, the specific residue-to-residue interactions between 
Ste2p and Gpa1p have not been determined.  
Several models have been proposed for signal transfer from the activated receptor 
to the Gα protein. The “gear shift”, “lever arm” and “sequential fit” models have in 
common that the α5 helix (C-terminus) of Gα is the key transmission domain for the 
receptor-G protein signal transfer (20). The binding of Gα to the activated receptor is 
suggested to cause movement of the α5 helix that affects GDP binding at the β6-α5 loop 
(21). Recently, using structural and kinetic modeling of the C-terminus of transducin, Gα 
was proposed to undergo rotational and translational movements during activation (20). It 
has also been suggested that the receptor must induce conformational changes in the G 
protein that result in the exchange of GDP for GTP (22). Evidence for this complex series 
of interactions and for structural transitions in the G protein have also been 
experimentally determined using spin-labeled, reconstituted Gαi and rhodopsin (21).  
This study identifies specific residue-to-residue interactions between Ste2p and 
Gpa1p in both the activated and inactive state using biochemical analysis by disulfide 
cross-linking. The patterns of Gpa1p interaction with the inactive and active forms of 
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Ste2p suggest possible rotational and “withdrawal” movements at the C-terminus of 
Gpa1p that are required for proper Ste2p coupling and Gpa1p activation.  These 
experimental conclusions are used to develop a proposed mechanism for Ste2p-Gpa1p 
signal transfer. The approaches and information from this study will be valuable for 
future studies on mammalian GPCRs signaling pathways. 
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Chapter 2 
Material and Methods 
Media, Reagents, and Strains and Transformation 
Saccharomyces cerevisiae strains LM102 [MATa, bar1, leu2, trp1, ura3, FUS1-
lacZ::URA3, ste2∆ (23)] and TM5117 [MATa, bar1, leu2, his3, ura3, FUS1-lacZ::URA3, 
ste2∆, gpa1∆ (23)] were used for biological activity assays and the protease-deficient 
strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (24)] was 
used for protein isolation and immunoblot analysis. The STE2 and GPA1 mutant 
plasmids were transformed by the method of Geitz (25) into the S. cerevisiae strains. 
 
Cysteine Scanning Mutagenesis 
C-terminal FLAG™ and His tagged STE2 with the two cysteine residues (Cys59 
and Cys252) substituted with serine and cloned into the plasmid p424-GPD to yield 
plasmid pBEC2 (23, 26) was used for expressing Ste2p. The plasmid pBEC2 was 
engineered by site-directed PCR mutagenesis to replace 22 residues, one at a time, in 
Ste2p (Ala228-Ile249) with cysteine. The open reading frame of GPA1 was PCR amplified 
from the plasmid YepGαβγ (27) and cloned into the plasmids p426 and p423-GPD (28) 
to yield plasmids pBUG6 and pBUG3 for expression in the BJS21 and TM5117 strains, 
respectively. The pBUG6 and pBUG3 were engineered by site-directed mutagenesis to 
replace 11 residues in Gpa1p (Ile461-Ile471) with cysteine. The sequence of all cysteine 
mutants was verified by DNA sequence analysis completed by the molecular biology 
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resource facility located on the campus of the University of Tennessee. Mutagenic and 
sequencing primers were purchased from Invitrogen (Carlsbad, CA).  
 
Membrane Extraction and Immunoblots 
BJS21 cells expressing STE2 and GPA1 mutant constructs grown in selective 
media were used to prepare total cell membranes isolated as previously described (29). 
Membrane extracts were resuspended in HEPES buffer (50 mM HEPES, 150 mM NaCl, 
pH 7.5, 20% glycerol). For immunoblotting blots were probed with FLAG™ antibody 
(Sigma/Aldrich Chemical, St. Louis, MO) to detect Ste2p or an antibody directed against 
Gpa1p (Santa Cruz Biotechnology, Inc., CA). The signals generated were quantitated 
using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation 
system (BioRad, Hercules, CA) to determine expression levels. 
 
Growth Arrest Assays 
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at 
30 ºC in MLT (minimal medium (30) lacking tryptophan), harvested, washed three times 
with water and resuspended at a final concentration of 5 x 106 cells/ml (24).  Cells (1 ml) 
were combined with 3.5 ml agar noble (1.1 %) and poured as a top agar lawn onto MLT 
medium agar plates.  Filter disks (BD, Franklin Lakes, NJ) impregnated with α-factor 
pheromone (0.125 – 2.0 μg) were placed on the top agar.  The plates were incubated at 
30ºC for 18 hours and then observed for clear halos around the discs.  The diameter of 
halos around the discs were measured and analyzed by linear regression analysis using 
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Prism software (GraphPad Software, San Diego, CA).  The experiment was repeated at 
least three times and reported values represent the mean of these tests. 
 
Fus1-lacZ Assays 
LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants 
were grown at 30ºC in selective media, harvested, washed three times with fresh media 
and resuspended at a final concentration of 5 x 107 cells/ml.  Cells (0.5 ml) were 
combined with α-factor pheromone (final concentration of 1 μM) and incubated at 30ºC 
for 90 minutes.  The cells were transferred to a 96-well flatbottom plate in triplicates, 
permeabilized with 0.5% Triton X-100 in 25 mM PIPE buffer and then β-galactosidase 
assays were carried out using fluorescein di-β-galactopyranoside (Molecular Probes, OR) 
as a substrate (31).  The reaction mixtures were incubated at 37ºC for 60 minutes and 1.0 
M Na2CO3 was added to stop the reaction.  The fluorescence of the samples (excitation of 
485 nm and emission of 530 nM) was determined using a 96-well plate reader Synergy2 
(BioTek Instruments, Inc., Winooski, VT).  The data were analyzed using Prism software 
(GraphPad Software, San Diego, CA).  The experiments were repeated at least three 
times and reported values represent the mean of these tests.  
 
Saturation Binding Assay 
Tritiated α-factor (9.3 Ci/mmol) was used in saturation binding assays on whole 
cells. LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants were 
harvested, washed three times with YM1 [yeast minimum medium with 0.5 M potassium 
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phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium 
fluoride, and 1% BSA], and adjusted to a final concentration of 4 × 107 cells/ml in 
binding medium YM1i (YM1 plus protease inhibitors). Cells (630 μl) were combined 
with 70 μl of 10X YM1i supplemented with [3H]α-factor and incubated at room 
temperature for 30 min. The final concentration of [3H]α-factor ranged from 0.4× 10–9 to 
50 × 10–9 M. Upon completion of the incubation interval, 200 μl aliquots of the cell–
pheromone mixture were collected in triplicate and washed over glass fiber filter mats 
using the Standard Cell Harvester (Skatron Instruments, Sterling, VA). Retained 
radioactivity on the filter was counted by liquid scintillation spectroscopy. LM102 cells 
lacking Ste2p were used as a nonspecific binding control for the assays. Specific binding 
for each mutant receptor was calculated by subtracting the nonspecific values from those 
obtained for total binding. Specific binding data were analyzed by nonlinear regression 
analysis for single-site binding using Prism software (GraphPad Software, San Diego, 
CA) to determine the Kd (nM), and Bmax values (receptors/cell) for each mutant receptor 
were calculated. The final values represent the binding constants from at least three 
independent experiments.  
 
Disulfide Crosslinking 
Membrane samples were incubated with or without Cu-P (1.0 μM Cu and 3.0 μM 
1,10-phenanthroline) in the absence or presence of a saturating amount of α-factor (5 μM) 
at room temperature for 30 min and then quenched by addition of EDTA (10 mM). The 
membrane samples were resuspended in non-reducing SDS sample buffer (BioRad, 
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Hercules, CA), separated by 10% SDS-PAGE, and then analyzed by immunoblotting as 
previously described (29). The disulfide reaction was reversed by reducing with 4% 2-
mercaptoethanol (β-ME) in the SDS sample buffer. For in vivo cross-linking, cells were 
grown to mid-log phase, harvested, and washed with water by centrifugation (4000g for 5 
min). The cells were resuspended in 100 mM LiAc and incubated at 30ºC for 30 min with 
mixing. After centrifugation, the cells were resuspended in 25% PEG with 250 mM LiAc 
for another 60 min incubation. Cells were washed with HEPES buffer three times after 
LiAc treatment. To evaluate the effect of receptor activation on in vivo crosslinking, 
whole cells were first incubated with KF (10 mM) and NaN3 (10mM) in HEPES buffer at 
room temperature for 15 min to inhibit receptor endocytosis (32) and then α-factor was 
added to a final concentration of 5 μM. Disulfide cross-linking was induced by adding 
Cu-P to final concentrations of 0.5 mM Cu and 1.5 mM 1,10-phenanthroline as 
previously described for whole cell experiments  in yeast (33). Membrane extraction was 
carried as described above with HEPES buffer containing 10 mM EDTA/NEM. 
 
Prediction and Modeling 
All models of 3-D structures were generated by the Phyre Structural 
Bioinformatics Group prediction tools (34). The structures were viewed and labeled with 
the PyMOL pdb viewer software (DeLano Scientific LLC, Palo Alto, CA). Aligment of 
the last 11 amino acids of transducin (Gα of rhodopsin) with Gpa1p was carried out using 
European Bioinformatics Institute online sequence alignment tools 
(http://www.ebi.ac.uk/).  
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Chapter 3 
Results 
Phenotypes of Ste2p IL3 Cys Mutants 
The Cys-less Ste2p (C59S and C252S), with FLAG™ and HIS-epitope tags in the 
C-terminus, engineered as the background for the specific cysteine mutations has been 
previously shown to have expression levels and biological activities identical to those of 
the wild type receptor as determined by several assays (23, 26). Substitution of single 
cysteine residues from L228C through I249C in intracellular loop 3 (IL3) of Cys-less 
Ste2p resulted in constructs that were expressed and had biological activities identical or 
similar to (within 25% of Cys-less, except for R233C, L236C, and K239C) that of the 
Cys-less receptor (see Table 4.1). In addition to quantitation of the Western blot signals, 
saturation binding assays were carried out on selected mutants (L228C and A229C from 
the TM5-IL3 boundary, R233C and R234C from the middle of IL3, and L248C and 
I249C from the IL3-TM6 boundary). The receptors showed almost equal Kd values for 
ligand binding and were expressed at levels within 12% difference (L228C, A229C, 
L248C, and I249C) to about 55-63% (R233C and R234C) of the Cys-less control  
respectively (Figure 4.1). Since the A229C mutant does not crosslink whereas the L228C, 
L248C and I249C do, we conclude that the expression levels are not the reason for the 
differences in crosslinking we noted. 
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Table 4.1 Summary of phenotypes of Ste2p IL3 Cys substitution mutants. The 
expression levels as measured by western blots and biological activities all had standard 
deviations between ±4 and ±7 percent. All assays were done three times independently. 
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Figure 4.1 Whole cell saturation binding assay of [3H]α-factor to Cysless and IL3 
Cys mutant receptors.  A graph of CPM (count per minute of radioactivity of cells) 
versus the concentration of the [3H]α-factor is shown. The data represents specific 
binding to cells as determined by subtracting the binding to cells lacking the receptor 
from binding to cells containing the containing Ste2p Cys mutant receptors.  Below the 
graph is a table containing a summary of the binding affinities (Kd) and surface 
expression of the receptors. 
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Expression and Activities of Gpa1p Cys-Mutants 
Most of the cysteine residues in Gpa1p are localized within highly conserved 
stretches of Gpa1p that share about 45% amino acid identity to transducin (17).  In 
addition some of these cysteine residues, especially C3, are very important for biological 
activities such as thioacetylation, palmitoylation, signaling, and membrane localization 
(35).  Thus, we did not mutate the endogenous Cys residues, because we were concerned 
that removing these cysteine residues would affect the localization and signaling of the 
Gpa1p.  The Gpa1p Cys mutants generated in this study have expression levels similar to 
wild type Gpa1p (Figure 4.2A). A high molecular weight protein [denoted as a non-
specific (NS) signal] that reacted with anti-Gpa1p was seen in all samples and also in 
extracts from TM5117 cells that were deleted for Gpa1p. The yeast strain TM5117 used 
to express the Gpa1p mutants has the endogenous GPA1 deleted resulting in high FUS1-
lacZ activities in the absence of pheromone because the Gβγ subunits constitutively 
activate the signal transduction pathway (Figure 4.2B). Expression of the mutant Gα 
subunits with the various Cys-substituted mutations showed that all could interact with 
the endogenous Gβγ subunits leading to reduced FUS1-lacZ activities in the TM5117 
yeast strain in the absence of pheromone (Figure 4.2B). In the presence of α-factor, the 
FUS1-lacZ activities increased, implying that all of the Gα mutants can couple 
productively with both the Ste2p receptor and the G protein βγ subunits. However, the 
mutants K468C, I469C and I471C exhibited about 60-70% capacity to activate signal 
transduction as measured by FUS1-lacZ activity in comparison to the other Cys-mutants.  
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Figure 4.2 Expression and signaling activity of Gpa1p Cys-mutants. A: Immunoblot 
of Gpa1p Cys mutants probed with anti-Gpa1p. NS represents a non-specific reactive 
band. B: β-galactosidase activity from the induction of the reporter gene Fus1-LacZ by 
activation of Ste2p mediated signaling in strains containing Gpa1p Cys mutants with 
(gray bars) and without (black bars) added pheromone. The data is normalized to activity 
in the Gpa1p-deleted mutant. C: Sequence alignment of eleven amino acids of Gpa1p and 
transducin at C-terminal end. 
 
 
127
Disulfide Crosslinking of Ste2p and Gpa1p 
  The molecular weight of the epitope tagged Cys-less Ste2p used to generate the 
IL3 Cys mutants is about 51 kDa. This receptor is normally observed as a monomer (51-
55 kDa, appearing with three bands due to N-glycosylation at two sites on the N-
terminus) and a dimer (106-110 kDa) on blots (23). The wild type Gpa1p used in this 
study is observed at 52-54 kDa (Figure 4.2A). The Ste2p-Gpa1p disulfide crosslinked 
product (~103-108 kDa) is therefore expected to be at a position similar to that of the 
Ste2p dimer (~102-110 kDa) on immunoblots. Since the IL3 Cys mutants have been 
shown to form homo-dimers we needed to differentiate a 103-108 kDa Ste2p homodimer 
band from a Ste2p-Gpa1p heterodimeric cross-linked product at a similar position on 
immunoblots. To detect the Ste2p-Gpa1p cross-linked product we used an antibody 
directed against Gpa1p. This antibody reacted with the 52-54 kDa (Gpa1p) band and 
detected a 103-108 kDa Ste2p-Gpa1p heterodimer since Gpa1p does not form a 
homodimer. As seen in Figure 4.2A the wildtype Gpa1p and its Cys analogs exhibit only 
one strong band at the molecular weight expected for the monomer (~52 kDa). All of the 
Gpa1p constructs and the Gpa1p deletion strain exhibit a very weak band at a high 
molecular weight (~130 kDa). These results clearly show that Gpa1p and the Cys analogs 
examined herein do not form homodimers. 
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To determine whether IL3 residues (L228-I249) in Ste2p interacted with the C-
terminal (I461-I471) residues in Gpa1p as measured by disulfide crosslinking, the IL3 
Cys-mutants were each co-expressed with all the Gpa1p Cys-mutants including wild type 
Gpa1p. Thus 23 different IL3 receptors (22 with one Cys residue in IL3 and the control 
Cys-less Ste2p) were co-expressed with 12 different Gpa1p proteins (11 with one Cys 
residue in the C-terminus and the control Gpa1p without Cys) to give 276 different 
combinations of Ste2p/Gpa1p. Membranes extracted from all of the different 
combinations were incubated with or without 5 μM α-factor to activate Ste2p and then 
treated with Cu-P to facilitate Cys-Cys disulfide formation (36). To illustrate the Ste2p-
Gpa1p cross-linking results we compare Ste2p-I246C, Ste2p-L247C and a Cys-less Ste2p 
control interacting with various Gpa1p Cys mutants (Figure 4.3). Of the 36 expression 
combinations shown in Figure 4.3, only 2 (Ste2p-L247 C with either Gpa1pN465C or 
Gpa1pK467C) showed bands at the position expected for a Ste2p-Gpa1p crosslinked 
product. These are indicated by asterisks in the Figure. Interestingly, the L247C-N465C 
crosslink is formed only in the absence of α-factor whereas the L247C-K467C crosslink 
is formed only in the presence of the pheromone.  To determine whether the endogenous 
cysteine residues in Gpa1p could cross-link to Ste2p, all the Ste2p Cys mutants that we 
generated were co-expressed with the wildtype Gpa1p (containing all endogenous 
cysteine residues) for cross-linking as shown in blots in Figure 4.3.  We did not observe 
any cross-linking between the wildtype Gpa1p and any of the Ste2p Cys mutants.  Thus 
the endogenous cysteine residues were not involved in Ste2p-Gpa1p crosslinking.    
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Figure 4.3 Immunoblots of two cysteine mutants of the IL3 region of Ste2p 
co-expressed with eleven Gpa1p Cys-mutants probed with anti-Gpa1p. Membrane 
preparations from transformants that were untreated (lanes -, -), treated with Cu-P in the 
absence of α-factor (lanes -, +) or treated with Cu-P in the presence of α-factor (lanes +, 
+) were probed with anti-Gpa1p antibody to detect the presence of Gpa1p (Gα) at either 
the 52-54 kDa or 103-108 kDa (Ste2p-Gα cross-linked) position. The samples were 
resolved on 10% SDS-PAGE. The blot images were spliced together from different gels 
to place the mutants in order according to the residue number of the Gpa1p cysteine 
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replacement. The top panel is data from a Ste2p Cys-less strain co-transformed with 
various Gpa1p Cys mutants. The middle and bottom panels present similar experiments 
from Ste2p-I246C and Ste2p-L247C, respectively. The combinations that showed 
crosslinks are designated with asterisks. 
 
 
 
 
 
 
 
Figure 4.4 Diagrammatic representation of cross-links formed between Ste2p and 
Gpa1p Cys-substituted mutants in the active and inactive state. The cysteine residue 
is that which would be present in the individual mutated Ste2p or Gpa1p proteins. 
 
Out of the 22 Ste2p Cys-mutants tested, 5 mutants (L228C, S243C, L247C, 
L248C and I249C) showed a cross-linked band with 5 out of the 11 Gpa1p Cys-mutants 
(Q463C, N465C, K467C, I469C and G470C) in either the ligand-unbound or ligand-
bound state of Ste2p (schematically indicated in Figure 4.4).  Examination of all the anti-
Gpa1p blots quantitatively showed that the NS signal intensity varied and was 
independent of the Ste2p-Gpa1p signal. Furthermore, CuP catalyzed oxidation in the 
absence of alpha-factor or in the presence of alpha-factor resulted in a quantifiable 
I461 I  C463 Q C465  L C467 K  C469 C470 I471
C228 A I  R S R R F L G L K Q F D C243 F H C247 C248 C249
Ste2p-Gpa1p cross-linking in ground state
Ste2p-Gpa1p cross-linking in ligand bound state
Ste2p: TM5 TM6
Gpa1p:
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reduction in Gpa1p when the crosslinked heterodimer Ste2p-Gpa1p was formed, and the 
sum of the band intensities of Ste2p-Gpa1p and Gpa1p are in reasonable agreement with 
the intensity of Gpa1p in the untreated control.  We conclude that the weak NS signal can 
not be related to the amount of Gpa1p or Ste2p-Gpa1p in the sample.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Immunoblots of various combinations of Ste2p and Gpa1p Cys mutants 
probed with anti-FLAG™ antibody (anti-Ste2p) and anti-Gpa1p.   The samples were 
resolved on a 4-12 % gradient SDS-PAGE. A: The blots were probed with anti-FLAG to 
detect the presence of Ste2p at either ~51-55 kDa (Ste2p monomer) or ~108-110 kDa 
(Ste2p-dimer) or ~103-108 kDa (Ste2p-Gα cross-linked) position. B: The blots were also 
probed with anti-Gpa1p antibody to detect the presence of Gpa1p (Gα) at either the ~53-
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54 kDa (monomer) or ~103-108 kDa (Ste2p-Gα cross-linked) position. The blot images 
were spliced together from different gels. The last two combinations 
Ste2p(I249C)/Gpa1p(470C) were run in the presence and absence of 4% β-
mercaptoethanol. 
 
The Gpa1 polyclonal antibody (Santa Cruz) was generated to a peptide 
comprising residues 183-472 (290 residues) of Gpa1p, so that this polyclonal antibody 
was expected to react with Gpa1p with single cysteine mutations within the small region 
(461-471) tested in our studies and also detect Gpa1p crosslinked through its extreme C-
terminus to Ste2p.  To confirm that the signal on the anti-Gpa1p blots are indeed Ste2p-
Gpa1p cross-linked all the Cu-P treatments of mutants with detectable cross-linked 
products were probed using both anti-Gpa1p (Figure 4.5B) and anti-FLAG (Figure 4.5A) 
to detect Ste2p-monomer (53-55 kDa), Ste2p-dimer (106-110 kDa) and Ste2p-Gpa1p 
cross-linked product (103-108 kDa). This allowed us to distinguish between Ste2p 
homodimers and the crosslinked Ste2p-Gpa1p protein. Both antibodies revealed the same 
crosslinking patterns for Ste2p and Gpa1p. However, because the Ste2p probe also 
revealed homodimer and multiple-glycosylated proteins, these bands are much broader 
and it is more difficult to discern the Ste2p-Gpa1p crosslinked product which is often 
obscured by the Ste2p dimers (compare top and bottom gels). The Ste2p-Gpa1p cross-
linked products were nearly completely reversed by treatment with 4% β-ME (see Figure 
4.5, last three lanes for I249C-G470C), indicating that a disulfide bond connected the 
hetero-dimeric Ste2p-Gpa1p.  The fact that probing with both anti-Ste2p and anti-Gpa1p 
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(Figure 4.5B) resulted in the same signal on the gels indicates that the Santa Cruz 
antibody can interact with the Ste2p-Gpa1p crosslinked product.   
In the inactive state (without α-factor binding, Figure 4.4B α-factor “-“ lanes) 
L248C in IL3 reacted with I469C in Gpa1p, whereas both L247C and I249C in IL3 
reacted with N465C in Gpa1p (Figure 4.4, broken lines). Although previous studies 
showed that I246C is highly accessible to a sulfhdryl reagent (37) this residue did not 
react with the Gpa1p residues tested in this study. No detectable disulfide product was 
observed for residues located in the middle of the IL3 loop or at the TM5 boundary in the 
inactive conformation of Ste2p.  In the ligand-bound, active conformation (Figure 4.5B 
α-factor “+” lanes) both L228C (TM5) and I249C (TM6) reacted with G470C of Gpa1p. 
S243C and L247C of the receptor reacted with K467C of Gpa1, whereas receptor I249C 
reacted with I469C of Gpa1 (Figure 4.4, solid lines; Figure 4.5B). The Ste2p IL3 Cys 
mutants (L228C, S243C, L247C, L248C and I249C) all displayed increased Ste2p-
homodimer formation when treated with Cu-P in the absence of α-factor (ligand) binding 
to Ste2p (Figure 4.5A lanes labeled “– +”). In the presence of α-factor binding to Ste2p 
(Figure 4.5A lanes labeled “+ +”) Ste2p-homodimer formation was reduced.  
To test whether the IL3-Gpa1p interactions observed in the membrane samples 
existed in the whole cell before membrane preparation, in vivo Cu-P treatment was 
carried out on whole cells. For these experiments, cells co-expressing Ste2p-I249C and 
Gpa1p mutants, N465C, L466C, K467C, K468C, I469C, G470C and I471C in the 
presence or absence of α-factor were used. In this series of experiments N465, I469 and 
G470 (indicated by asterisks) formed the heterodimers whereas L466, K467, K468 and 
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I471 did not. These results (Figure 4.6) show that in vivo the interaction of receptor 
mutant I249C with Gpa1p was similar to what was observed in membrane preparations. 
 
 
 
 
 
 
 
Figure 4.6 Immunoblots of membranes from whole cells expressing Ste2p-I249C 
together with various Gpa1p-Cys mutants (N465C-I471C) probed with anti-Gpa1p. 
Samples were untreated (lanes -,-) or treated with Cu-P in absence (lanes -, +) or the 
presence (lanes +, +) of α-factor. Membrane samples prepared from these cells were 
resolved on 10% SDS-PAGE. The combinations that showed crosslinks are designated 
with asterisks. 
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Chapter 4 
Discussion 
We have used disulfide cross-linking to determine specific residue-to-residue 
interactions between a yeast GPCR, Ste2p, in the active and inactive state and its cognate 
Gα, Gpa1p, allowing identification of conformational changes involved in signal 
transduction. Ste2p IL3 was observed to tolerate Cys substitutions well in our 
experiments (37). The alignment of the C-terminus of Gpa1p with the last 11 amino acids 
of transducin showed that in this region these two proteins are 50% identical and 70% 
similar (Figure 4.2C). This portion of transducin was suggested to directly interact with 
opsin and was used for co-crystallization with opsin to determine its binding to opsin 
(38). Cysteine substitution of the individual eleven residues (I461-I471) of Gpa1p tested 
in this study was well tolerated except for K468C, I469C and I471C which all resulted in 
a partial pheromone response (Figure 4.2B), consistent with previous studies (17). 
Signaling defects caused by mutation of the last five residues of Gpa1p have been 
observed in most studies (14-16, 39) suggesting that these residues are indeed critical for 
proper receptor coupling and Gpa1p activation. None of our mutations affected the 
coupling of Gpa1p with the Gβγ protein subunits, implying that the carboxyl tail of 
Gpa1p is essential for Ste2p coupling but not for interaction with Gβγ.  
The crystal structure of opsin in its G protein-interacting conformation shows that 
cytoplasmic ends of TM5 and TM6 provide a surface for hydrophobic interactions with 
the C-terminus of transducin Gα (38). The disulfide cross-linking results from our study 
indicated that analogously to the transducin-opsin interaction the C-terminus of Gpa1p 
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interacts with TM5 and TM6 of Ste2p. In opsin, TM5 and TM6 are involved in van der 
Waals interactions with the C-terminus of transducin, and a hydrogen bonded network 
links the transducin and opsin residues (38). Cysteine disulfide cross-linking studies on 
Cys-mutant residues in Ste2p IL3 suggested that α-factor binding to Ste2p resulted in 
conformational changes involving the hydrophobic residues at the cytoplasmic ends of 
TM5 and TM6 (Figure 4.5A). The close proximity of these hydrophobic residues (L228, 
I247, L248, and L249) of Ste2p to the extreme C-terminus of Gpa1p indicates that these 
residues provide a hydrophobic environment that favors the Gpa1p C-terminus 
interaction. The crosslinking of S243C (Ste2p) with Q463C and K467C (Gpa1p) suggests 
that the three polar residues are involved in a hydrogen bond bridged network. These 
hydrogen-bonded bridges may be present during receptor activation, since these cross-
links were only observed in the active form of the receptor. However, this may be just 
one of many networks, so the S243-Q463-K467 interaction may not be sufficient for full 
activation of the receptor and/or Gpa1p.  
In the classical GPCR-G protein ternary complex model the binding of an agonist 
to the receptor induces the formation of a ternary complex consisting of a ligand, the 
receptor, and a G protein, followed by the exchange of GDP for GTP. The complex 
dissociates to Gα-GTP, Gβγ, and the receptor (9, 19). Although several models have been 
proposed to explain the coupling between GPCRs and G proteins, the coupling mode is 
still not well understood. The results from this study concur with the “precoupled” model 
which suggests that the receptor and G protein are precoupled and may form a stable 
complex regardless of the receptor activation state (40). The cross-linking of Ste2p Cys-
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mutants to Gpa1p Cys-mutants in the presence and absence of ligand implies that the two 
proteins are in close proximity both in the active and inactive receptor conformation. 
These results provide physical evidence that the receptor-G protein complex exists prior 
to activation and that it is not formed by random collision where the Gα couples with the 
active receptor as suggested by the “collision coupling” model (41).  
Activation of the Gα proteins by GPCRs has been observed to alter interactions of 
residues in the GDP binding domains that open the GDP-binding cleft, allowing GDP 
dissociation and the subsequent binding of GTP. Since the receptor binding domain of 
Gα is on the opposite face of this protein from the GDP-binding cleft, the interaction with 
the activated receptor must be transmitted to the GDP binding site by conformational 
changes (18, 19, 21, 22, 41, 42). Recently, it has been shown that the exchange of GDP 
for GTP in Gα proteins during receptor activation is induced by interactions of Gα with 
the receptor regardless of the presence or absence Gβγ. Thus, interactions of receptor 
with Gα proteins are the main requirements for the GDP/GTP exchange in Gα (9). 
Conformational changes at the C-terminus of transducin Gα involving a helix-switch 
were proposed based on structural and kinetic modeling. This helix-switch mechanism 
suggests that the α5-helix (C-terminus) of transducin Gα rotates counter-clockwise 
around its axis by 90° and tilts relative to the membrane by 42° (20) during activation.  
Our disulfide crosslinking results suggest that two conformational changes affect 
the interactions of residues at the Gpa1 carboxyl terminus with residues at the 
cytoplasmic ends of TM5-TM6 of the receptor during Ste2p activation. The first 
conformational change, which is a rotational movement of the C-terminus of Gpa1p, 
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would be explained by the helix-switch mechanism model that is based on kinetic 
modeling (20). This movement is supported by the switch of the disulfide crosslinks from 
Gpa1p-N465C/Ste2p-L247C or Gpa1p-N465C/Ste2p-I249C in the inactive conformation 
to Gpa1p-K467C/Ste2p-L247C or Gpa1p-I469C/Ste2p-I249C in the active conformation 
(see Figure 4.7). Since the C-terminus of the Gpa1p is predicted to have a helical 
structure similar to that of transducin (17) a rotation of the helix of ~120° is required to 
switch a Gpa1p-N465C/Ste2p-L247C interaction to a Gpa1p-K467C/Ste2p-L247C 
interaction. Based on our Ste2p crosslinking studies we have postulated that TM6  
undergoes ~30° clockwise rotation upon ligand binding (Fig 4.5A), similar to what has 
been suggested for TM6 of some mammalian GPCRs (2).  Therefore, it is likely that 
Gpa1p may not have to undergo the full ~120° rotation to switch the residue interactions; 
an ~90° anti-clockwise rotation would suffice. 
The second conformational change that would be consistent with our disulfide 
crosslinking results is what we call the “withdrawal” movement. This movement is 
necessary to explain the switch of the interactions between Gpa1p-N465/Ste2p-I249 in 
the inactive conformation to Gpa1p-I469/Ste2p-I249 in the active conformation. This 
switch requires the C-terminus (α5-helix) of Gpalp to move a distance that is 
approximately the height of the pitch of an α-helix (~5.4 Å) and undergo a simultaneous 
horizontal translation resulting in about 5 Å withdrawal from Ste2p. The concerted 
rotational and translational movements are proposed to result in a shift of the Gpa1p α5-
helix from the TM6 cytoplasmic end towards the inner core of the receptor closer to TM5 
and other TMs such as TM3 similar to the “translational” movement predicted by the 
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helix-switch mechanism derived from kinetic modeling (20). The “withdrawal” 
movement of Gpa1p α5-helix agrees with the α5-transmission rod concept of mammalian 
Gα proteins in which the α5-helix acts as a transmission “piston rod” to propagate the 
conformational changes from the receptor-G protein interface to the nucleotide binding 
pocket (19, 20). We propose that the Gpa1p α5-helix (“rod”) rotates and moves away 
from Ste2p. These movements may cause distortion at the β6-α5 loop of Gpa1p that 
connects the C-terminus to the nucleotide-binding cleft, allowing GDP dissociation and 
the subsequent exchange of GDP for GTP.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Proposed 3D model illustrating conformational changes in the 
cytoplasmic ends of TM5-TM6 from Ste2p and the C-terminus of Gpa1p during 
activation. Ste2p and Gpa1p residues are labeled green and blue, respectively. A 
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(inactive state): The C-terminus of Gpa1p is suggested to be closer to TM6 than TM5 in 
the inactive state. Upon α-factor binding changes occur at the cytoplasmic ends of TM5 
and TM6. TM5 and TM6 are proposed to undergo rotation of ~30° in the anti-clockwise 
and clockwise directions, respectively (indicated by green arrows) The C-terminus of 
Gpa1p undergoes two possible changes (indicated by yellow arrows), an anti-clockwise 
rotation of ~90° and a withdrawal of ~5.0 Å (horizontal and vertical shifts) from the inner 
core of the receptor to the cytoplasmic end. B (active state): TM5 and TM6 are closer due 
to a shift in TM6 towards TM5 as observed in other GPCRs (2, 43). The C-terminus of 
Gpa1p is now closer to TM5 and withdrawn into the cytoplasmic surface of TM5-TM6. 
There are possible H-bond links between S243 of Step and Q463/K467 of Gpa1p. 
 
Several studies have shown that GPCR activation results in conformational 
changes at the TM5-TM6 cytoplasmic ends that appear to be essential for G protein 
activation in all GPCRs (2, 43-45). In this study we propose that the conformational 
changes that occur at the TM5 and TM6 cytoplasmic ends induce rotational and 
translational movements at the C-terminus of the Gpa1p that results in withdrawal of the 
α5-helix of Gpa1p from Ste2p. The rotational and translational conformational changes 
are consistent with a proposed model for the transducin-opsin system (20). Although, 
further experimental work, such as identifying other residues in Ste2p and Gpa1p that are 
involved in these movements will be needed to refine the mechanism of activation, the 
information obtained in this study will serve as a platform for further understanding of 
GPCR-G protein interactions in other systems. 
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PART V 
Crosslinking of an α-factor Analog [K0(BioACA), K7(DHPA), Nle12]α-
factor (Bio-DHPA7 α-factor) into its G Protein-Coupled Receptor, Ste2p 
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Abstract for Part V 
 Fundamental knowledge about how G protein-coupled receptors and their ligands 
interact is important for understanding receptor-ligand binding and the development of 
new drug discovery strategies. We have used periodate-mediated crosslinking and 
matrix-assisted laser desorption/ionization (MALDI) spectrometric analyses to 
investigate the interaction of the center of the Saccharomyces cerevisiae tridecapeptide 
pheromone, α-factor (WHWLQLKPGQPMY), and Ste2p, its cognate G protein-coupled 
receptor.  Chemically synthesized [Lys0(BioACA),Lys7(DHPA),Nle12]α-factor with a 
3,4-dihydroxyphenylacetyl (DHPA) attaching to lysine at position 7 (Bio-DHPA7 α-
factor) was used to bind with Ste2p. Even though bio-DHPA7 α-factor exhibited about 
40-fold decrease in binding affinity with Ste2p, it was able to activate growth arrest in 
yeast cell. Bio-DHPA7 α- factor was crosslinked with Ste2p as demonstrated by Western 
blot analysis using NeutrAvidin-HRP conjugates to detect Bio-DHPA7 α-factor and Ste2p 
crosslinked product. Ste2p-ligand crosslinked complex was purified with His affinity 
resin to pull down Ste2p that has a His tag at the C-terminus and with Avidin beads to 
capture Bio-DHPA7 α- factor. After cyanogen bromide digestion, a crosslinked fragment 
at the size of ~13 kDa was detected in Western blot probed with NeutrAvidin-HRP and 
also in MALDI-TOF mass spectrum. The result of chemical crosslinking suggests that 
Bio-DHPA7 α-factor interacts with transmembrane domain 2 to 3 flanking extracellular 
loop 1 (TM2-EL1-TM3) region. Site-directed mutagenesis at this region is currently 
being carried out to identify the exact crosslinked residue of Ste2p with DHPA7 α-factor. 
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This is the first study to investigate the interacting residues between Ste2p and position 7 
of α-factor. 
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Chapter 1 
Introduction 
G protein-coupled receptors (GPCR) are composed of a superfamily of membrane 
proteins that have a common structure of seven transmembrane domains. The 
superfamily is divided into 6 groups (rhodopsin-like GPCRs, secretin receptor family 
GPCRs, metabotropic glutamate GPCRs, fungal mating pheromone receptors, cyclic 
AMP receptors, and Frizzled/Smoothened) based on the sequence homology and 
functional similarity (1). The human genome encodes about 800-1000 GPCRs which 
mediate a variety of signal transduction pathways (2), such as light, odorants, hormone, 
and small molecule neurotransmitters. About 50% of the current medicines and 25% of 
the top 100 best-selling drugs target GPCRs (3). Knowledge of GPCR structures, 
including how they interact with their ligands and how they are activated, is an important 
component aiding the development of novel drugs (4). 
Understanding the interaction between ligands and their cognate GPCRs is 
necessary for designing analogues useful in therapy of many human disorders. Using 
Ste2p as a model to understand GPCR structure, the Konopka lab has shown by random 
mutagenesis that residues near the extracellular ends of the transmembrane domains are 
important for ligand binding and Ste2p activation (5, 6). According to the results of site-
directed mutagenesis in the Becker lab, several residues (S47, T48, T50, L102, F204, 
N205, Y266, L276, and A280) at transmembrane domains of Ste2p have been identified 
to be important for ligand binding and receptor activation (7, 8). In order to determine 
direct contact points between α-factor and Ste2p, chemical (DOPA) and photoaffinity 
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(Bpa) crosslinkers were used to label the ligand and capture the receptor. During α-factor 
binding, a tryptophan at the N-terminus of α-factor is in close proximity to the Lys269 side 
chain near the extracellular surface of the TM6-TM7 bundle of Ste2p (9, 10). A tyrosine 
at the C-terminus of α-factor is likely to interact with Arg58 and Cys59 at transmembrane 
domain 1 of Ste2p (11, 12).  A conclusion of these studies was that the chemical 
crosslinker 3,4-dihydroxyphenylalanine (DOPA) is apparently more specific in 
generating covalent linkage with specific residues of the receptor, which can be applied 
to indetify the exact contact residues between DOPA-labeled peptide and the receptor. 
Here, to indentify binding sites between α-factor and Ste2p, we used 3,4-
dihydroxyphenylacetyl (DHPA) as a crosslinker to label lysine residue in position 7 of α-
factor to create [K0(BioACA), K7(DHPA), Nle12]α-factor (Bio-DHPA7-α-factor). DHPA 
is similar to DOPA in that both contain the dihydroxyphenyl moiety involved in chemical 
activation and crosslinking. DOPA was used as a replacement for an amino acid in α-
factor in previous studies, wheareas DHPA was linked to the epsilon-amine of Lys7 of α-
factor in the present study. Bio-DHPA7-α-factor was able to bind with Ste2p and activate 
downstream cellular responses.  After His-tag (for purification of tagged Ste2p) 
purification and cyanogen bromide digestion, avidin (to capture any biotinylated peptide) 
purification was performed to capture crosslinked α-factor and Ste2p, and a 10-15 kDa 
crosslinked fragment containing biotin and DHPA was identified. MALDI-TOF mass 
spectrometric analysis confirmed the digested fragment, which suggests that Bio-DHPA7-
α-factor formed a covalent cross-linkage with the residue at the boundary of 
transmembrane 2 and 3 flanking extracellular loop 1 (TM2-EL1-TM3).  
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Chapter 2 
Materials and Methods 
Media, Reagents, Strains and Plasmids 
Saccharomyces cerevisiae strain LM102 [MATa, bar1, his4, leu2, trp1, met1, 
ura3, FUS1-lacZ::URA3, ste2Δ (13)] was used for growth arrest and binding assays and 
protease deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR (14)] was used for protein isolation and immunoblot analysis. The plasmid 
pBEC1 containing C-terminal FLAG and His tagged STE2 (13) was transformed by the 
method of Geitz (15) into LM102 and BJS21 cells. Transformants were selected by 
growth on yeast media (16) lacking tryptophan (designated as MLT) to maintain selection 
for the plasmid. The Cells were cultured in MLT and grown to mid-log phase at 30°C 
with shaking (200 rpm) for all assays. The tridecapeptide pheromone α-factor analog 
[(BioACA)-Lys0 (3,4-dihydroxyphenylacetyl)-Lys7, Nle12] (designated Bio-DHPA7 α-
factor) was synthesized using automated solid-phase peptide synthesis and purified by 
reverse-phase high-performance liquid chromatography (HPLC) to greater than 99% 
homogeneity. All protected amino reagents were purchased from Advanced Chem Tech 
(Louisville, KY) and all solvents and reagents were of the highest purity available. 
 
Mass Spectrometric Analysis of Peptides 
For matrix-assisted laser-desorption ionization (MALDI) analysis the peptides 
were resuspended in 50:50 water-acetonitrile with 0.1% trifluoroacetic acid (TFA) at a 
final concentration of 0.1μg/μl. A 20mg/ml α-cyano-4-hydroxy-trans-cinnamic acid [(α-
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ACHA), Sigma/Aldrich Chemical Company, St. Louis, MO] matrix was prepared by 
dissolving recrystallized α-ACHA in 50:50 water-acetonitrile with 0.1% TFA. An equal 
volume (0.5 μl) of peptide solution was mixed with matrix before spotting on the MALDI 
plate. The MADLI-TOF spectra were acquired on a Bruker Daltonics (Boston, MA) 
Microflex using the reflector methods. 
 
Growth Arrest Assays 
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at 
30ºC in MLT, harvested, washed three times with water and resuspended at a final 
concentration of 5 x 106 cells/ml (14). Cells (1 ml) were combined with 3.5 ml agar noble 
(1.1%) and poured as a top agar lawn onto MLT medium agar plate. Filter disks (BD, 
Franklin Lakes, NJ) impregnated with α-factor or various α-factor analogs were placed 
on the top agar. The plates were incubated at 30ºC for 18 hours and then observed for 
clear halos around the discs. The experiment was repeated at least three times. 
 
Binding Competition Assays 
This assay was performed using LM102 cells expressing C-terminal FLAG and 
His tagged Ste2p. Tritiated [3H]-α-factor (10.2 Ci/mmol, 12 μM) prepared as previously 
described (14, 17) was used in competition binding assays on whole cells. The cells were 
grown at 30ºC in MLT, harvested, washed three times with YM1 [0.5 M potassium 
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium 
fluoride, and 1% BSA] and adjusted to a final concentration of 2 x 107 cells per ml in 
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YM1 plus protease inhibitors [YM1i] (18). For competition binding studies, cells (600 μl) 
were combined with 150 μl of ice cold YM1i supplemented with 6 nM [3H]α-factor in the 
presence or absence α-factor analogs and incubated at room temperature for 30 minutes. 
The final concentrations of α-factor analogs ranged from 0.5 x 10-10 to 1 x 10-6 M. After 
incubation, triplicate aliquots of 200 μl samples were filtered and washed over glass fiber 
filter mats using the Standard Cell Harvester (Skatron Instruments, Sterling, VA) and 
placed in scintillation vials. The radioactivity [3H] on the filter was counted by liquid 
scintillation spectroscopy. The binding data were analyzed by non-linear regression 
analysis for one-site competition binding using Prism software (GraphPad Software, San 
Diego, CA) to determine the binding affinity (Kd) for each peptide. The Ki values were 
calculated by using the equation of Cheng and Prusoff, where Ki = EC50 / (1 + [ligand] / 
Kd) (7).  
 
DHPA Chemical Crosslinking 
BJS21 cells expressing C-terminal FLAG and His tagged Ste2p were grown and 
total cell membranes were isolated as previously described (14). Protein concentration 
was determined by BioRad (BioRad, Hercules, CA) protein assay (13). The membranes 
were re-suspended in NEBuffer [20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 
12.5 mM EDTA, 0.5 mM DTT (19)] incubated with Bio-DHPA7 α-factor analog (1 μM) 
in the presence or absence of 100 μM α-factor (WHWLQLKPGQPNle12Y) for 120 
minutes at 4°C. For periodate mediated crosslinking, a final concentration of 1.0 mM 
NaIO4 was added to the mixture and incubated for 2 minutes. A final concentration of 
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100 mM DTT (1,4-Dithiothreitol) was used to quench the reaction (19). The cross-linked 
membranes were washed three times with CAPS buffer [Ncyclohexyl-3-
aminopropanesulfonic acid (Sigma, St. Louis, MO.), 10 mM, pH 10] by centrifugation to 
remove non-bound Bio-DHPA7 α-factor. The washed crosslinked samples were 
fractionated by SDS-PAGE and then transferred to immunoblots. The blots were probed 
with an antibody directed against the FLAG tag at C-terminal of Ste2p and with 
NeutrAvidin-HRP conjugate (Pierce, Rockford, IL) to detect biotin tag on Bio-DHPA7 
pheromone covalently linked to Ste2p. The signal generated were analyzed using 
Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation system 
(BioRad, Hercules, CA).  
 
Purification of Intact Crosslinked Ste2p 
Crosslinked Ste2p was enriched using His-SelectTM HC-Nickel affinity gel 
(Sigma/Aldrich Chemical Co., St. Louis, MO) following the manufacturer’s directions. 
Approximately 10 mg cell membrane containing crosslinked Ste2p were resuspended in 
ice-cold solubilization buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-
100) with protease inhibitors (PMSF, pepstatin A and leupeptin) and incubated overnight 
at 4ºC with end-over-end mixing, then centrifuged at 15,000 x g for 30 minutes to remove 
non-soluble material. The solubilized proteins were then mixed with His-Nickel resin and 
incubated at 4ºC with end-over-end mixing for 1 hour. The resin was collected by 
centrifugation at low speed (500 x g, 1 minute) and resuspended and collected four times 
in wash buffer (50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, and 5 mM 
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imidazole). Ste2p was eluted by resuspending the resin in 1 ml ice-cold elution buffer (50 
mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, and 250 mM imidazole) and 
incubated at 4ºC with end-over-end mixing for 10 minutes. The resin was pelleted by 
centrifugation (2000 x g, 1 minute) and the supernatant, containing eluted Ste2p, 
transferred to a fresh tube. The samples were analyzed by immunoblotting using an 
antibody directed against the FLAG tag at C-terminal of Ste2p and with Neutravidin-
HRP conjugate to detect the biotin tag on the DHPA peptide covalently linked to Ste2p. 
 
Digestion of Crosslinked Ste2p 
Crosslinked Ste2p samples eluted from the His-Nickel resin were digested with 
cyanogen bromide (CNBr). The eluted samples containing Ste2p (~20 μg) were dried by 
vacuum centrifugation (Thermo Scientific, Waltham, MA) then dissolved in 100% 
trifluoroacetic acid (TFA) containing 10 mg/ml CNBr. Deionized distilled water 
(ddH2O) was then added to adjust the final TFA concentration to 80%, and the samples 
were incubated at 37°C in the dark for 18 hours (14, 20). The samples were dried by 
vacuum centrifugation and washed three times with ddH2O, and then 1 M Tris-HCl (pH 
8.0) was added to neutralize the acidic mixture. 
 
Purification of Crosslinked Ste2p Fragments 
After CNBr digestion, crosslinked Ste2p fragments were resuspended in PBS 
buffer (0.1 M sodium phosphate, 0.15 M sodium chloride; pH 7.0), mixed with 
NeutrAvidin resin (Pierce Thermo Scientific, Rockford, IL,USA) and incubated for 6 
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hours at 4ºC with end-over-end  mixing (21). The resin was collected by centrifugation at 
low speed (1000 x g, 1 minute) and washed four times in PBS buffer. Crosslinked Ste2p 
fragments were eluted by resuspending the resin in 200 μl ice cold elution buffer (0.1 M 
glycine, pH 2.5) and incubating at 4ºC with end-over-end mixing for 5 minutes. The resin 
was pelleted by centrifugation (2000 x g, 1 minute) and the supernatant, containing the 
eluted crosslinked Ste2p fragments, transferred to a fresh tube containing 20 μl of TBS 
(0.5 M Tris HCl, pH 7.4, 1.5 M NaCl). 
 
MALDI-TOF Analysis of Crosslinked Peptides 
The eluted samples from the avidin resin were further washed and concentrated 
using a pipette with C18 chromatographic media (ZipTipC18 pipette tips; Millipore 
Corporation, Billerica, MA) following the manufacturer’s directions and resuspended in 
60% acetonitrile 40% water (0.1% TFA). For MALDI-TOF analysis α-CHCA [20 mg/ml 
(in 50:50 acetoneisopropanol)] was used as the matrix. The samples (0.5 μl), were either 
mixed with 0.5 μL of matrix before spotting on the target or 1.0 μl of matrix was spotted 
and allowed to dry before applying 1.0 μL of samples (14). MALDI-TOF spectra were 
acquired on a Bruker Daltonics Microflex using the reflector method. Masses were 
calculated using PROWL peptide mass prediction tools (22) and also based on the 
chemistry of the DHPA cross-linking (19). 
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Chapter 3 
Results 
Synthesis and Characterization of Bio-DHPA7 α-factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Structures of α-factor and Bio-DHPA7 analogue. Biotin (Bio) is conjugated 
through its carboxyl group to the ε–amine of Lys1 using aminocaproate as a linker and 
3,4-dihydroxyphenylacetyl (DHPA) is attached to Lys7 residue to form [K0(BioACA), 
K7(DHPA), Nle12]α-factor (Bio-DHPA7 α-factor) analogue of α-factor. 
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 The synthesis of α-factor analogs containing 3,4-dihydroxyphenylacetyl (DHPA) 
was carried out by automated solid phase synthesis using standard coupling and 
deprotection protocols (10, 12). Fmoc protected peptide was obtained in high yield and 
purity and was used in the hydroxysuccinimiude mediated addition of biotinylamido 
caproate (9). The final peptides used in bioassays and cross-linking studies were virtually 
homogeneous as judged by gradient HPLC and had the expected molecular weights. The 
structures of α-factor and Bio-DHPA7 analogue are shown in Figure 5.1; MALDI-TOF 
analyses and MS/MS spectra are shown in Figure 5.2. Observed mass of the peptides as 
determined by MALDI-TOF were similar to masses predicted by the PROWL peptide 
mass prediction tools (23).  
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of α-
factor and Bio-DHPA7 analog. (Continued on next page) 
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Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of α-
factor and Bio-DHPA7 analog. Panel A (left): Observed masses of the peptides 
determined by MALDI-TOF. Panel B (right): MALDI post-source decay spectra. 
(Continued on next page) 
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Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of α-
factor and Bio-DHPA7 analog. Panel A (left): Observed masses of the peptides as 
determined by MALDI-TOF were similar to masses predicted by PROWL peptide mass 
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prediction tools (22): [Nle12]α-factor 1665.96 Da, [K0, Nle12]α-factor 1794.15 Da, 
[K0(BioACA), Nle12]α-factor 2133.61 Da, [K0, K7(DHPA), Nle12]α-factor 1944.34 Da, 
and [K0(BioACA), K7(DHPA), Nle12]α-factor  2283.74 Da. Panel B (right): One-letter 
inserts are abbreviations of amino acid residues. Peptides and spectra are labeled with 
identified y and b ion types. 
                          
A total of four α-factor analogues were synthesized: [K0, Nle12]α-factor has a 
lysine added at the N-terminus of α-factor (position 0), [K0(BioACA), Nle12]α-factor has 
a biotin added to the lysine at position 0, [K0, K7(DHPA), Nle12]α-factor has lysine at 
position 0 and dihydroxyphenylacetyl (DHPA) attached to the lysine at position 7, and 
[K0(BioACA), K7(DHPA), Nle12]α-factor (Bio-DHPA7 α-factor) has biotin labeling on 
the lysine at position 0 and DHPA attached to the lysine at position 7. MALDI-TOF Mass 
spectrometry was used to determine molecular mass of α-factor analogues (Figure 5.2). 
According to mass spectra, [K0, Nle12]α-factor showed a monoisotopic peak at 1793.662 
Da (predicted 1794.15 Da), [K0(BioACA), Nle12]α-factor showed a peak at 2132.381 Da 
(predicted 2133.61 Da), [K0, K7(DHPA), Nle12]α-factor showed a peak at 1943.477 Da 
(predicted 1944.34 Da), and [K0(BioACA), K7(DHPA), Nle12]α-factor showed a peak at 
2282.032 Da (predicted 2283.74 Da). Some of the peptides showed more than one peak, 
which might be due to impurities in the samples. FAST program in MALDI-TOF was 
used for further fragmentation and detailed mapping of peptide sequence. Ionized 
fragments matched the sequence of α-factor analogues (Figure 5.2). 
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Binding and Bioactivity of Bio-DHPA7 α-factor 
 
 
 
 
 
 
 
 
 
Figure 5.3 Binding and bioactivity of α-factor analogues.  A: Binding ability of the 
peptides was determined by competition binding with [3H]-labelled α-factor for Ste2p. B: 
Growth arrest assay was used to check activation of Ste2p signaling pathway. 
 
A competition binding assay was performed to determine the binding affinity of 
α-factor analogues (Figure 5.3A). The modification and addition of lysine, biotin, and 
DHPA on -factor decreased binding affinity of the peptides so a shift toward higher 
concentrations was observed for competition, due to lower binding efficacy of Bio-
DHPA7 α-factor. The growth arrest assay was performed to check biological activity of 
α-factor analogues. As shown in Figure 5.3B, Bio-DHPA7 α-factor formed smaller halos 
when compared with α-factor. When the concentration of peptide was increased by 4 
fold, distinct halos were observed. When compared with -factor, attachment of DHPA 
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at Lys7 decreased binding affinity 30 fold and biological activity by 50%; whereas the 
addition of biotin decreased binding affinity 18 fold and biological activity by 75%. 
Through competition binding and halo assay, we know that Bio-DHPA7 α-factor is able 
to bind and activate Ste2p signaling pathway, even though the binding affinity is lower 
than that of -factor. 
 
Bio-DHPA7 α-factor Crosslink into Ste2p 
 
 
 
 
 
 
 
 
 
Figure 5.4 Western blot analysis of Bio-DHPA7 α-factor crosslinked with Ste2p.  
Crosslinked product of Bio-DHPA7 α-factor and Ste2p appeared before (A) and after (B) 
His-Nickle purification on western blots probed with NeutrAvidin-HRP conjugate (upper 
panels). K0(BioACA) α-factor was used as a negative control for crosslinking; an excess 
amount of α-factor was used to compete with the crosslinking of Bio-DHPA7 α-factor. 
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Western blots at lower panels were probed with FLAG antibody to show total loading of 
Ste2p.  
 
Since Bio-DHPA7 α-factor was able to bind Ste2p and activate the signaling 
pathway, chemical crosslinking with NaIO4 was carried out in the presence of DHPA 
peptide (10 µM) and Ste2p membrane protein (500 µg). As shown in Figure 5.4A, Bio-
DHPA7 α-factor was crosslinked with Ste2p, and the signal was decreased in the presence 
of excess α-factor (1 mM), which means the crosslinking is specific for binding pocket of 
Ste2p. Notably, when Bio-DHPA7 α-factor was used as a negative control for 
crosslinking, it showed no signal in NeutrAvidin Western blot, which proves that NaIO4 
crosslinking is very specific to DHPA side chain. After crosslinked samples were purified 
with His-Nickel resin, background signal was reduced and Ste2p-DHPA α-factor 
crosslink became more distinct (Figure 5.4B). Non-specific background signal can be 
further reduced by using less peptide in the crosslinking reaction or by more diluted 
primary antibody (NeutrAvidin-HRP) for immunoblot analysis (data not shown). 
In order to identify a specific Ste2p residue that crosslinked with Bio-DHPA7 α-
factor, binding with Bio-DHPA7 α-factor (20 µM) on a large scale membrane preparation 
(10 mg) was performed to enrich crosslinked product for His-Nickel and NeutrAvidin 
purification and cyanogen bromide (CNBr) digestion. Crosslinked product was purified 
separately with His-Nickel resin to pull down Ste2p by its His tag at the C-terminal and 
with NeutrAvidin resin to capture Bio-DHPA7 α-factor. After His-Nickel purification, a 
distinct band representing Ste2p appeared at approximate 55 kDa position in a Western 
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blot probed with FLAG antibody (Figure 5.5). The same band at 55 kDa also showed up 
when the Western blot was probed with NeutrAvidin-HRP conjugate, which suggested 
that the band is a crosslinked product of Ste2p and Bio-DHPA7 α-factor. Furthermore, 
after NeutrAvidin purification, a distinct band also showed up at the size corresponding 
to Ste2p when Western blot was probed with NeutrAvidin. The same band appeared in 
anti-FLAG Western blot as well, which indicated the crosslinked product of Bio-DHPA7 
α-factor and Ste2p was purified. 
 
 
 
 
 
 
 
 
 
Figure 5.5 Western blot analysis of Bio-DHPA7 α-factor and Ste2p crosslink after 
His-Nickel and NeutrAvidin purification. After treatment with 1 mM NaIO4, 
crosslinked samples were lysed and purified with His-Nickel and NeutrAvidin resins. 
Eluted protein were separated in SDS-PAGE for Western blot analysis probed with 
NeutrAvidin-HRP conjugate and FLAG antibody. 
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Figure 5.6 Western blot analysis of purified Bio-DHPA7 α-factor and Ste2p 
crosslink after cyanogen bromide digestion. His-Nickel and NeutrAvidin purified Bio-
DHPA7 α-factor and Ste2p crosslink was subjected to cyanogen bromide digestion. 
Digested peptide was then separated in SDS-PAGE for Western blot analysis and probed 
with NeutrAvidin-HRP (A). Cyanogen bromide cut at methionine residues of Ste2p and 
generates eight digested fragments (B). 
 
 After His-Nickel and NeutrAvidin purification, cyanogen bromide (CNBr) was 
then used to digest the crosslinked product of Bio-DHPA7 α-factor and Ste2p. CNBr 
hydrolyzes peptide bonds at the C-terminus of methionine residues and generated eight 
digested fragments of Ste2p. Digested sample was then separated in SDS-PAGE for 
Western blot analysis. After probing with NeutrAvidin-HRP (Figure 5.6A), a crosslinked 
fragment appeared at the size between 10-15 kDa. Therefore, according to the predicted 
digestion of Ste2p (Figure 5.6B), transmembrane domain 2-extracellular loop 1- 
transmembrane domain 3 (TM2-EL1-TM3) (~10.6 kDa) is very likely to be the fragment 
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that interacts with Bio-DHPA7 α-factor (~2 kDa). Matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometric analysis was performed to ionize the 
fragment and generate a monoisotopic spectrum (Figure 5.7). A peak appeared at mass-
to-charge ratio (m/z) of 12404.046, which is close to the expected size of the crosslinked 
fragment.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Mass spectrum of MALDI-TOF analysis for crosslinked fragment of Bio-
DHPA7 α-factor and Ste2p. Crosslinked product of Bio-DHPA7 α-factor and Ste2p was 
purified with His-Nickel and NeutrAvidin resins and digested with cyanogen bromide. 
Expected molecular mass is at 12895.232 Da and the monoisotopic peak appeared at 
12404.046 (m/z).  
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Because DHPA forms crosslinked complex with certain favored amino acids 
(cysteine, lysine, histidine) when they are in close proximity, according to the protein 
sequence of Ste2p, there are six residues (K77, H94, K100, H126, K151, and K160) in TM2-
EL1-TM3 that would be favored to interact with Bio-DHPA7 α-factor (Figure 5.8). 
Among the six residues, H94, K100, and H126 are more likely to be near the binding pocket 
of Ste2p because they are either close to the transmembrane domain or in the 
extracellular loop. Therefore, site-directed mutagenesis of K100 and H126 was carried out. 
We constructed two alanine mutants (K100A and H126A). The results indicated, 
however, that these mutants still crosslinked with Bio-DHPA7 α-factor. Mutation at the 
other residues is required to determine the exact binding site and tandem mass 
spectrometry (MS/MS) may be a better alternative to identify crosslinked residue. 
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Chapter 4 
Discussion  
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Diagram of Ste2p. The residues from intracellular loop 1 (IL1) to 
intracellular loop 2 (IL2) was highlighted. Six residues (K77, H94, K100, H126, K151, and 
K160) in TM2-EL1-TM3 region are the candidates to interact with Bio-DHPA7 α-factor. 
 
Labeling the ligand with DOPA (3,4-dihydroxyphenylalanine) to serve as a 
crosslinker has been used to identify interacting residues of Ste2p with the N-terminal 
and C-terminal ends of α-factor (10, 12). This is the first study to use a DOPA-like 
compound, DHPA (3,4-dihydroxyphenylacetyl), as a crosslinker to investigate whether 
lysine at the center (seventh amino acid) of the ligand binds with Ste2p. DOPA and 
DHPA share the dihydroxyl ring, which can be oxidized by NaIO4 to form an ortho-
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quinone intermediate. This activated product has the tendency to react with the side chain 
of cysteine, histidine, and lysine (24) and therefore can be used to map peptide ligand-
protein interaction. According to the results presented, adding DHPA to the epsilon-
amine of the lysine residue at position 7 of α-factor decreased binding affinity of the 
peptide about 30 fold. However, with an adequate amount of Bio-DHPA7 α-factor present 
in the binding reaction, it was able to compete with the binding of α-factor, and Bio-
DHPA7 α-factor triggered downstream growth arrest activity, even though the halos were 
smaller than those formed in the presence of α-factor. Therefore, we conclude that Bio-
DHPA7 α-factor is likely to interact with the same binding pocket of Ste2p because of its 
ability to compete with α-factor and transduce a downstream signal. 
 After crosslinking, His-Nickel and NeutrAvidin purification enriched for the 
Ste2p-DHPA crosslinked product. Cyanogen bromide hydrolysis indicated a crosslinked 
band at 10-15 kDa as detected in a Western blot probed with NeutrAvidin, which 
corresponded to the TM2-EL1-TM3 fragment (T72-M165, ~10.6 kDa). The monoisotopic 
mass of TM2-EL1-TM3 fragment after CNBr digestion is expected to be 10613.811 Da 
and Bio-DHPA7 α-factor is 2282.032 Da. The expected size of TM2-EL1-TM3 and Bio-
DHPA7 α-factor complex was expected to be about 12895 Da, but the measured peak 
after MALDI-TOF fractionation indicated a molecular of 12404.046 m/z. The reason for 
the mass difference of ~491 Da needs to be further studied. The mass spectrum from 
MALDI-TOF analysis (Figure 5.7) showed the monoisotopic peak at 12404.046 (m/z) 
within a broad band ranging from 12000 to 13000 (m/z).  It is possible that the true 
crosslinked peak was overshadowed by the broad band.  
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Chapter 1 
General Conclusions and Discussion 
Unnatural Amino Acid Replacement in a Yeast G Protein-Coupled Receptor in its 
Native Environment (Incorporation of p-benzoyl-L-phenylalanine, Bpa, into Ste2p) 
In this study, we demonstrated site-specific incorporation of Bpa into Ste2p, a 
yeast GPCR, by using an orthologous tRNA/aminoacyl-tRNA synthetase pair. Eight 
mutant STE2 constructs (F55TAG, S107TAG, G115TAG, V127TAG, G188TAG, Y193TAG, 
F204TAG, and Y266TAG) were created by engineering the amber TAG stop codon at 
specific sites within the open-reading frame. An advantage of using the orthologous 
tRNA/aminoacyl-tRNA synthetase pair to incorporate Bpa into Ste2p in the yeast cell is 
that the GPCR remains in its native environment and is therefore able to interact with 
downstream effector molecules, such as the heterotrimeric G proteins, thus allowing 
assessment of both ligand binding and signal transduction pathway. The incorporation 
was verified by mass spectrometry, and our result indicates that, once incorporated, the 
photo-reactive Bpa in Ste2p in certain positions can be used to crosslink with the ligand. 
We demonstrated that Bpa incorporated into both the F55 (located in transmembrane 
domain 1, TM1) and Y193 (located in extracellular loop 2, EL2) receptors was able to 
capture biotinylated α-factor. Photo-reactive crosslinking can be largely competed out by 
the presence of excess nonbiotinylated α-factor. While F55 is positioned in the binding 
pocket of the receptor and was expected to interact with the pheromone (1), the ability of 
Bpa in Y193 to capture the ligand suggests a possible role for EL2 in ligand binding. We 
also used a novel method to supply Bpa to yeast cells via the di/tripeptide transport 
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system that is common to many eukaryotes (2, 3). Expression of the Y193TAG receptor as 
well as the F55TAG and G188TAG receptors was noticeably enhanced when the cells were 
grown in the presence of Met-Bpa at 0.1-0.5 mM when compared to Bpa. Because 
peptide transporters are ubiquitous in living cells (3), this method can be used to increase 
the delivery of unnatural amino acids and extend this approach to amino acids that are 
impermeable to yeast cells. These results set a stage for the use of unnatural amino acid 
technology in exploring the structure and interaction of integral membrane proteins in 
their native environment. 
 
Changes in Conformation at the Cytoplasmic Ends of the Fifth and Sixth 
Transmembrane Helices of a Yeast G Protein-Coupled Rreceptor in Response to 
Ligand Binding (Cysteine mutations for disulfide crosslinking of residues in Ste2p) 
 The third intracellular loop of Ste2p has been shown to play an important role in 
signal transduction and is involved in Gpa1p (Gα protein in S. cerevisiae) activation (4-
6). Transmembrane domain 5 (TM5) and 6 (TM6) that flank the intracellular loop 3 (IL3) 
have also been shown to interact with each other and have been suggested to play a 
critical role in signaling (7). In this study, we have used cysteine mutation and disulfide 
crosslinking analysis to determine conformational changes of residues in IL3 and the 
ends of TM5 and TM6 transmembrane domains of Ste2p during ligand-induced 
activation. The result showed strong dimer formation occurred in the IL3 Cys mutants, 
which is consistent with the conclusion in rhodopsin where IL3 was identified to play a 
role in receptor oligomerization (8-10). Dimer formations observed in our study were 
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also detected in intact cells, indicating that the disulfide bond formation between the two 
monomers of Ste2p occurs in the native environment of the receptor. The pattern of 
disulfide formation in our study, with R233C, L236C, and K239C mutant receptors 
having the highest percent of disulfide formation, suggests that the residues in IL3 (R233–
Q240) may form a 310 helix. Disulfide formation involving residues in the middle of IL3 
was not sensitive to ligand binding, implying that residues in the IL3 loop do not change 
conformation or availability during receptor activation. In contrast, addition of α-factor 
affected the levels of disulfide formation in Cys-substituted receptors at the boundaries of 
TM5 and TM6, suggesting that activation of Ste2p involved ligand-induced 
conformational changes in the cytoplasmic ends of TM5 and TM6. A proposed model 
according to our experimental data would be: upon ligand binding the two dimer 
interfaces (TM5/TM5 and TM6/TM6) of Ste2p at the cytoplasmic end shift away from 
each other or become less flexible so they cannot form the disulfide bond linkage. The 
reduction of dimer at the cytoplasmic end of TM5 and TM6 was not observed in the 
presence of an α-factor antagonist, suggesting that antagonist binding to Ste2p does not 
induce the conformational change or alter the flexibility at the TM5 and TM6. In 
conclusion, we showed for the first time changes in receptor conformation or flexibility 
that influence disulfide formation in the region of IL3 of Ste2p close to the TM5 and 
TM6 boundaries. The hydrophilic residues located in the middle of the IL3 loop (R231–
Q240) do not change conformation/availability during receptor activation, whereas many 
hydrophobic residues at the TM5 and TM6 cytoplasmic ends do. These conformational 
changes require ligand-induced activation of Ste2p and appear to depend on Ste2p–Gα 
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protein interactions. The pattern of disulfide formation observed is consistent with a 
310 helical structure in the center of IL3 and suggests that the IL3 loop of two Ste2p 
subunits remain close in proximity both in the active and inactive states of the receptors. 
Since Ste2p has been shown to have structure–function relationships similar to the 
physiologically and pharmacologically important rhodopsin-like GPCR family (11), the 
role of IL3 observed in this study has implications not only for Ste2p but also other 
GPCR systems. 
 
Residue-to-Residue Interactions between a G Protein-Coupled Receptor (GPCR) 
and its Gα Protein in the Saccharomyces cerevisiae Model System (Cysteine 
mutation for disulfide crosslinking of residues in Ste2p and Gpa1p) 
Several studies have shown that GPCR activation results in conformational 
changes at the TM5-TM6 cytoplasmic ends that appear to be essential for G protein 
activation in all GPCRs (12-15). Studies on the interactions between Ste2p and Gpa1p, its 
Gα protein, indicate that the Ste2p third intracellular loop (IL3) is involved in Gpa1p 
activation (4-6, 16). Like other Gα proteins in mammals, the region of Gpa1p that has 
been most commonly predicted to interact with Ste2p is the C-terminus (17-19). We have 
applied cysteine mutation and disulfide crosslinking to determine specific residue-to-
residue interactions between Ste2p and Gpa1p. Using combinatorial expression and assay 
of 242 Ste2p and Gpa1p cysteine mutants, five Ste2p residues (L228C, S243C, L247C, 
L248C, and I249C) located at the cytoplasmic ends of the transmembrane domain 5 
(TM5) and 6 (TM6) were identified to interact with five residues (Q463C, N465C, 
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K467C, I469C, and G470C) of the C-terminus of Gpa1p. The patterns of Gpa1p 
interaction with Ste2p in the presence and absence of α-factor suggest that the C-terminus 
of Gpa1p is closer to TM6 than TM5 in the inactive state of Ste2p. Upon α-factor 
binding, TM5 and TM6 of Ste2p should undergo ~30° of rotation in counterclockwise 
and clockwise directions, respectively, and TM6 would shift closer to TM5 as observed 
in other GPCRs (2, 43). The C-terminus of Gpa1p also undergoes two possible changes, 
rotational and “withdrawal” movements that are required for proper Ste2p coupling and 
Gpa1p activation. A rotation of the helix (C-terminus) of Gpa1p for ~120° is required for 
the change of interaction from Ste2p-L247C/Gpa1p-N465C in the inactive state to Ste2p-
247C/Gpa1p-467C in the active state. Since TM6 is likely to undergo ~30° clockwise 
rotation upon ligand binding , Gpa1p may not have to rotate a full ~120° after activation; 
a ~90° of counterclockwise rotation in Gpa1p would be sufficient. The second 
conformational change consistent with our disulfide crosslinking results is what we call 
the “withdrawal” movement. There is a switch of interaction from Ste2p-I249C/Gpa1p-
N465C in the inactive state to Ste2p-I249C/Gpa1p I469C in the active state. This switch 
requires the C-terminus of Gpa1p to move a distance that is approximately the height of 
an α-helix (~5.4 Å) and undergo a horizontal translation, which may result in about 5 Å 
withdrawal movement of Gpa1p from Ste2p after activation. Concerted rotational and 
translational movements between Ste2p and Gpa1p upon ligand binding are proposed 
whereby the C-terminus of Gpa1p shifts from the TM6 cytoplasmic end towards the inner 
core of the receptor closer to TM5 and other TMs, such as TM3. Overall, we have 
proposed the conformational changes in TM5 and TM6 of Ste2p upon ligand binding, 
184 
 
which induces rotational and translational withdrawal movements at the C-terminus of 
the Gpa1p. This proposed model is similar to the “translational” movement predicted by 
the helix-switch mechanism derived from kinetic modeling (20). This study is the first to 
identify specific residue-to-residue interactions between a GPCR and its cognate Gα 
protein in its active and inactive states. 
 
Crosslinking of an α-factor Analog [K0(BioACA), K7(DHPA), Nle12]α-factor (Bio-
DHPA7-α-factor) into its G Protein-Coupled Receptor, Ste2p (Incorporation of 3,4-
dihydroxyphenylacetyl, DHPA, into α-factor and its crosslinking to Ste2p) 
 Besides utilizing photo-reactive crosslinking with Bpa-labeled ligand (1, 21) to 
probe the binding domain of Ste2p, we have also applied a periodate-mediated 
crosslinking with 3,4-dihydroxyphenylalanine (DOPA) labeled α-factor to identify 
specific interacting residues in Ste2p (22, 23). In this study, we used a DOPA-like 
compound, DHPA (3,4-dihydroxyphenylacetyl), as a crosslinker to investigate where 
lysine at the center (seventh amino acid) of α-factor binds with Ste2p. DOPA and DHPA 
share the dihydroxyl ring, which can be oxidized by NaIO4 to form an ortho-quinone 
intermediate. This activated product has the tendency to interact with the side chains of 
cysteine, histidine, and lysine (24) and therefore can be used to map peptide ligand-
protein interactions. Chemically synthesized [K0(BioACA), K7(DHPA), Nle12]α-factor 
(Bio-DHPA7 α-factor) with a DHPA attached to lysine at position 7 and biotin attached to 
lysine added to the amino-terminus of α-factor was used to bind to Ste2p. Even though 
attachment of DHPA at Lys7 decreased binding affinity about 30 fold, it was able to 
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activate growth arrest in the yeast cell. With an adequate amount of Bio-DHPA7 α-factor 
present in the binding reaction, it was able to compete with the binding with α-factor. 
Therefore, we conclude that Bio-DHPA7 α-factor is likely to interact with the same or 
similar pocket of Ste2p because of its ability to compete with α-factor and transduce a 
downstream signal. Bio-DHPA7-α-factor was crosslinked into Ste2p as demonstrated by a 
Western blot probed with NeutrAvidin-HRP conjugates to detect Bio-DHPA7 and Ste2p 
crosslinked product. The Ste2p-ligand crosslinked complex was then purified with His-
Nickel to pull down Ste2p with its His tag at the C-terminus and with avidin beads to 
capture biotin-labeled ligand and its crosslinked products. Cyanogen bromide digestion 
was applied and a crosslinked fragment at the size of ~13 kDa was detected in the 
Western blot probed with NeutrAvidin-HRP and also by MALDI-TOF mass 
spectrometry. Due to the size of the crosslinked fragment we suggest that Bio-DHPA7 α-
factor was crosslinked with transmembrane domain 2 to 3 (T72-M165, ~10.6 kDa) flanking 
extracellular loop 1 (TM2-EL1-TM3) region. Site-directed mutagenesis and tandem mass 
spectrometry of this region are currently being carried out in order to identify the exact 
crosslinked residue of Ste2p with Bio-DHPA7 α-factor. This study is the first to 
investigate the interacting residues between Ste2p and position 7 of α-factor. By 
determination of the Ste2p residues that interact with the first, last, and middle residues of 
the ligand, we expect to be able to build a better model for the interaction pocket of Ste2p 
and α-factor. 
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Summary for the structure and activation of Ste2p 
The inactive, or resting, form of Ste2p serves as a restraint function to keep G 
proteins in the basal state and to prevent activation of pheromone response signaling in 
the absence of α-factor. Several pairs of residue interactions within the transmembrane 
domains (N84-Q149, V223-L247, Q253-S288, Q253-S292, and N205-Y266) (25, 26) have been 
identified to maintain inactive state of Ste2p. In addition, site-directed mutagenesis (26-
29) has also revealed that certain residues (S141, I153, I169, and L222, P258, A281, and T282) 
are essential to limit constitutive activity of Ste2p. These residues and interactions among 
transmembrane domains are crucial to hold the inactive confromation of Ste2p in order to 
avoid unnecessay cellular response. 
When the ligand α-factor appears, suggested by mutagenesis studies of Ste2p (29-
34), many residues (S47, T48, T50, F55, F99, Y101, L102, Y128, F204, N205, Y266, D275, L277, 
A281, and T282) at the extracellular transmembrane boundaries of the receptor have effects 
on binding affinity and interactions with α-factor. According to the photo-reactive and 
chemical crosslinking results from our lab (1, 22, 23, 35, 36), several residues (F55, R58, 
C59, Y193, and K269) of Ste2p have been identified to interact directly with the ligand and 
possibly reside at the binding pocket of of Ste2p for α-factor. We have also developed 
some preliminary evidence that a residue (or residues) in extracellular loop 1 flanking 
transmembrane domain 2 and transmembrane domain 3 interacts with the seventh residue 
of α-factor. Overall, α-factor binds or interacts with a number of residues on its receptor 
Ste2p to induce changes in the structure of the receptor from the inactive state to an 
active conformation. 
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After the ligand binds, confromational changes occur in Ste2p to “loosen” the 
resting structure to an active form. Many residues (L102, N105, S108, Y111, T114, N132, M180, 
Y203, F204, N205, L264, Y266, and D275) have been observed to play critical roles in Ste2p 
activation (29, 37, 38). According to the preliminary data from our lab, we have 
discovered possible interactions between residues at the transmembrane domains (R58-
Q135 and H94-E143) when the receptor is in its active conformation. Through cysteine 
mutation and disulfide crosslinking of Ste2p in the absence and presence of α-factor, we 
have also determined a rotational and transitional movement in transmembrane domain 5 
and 6 of actived Ste2p in concert with the activation of heterotrimeric G proteins (Gpa1p 
and Gβγ subunits). 
The intracellular loop 3 (6) and C-terminus (39) of Ste2p modulate the activities 
of the G protein complex. We identified five Ste2p residues (L228, S243, L247, L248, and 
I249) at the cytoplasmic ends of transmembrane domain 5 and 6 that interact with five 
residues (Q463, N465, K467, I469, and G470) at the C-terminus of Gpa1p. After the activation 
of Ste2p, the conformational changes of the receptor leads to a rotational and tarnsitional 
shift of Gpa1p, this results in about 5 Å withdrawal movement of Gpa1p away from the 
transmembrane core of Ste2p. The resultant conformational change of Gpa1p allows 
dissociation of GDP in exchange of GTP (40). The Gβγ subunits then dissociate from 
GTP-activated Gpa1p and transmit the signal to the MAP kinase cascade (41) and 
downstream effectors, which leads to transcriptional activation of response genes, 
changes in morphology, and cell growth arrest. 
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Chapter 2 
Future Studies 
 In these studies, we have applied three different crosslinking techniques in order 
to understand structure of a G protein-coupled receptor in Saccharomyces cerevisiae 
(Ste2p) and its interaction with the ligand (α-factor) and Gα protein (Gpa1p). First, p-
benzoyl-L-phenylalanine (Bpa) was incorporated into extracellular part of Ste2p as a 
means to capture α-factor (36). Bpa-labeled Ste2p was expressed successfully and two 
constructs was able to crosslink with α-factor.  Second, cysteine mutation and disulfide 
bond cross-linkage were introduced to intracellular loop 3 (IL3) of Ste2p and C-terminus 
of Gpa1p to investigate possible interactions. IL3 appeared to be at dimer interface (42) 
and was associated with Gpa1p for conformational changes upon ligand binding. Third, 
chemical crosslinker 3,4-dihydroxyphenylacetyl (DHPA) was used to label lysine residue 
at position 7 of  α-factor for crosslinking with Ste2p for determination of the binding 
domain. DHPA peptide bound to Ste2p specifically and was able to trigger downstream 
signaling. A region of Ste2p spanning from transmembrane domain 2-extracellular loop 
1-transmembrane domain 3 (TM2-EL1-TM2) is likely to interact with the DHPA labeled 
α-factor. Here in this chapter, I am going to talk about possible applications of these 
techniques for future studies in order to understand the structure of Ste2p in both the 
resting and activated state and its interaction with its ligand and with other proteins 
including its Galpha-protein, intracellular regulatory proteins, and other membrane 
proteins. 
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Incorporation of p-benzoyl-L-phenylalanine (Bpa) into Ste2p 
In order to understand the interaction between a peptide ligand and its cognate 
GPCR, Ste2p had been used as a model system to study its binding pocket for α-factor. 
Site-directed mutagenesis has been carried out in many studies (29-34) to determine 
possible residues that are important for α-factor binding. Mutation of several residues at 
the extracellular boundaries of TMs (S47, T48, T50, L102, F204, N205, Y266, D275, L277, A281, 
and T282) of Ste2p have shown to affect binding activity with the ligand after 
mutagenesis. Alpha-factor labeled with photo-reactive crosslinker (Bpa) and chemical 
crosslinker (DOPA) has been applied in our lab to capture Ste2p (1, 21-23), and residues 
R58, C59, and K269 were identified to be in close proximity to the binding pocket of the 
receptor. For this particular aspect of studies, the method of incorporating unnatural 
amino acid (Bpa) into Ste2p can be applied to substitute for these candidate residues to 
capture α-factor. Bpa crosslinking is very specific to amino acids within close range (3 Å) 
to Bpa and therefore has the advantage to define binding pocket of the receptor. 
However, there are some disadvantages of Bpa incorporation. For example in our 
study, we chose to incroporate Bpa into residues with similar aromatic functional group 
or residues known to be tolerant to amino acid substitution. The side chain of Bpa may be 
too large to substitute for some smaller amino acids in the receptor so that those receptors 
will not yield natural interactions with the ligand. Also the system of unnatural amino 
acid replacement with TAG stop codon mutation we used in our research is not perfect 
since we encountered problems with “readthrough” expression and target protein 
degradation. Nevertheless, new approaches to improve the efficiency of unatural amino 
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acid incroporation has been developed (43), which should be very useful for studies of 
protein-protein interactions.     
According to previous studies from our lab, the functional role of residues in the 
first extracellular loop (EL1) of Ste2p has been investigated by cysteine scanning 
mutagenesis (37). Five mutants were identified to be either partially (L102C and T114C) 
or severely (N105C, S108C, and Y111C) compromised in signaling.  Furthermore, 
solvent accessibility of residues Y101C and Y106C decreased dramatically upon ligand 
binding (44). It was proposed that EL1 plays an important role in conformational switch 
that activates Ste2p and initiates signal transduction pathway. Similar to the active states 
of other GPCRs (bovine rhodopsin and dopamine D2 receptor) (45, 46), upon ligand 
binding, there might be a shift in position of the helical region of EL1 that forms an 
activation pocket with the transmembrane (TM) domains. In addition, mutagenesis study 
from Konopka’s group (26) has shown that some mutants (S141P, I153F, I169K, and 
L222P) of Ste2p that contained substitution within the TM domains displayed a 
significant increase in constitutive activity that was α-factor independent. These residues 
on the contrary are important to hold the receptor in inactive state, possibly through 
interacting with other residues in different TM domains. In order to identify possible 
interactions between EL1 and other TM domains and within TM-TM domains in active 
and inactive states, incorporation of Bpa into EL1 and suggested TM residues can be 
applied for photoaffinity crosslinking. With the addition of chemical or enzymatic 
digestion, Bpa crosslinking has great potential to determine possible binding domains.  
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For another application of Bpa-labeled Ste2p, intracellular interacting proteins 
may be identified. After ligand binds, Ste2p receptor is phosphorylated, ubiquitinated, 
and internalized by actin-based endocytic machinery. The intracellular proteins involved 
in these regulatory interactions can be “captured” by Ste2p labeled in the C-terminus or 
intracellular loops. Enrichment and mass spectrometry of these crosslinked proteins can 
lead to determination of the intracellular “interactome” both in the resting and activated 
(α-factor addition) states. Also, clathrin (Chc1p), which is associated with formation of 
internalizing cargo for endocytosis, was found to co-localize with Ste2p (47). It is 
possible that clathrin interacts with Ste2p and forms an endocytic complex for trafficking 
inside the cell.  
A novel application of Bpa-labeled Ste2p would be to apply Bpa-mediated 
crosslinking to capture other membrane-bound proteins that are associated with Ste2p 
during ligand-mediated cell signaling or during mating.  There is a pheromone-dependent 
interaction between Ste2p and Ste3p (the a-factor receptor) in later stages of fusion 
between opposite mating types of S. cerevisiae that may be probed with a Bpa-labeled 
Ste2p (48).  
Finallly, Bpa-labeled Ste2p may be useful to identify TM-TM interactions of the 
resting or activated state of Ste2. Transmembrane domains 1 (TM1), 4 (TM4) and 7 
(TM7) of Ste2p were identified previously to be at the dimer/oligomer interface (49, 50). 
The method of Bpa incorporation can be applied in Ste2p to confirm protein-protein 
interaction with other proteins and to identify potential residue-to-residue binding sites. 
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Cysteine Mutation for Disulfide Crosslinking of Residues in Transmembrane 
Domains 
 
 
 
 
 
 
 
 
 
Figure 6.1 Two-dimensional structural model of the transmembrane region of the α-
factor receptor (26). The seven helices are arranged according to the structure of 
rhodopsin. Solid lines between Asn84 and Gln149, Val223 and Leu247, and among 
Gln253, Ser288, and Ser292 indicate intramolecular interactions suggested by 
mutagenesis studies (7, 26, 51). 
 
Comparison of functional equivalent regions between rhodopsin and Ste2p has 
revealed that there are several similarities of the polar amino acids in the transmembrane 
(TM) domains which might play essential roles for TM helix interaction and helix folding 
(11).  According to mutagenesis and molecular modeling studies (Figure 6.1), possible 
interactions within the core of TM helix bundle have been predicted (26, 51). Residue 
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Asn84 in TM2 is likely to interact with Gln149 in TM3 (N84-Q149) based on the 
observation that mutants in both residues displayed strong constitutive activity (26). 
Cysteines substitution at position Val223 in TM5 and position Leu247 (V223-L247) in 
TM6 formed a disulfide bond indicating an interaction between TM5 and TM6 (7). 
Residue Gln253 in TM6 was proposed to interact with Ser288 and Ser292 in TM7 (Q253-
S288 and Q253-S292) also based on constitutively active mutants (51). The structural model 
shows possible orientation of Ste2p in inactive state according to the interactions bewteen 
TM2-TM3, TM5-TM6, and TM6-TM7 domains.  
On the other hand, according to preliminary data from our lab of residue 
swapping in TM domains, some residue interactions in TM domains occurs after ligand 
binding, which suggests that interfering with TM interaction in the active conformation 
might lead to loss of function for Ste2p activation. In the active state of Ste2p, Arg58 in 
TM1 was found to potentially interact with Gln135 in TM3 (R58-Q135); His94 in TM2 is 
likely to interact with Glu143 (H94-E143). In conclusion, the polar residues in TM domains 
play important roles either to hold Ste2p in the inactive state (N84-Q149, V223-L247, Q253-
S288 and Q253-S292) or to promote conformational switch of Ste2p that initiates signal 
transduction pathway (R58-Q135 and H94-E143). In order to test these proposed interactions 
of polar residues in TM helix of Ste2p, cysteine mutation for disulfide crosslinking can 
be applied to examine these TM residues. This method has been applied successfully to 
capture the interaction of polar residues between Asn205 at TM5 bounday and Tyr266 in 
TM6 (N205-Y266) (25). Cysteine mutation has the advantage to substitute specific residues 
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of interest and disulfide crosslinking can determine whether they are close enough (2-3 
Å) for possible interaction to occur.  
 
Incorporation of 3,4-dihydroxyphenylacetyl (DHPA) into α-factor and Ste2p 
 In Part V of this dissertation, I have presented the crosslinking result of 3,4-
dihydroxyphenylacetyl (DHPA) labeled α-factor and Ste2p. After digestion with 
cyanogen bromide, a crosslinked band at 10-15 kDa was detected in the Western blot 
probed with NeutrAvidin, which was concluded to be at the region between 
transmembrane domain 2 and 3 flanking extracellular loop 1 (TM2-EL1-TM3, T72-M165). 
The band was purified and confirmed by matrix-assisted laser desorption/ionization 
(MALDI) mass spectrometric analysis. Until now, the exact binding residue of this 
fragment with Bio-DHPA7 α-factor has not yet been identified. It was suggested that the 
position 7 side chain of α-factor is more likely to interact with a pocket formed by 
extracellular domains of Ste2p (52). Therefore, a series of site-directed mutagenesis at 
TM2-EL1-TM3 region should be performed to identify the exact binding site. Multiple 
steps of purification (His-Nickel and FLAG resin) and digestion (cyanogen bromide and 
trypsin) should be considered in order to enrich the crosslinked fragment, which then can 
be subjected to tandem mass spectrometric analysis (MS/MS) (22) for detailed 
sequencing in order to confirm the exact binding site. 
An alanine scanning of α-factor by replacing each residue with Ala amino acid 
has been performed in order to understand the role of each residue of the peptide (53). 
Residues near the N-terminus (position 2, 3, and 4) are found to be important for receptor 
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activation and the ones near the C-terminus (position 11, 12, and 13) are important for 
binding with Ste2p. The center of α-factor contains a Pro-Gly sequence (position 7, 8, 9 
and 10), which is likely to promote a β-turn and help to orient the binding and signaling 
domains of the pheromone. The photoreactive crosslinker p-benzoylphenylalanine (Bpa) 
has been incorporated in to different positions of α-factor (1, 21). Bpa-labeled α-factor 
analogs displayed different affinities when binding with Ste2p and only a few (Bpa1, 
Bpa3, and Bpa13) of them was used to crosslink with the receptor. Since previous studies 
from our lab with DOPA and DHPA crosslinking have shown very prominent results (23, 
42), scanning through every residue of α-factor with chemical crosslinkers DOPA and 
DHPA should be considered in order to determine where it binds Ste2p. Furthermore, 
agonists, antagonists, and synergists of Ste2p can also be labeled with DOPA or DHPA, 
and then the binding site of Ste2p with different peptides can be evaluated. 
 The translational machinery to incorporate redox-active DHP group (3,4-
dihydroxyphenylalanine, DOPA) into proteins in E.coli has been optimized (54). We 
anticipate that future efforts from other labs will optimize DOPA or DHPA incorporation 
into targeted residues of a yeast protein by using orthogonal tRNA-aminoacyl tRNA 
synthetase pairs. The side chain of DOPA and DHPA has the advantage to crosslink 
specifically with certain amino acids (cysteine, histidine, and lysine) (24) and therefore 
can be used as an alternative to Bpa crosslinking. According to our previous results, 
chemical crosslinkers, DOPA and DHPA, normally display stronger crosslinking signal 
than photo-reactive Bpa. Therefore, development to incorporate DOPA or DHPA into 
yeast proteins, such as Ste2p, has a great potential to identify residue-to-residue 
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interactions. In the extracellular side, DHPA-labeled Ste2p can be used to capture the 
ligand and help define the binding pocket. In the intracellular side, DHPA can crosslink 
and help to identify Ste2p interacting proteins. 
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